<!DOCTYPE html>

<html> 

<head> <!-- /main page header -->
  <meta charset="UTF-8">
   <meta name="format-detection" >
   <meta name="viewport" content="user-scalable=no, initial-scale=5, minimum-scale=1, maximum-scale=5">
   <title>BD-MIMS</title>
   <link rel="stylesheet" href="css/main.css">
   <link rel="stylesheet" href="css/themes/default/jquery.mobile-1.3.1.min.css">
   <script src="js/jquery.js"></script>
   <script src="js/jqm.js"></script>
   <script scr="js/cordova.js"type="text/javascript"></script>
   <script>
    function init() {
      document.addEventListener("deviceready", onDeviceReady, false);
    }

    function onDeviceReady() {
      alert('Damn Niagga, its playtime!');
    }
  </script>
   
</head> <!-- /main page header -->


<body onload="init()"> 


<div data-role="page" id="" data-theme="a"> <!-- /first page -->


    <div data-role="header"> <!-- /this is header -->
      <h1> Drugs Acting on Nervous System</h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>

    </div> <!-- /this is header -->


<div data-role="content" data-theme="a">  <!-- /content div -->
  <ul data-role="listview" data-inset="true" data-theme="b">        
                   
    <li> Hypnotics
        <ul>
	       <li><a href="#Benzodiazepines">
	        Benzodiazepines </a>
	       </li>
	       <li><a href="#Barbiturates">
	        Barbiturates & Trichloroethanol derivatives</a>
	       </li>
	       <li><a href="#Misc. Hypnotics">
	        Misc. Hypnotics </a>
	       </li>	       	            
	    </ul>             
    </li>  
            

   
    
  <li> <a href="#Sedative"> Sedative & Tranquillisers: Anxiolytics</li>

   <li>  Antidepressant Drugs
	      <ul> 
            
            <li><a href="#Tricyclic & related antidepressants drugs">
	            Tricyclic & related antidepressants drugs</a>
	          </li>  
	          <li><a href="#Monoamine-oxidase inhibitors (MAOIs)">
	            Monoamine-oxidase inhibitors (MAOIs)</a>
	          </li>
	          <li><a href="#SSRIs & related antidepressants">
	            SSRIs & related antidepressants</a>
	          </li>  
				<li><a href="#Misc. Antidepressants">
              Misc. Antidepressants</a>
            </li>                                                               
	      </ul>    
	 </li>

	 <li><a href="#C.N.S Stimulant Drugs">C.N.S Stimulant Drugs</a></li> 


	 <li>  Drugs Used in Nausea, Vomiting & Vertigo
	      <ul> 
	           <li><a href="#Meniere's disease">
	           Drugs used in vestibular disorders <br>
	           including Meniere's disease</a>
	          </li> 
	          
	          <li><a href="#Symtomatic relief">
	            Symtomatic relief of nausea <br> 
	            from underlying diseases</a>
	          </li> 
            <li><a href="#nausea">
              Drugs used in nausea & vomiting induced <br>
				by cytostatic chemotherapy & radiotherapy</a>
            </li>                                                                  
	      </ul>    
	 </li>

 	    
 <li><a href="#Antiepileptic Drugs">Anticonvulsant/Antiepileptic Drugs</a></li>
 	         
 		<li>  Drugs used in Pariunsonism & Related Disorders
 		      <ul> 
 		           <li><a href="#Dopaminergic drugs">
 		            Dopaminergic drugs</a>
 		          </li> 
 		          <li><a href="#Antimuscarinic drugs">
 		            Antimuscarinic drugs</a>
 		          </li> 
 		          <li><a href="#tics">
 		            Drugs used in essential tremor, <br>
 		            chorea, tics & related disorders</a>
 		          </li> 
 		      </ul>    
 		 </li>


<li><a href="#Appetite">Appetite Suppressants/ Antiobesity Drugs</a></li> 
	 	      
<li><a href="#Dementia">Drugs for Dementia</a>
	       
<li><a href="#Drugs used in Substance Dependence">
	         Drugs used in Substance Dependence</a>
</li> 

<li><a href="#Antipsychotic Related Drugs">
           Antipsychotic Related Drugs</a>
          </li> 

	           


 </ul> 
</div> <!-- content div -->

   <div data-role="footer"data-position="fixed"> <!-- /first footer -->
      <h4></h4>
   </div><!-- /first footer -->
  </div> <!-- /first page -->
 
  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Benzodiazepines" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
    
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> FLURAZEPAM  </h3>
	          <p>FLURAZEPAM: Capsule<br>

<strong>Ind:</strong> Short-term treatment of insomnia where day time sedation is acceptable. <br><br>

<strong>C/I:</strong> Acute pulmonary insufficiency, respiratory depression, chronic psychosis.<br><br>

<strong>S/E:</strong> Hangover on the following day with drowsiness, dizziness, ataxia (particularly in elderly), confusion, dry mouth; G.1. disturbances; hypersensitivity reactions; visual disturbances; skin rashes; urinary retention; change in libido. Risk of dependence increases the higher the dose and the longer term treatment.<br><br>

<strong>Caution:</strong> Chronic pulmonary insufficiency, chronic renal or hepatic disease, the elderly, pregnancy, labour and lactation. Avoid long term use; withdraw gradually.<br><br>

<strong>Dosage & admin: Adult:</strong> Elderly,15 mg at bed time & Others, 15-30mg at bedtime.
Child: Not recommended.</p>
	        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>ALUCTIN Cap. Ambee</h3>
    <p>Flurazepam hydrochloride 30mg/capsule. 100's pack: 354.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FURAMANE Cap. Gaco</h3>
    <p>Flurazepam hydrochloride 30mg/capsule. 100's pack: 299.45 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->


       <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> MIDAZOLAM  </h3>
	          <p>  MIDAZOLAM: Tablet/Injection<br><br>
It is a water soluble benzodiazepine which is often used in preference to diazepam. Recovery is faster than with diazepam.<br><br>

<strong>Ind:</strong> Disturbance of sleep rhythm & all forms of insomina particularly difficulty in falling asleep either initially or after premature awakening. Sedation in premedication & induction of anaesthesia (local & general) before surgical and diagnostic procedure.<br><br>

<strong>C/I; S/E; Caution:</strong> See above under Flurazepam. Important- profound sedation reported with oral midazolam.<br><br>

<strong>Dosage & admin:</strong> By mouth: The usual adult dose is 7.5-15mg daily. In elderly & debilitated patient the recommended dose is 7.5mg. This dose is also applied to the patient with impaired liver & kidney function. For premedication of adult 15mg of midazolam should be given orally 30-60 minutes before the operation unless the parenteral route is preferred.<br>

<strong>By injection:</strong> Sedation, by i.v injection- over 30 seconds, 2mg (elderly 1-1.5mg) followed after 2 minutes by increments of 0.5-1mg if sedation not adequate; usual range 2.5-7.5mg (about 70mcg/kg), elderly 1-2mg.
Premedication, by i.m injection, 70-100mcg/kg
30-60 minutes before surgery; usual dose 5mg (2.5mg in elderly).
Induction, by slow i.v injection, 200-300mcg/kg (elderly 100-200mcg/kg).
Sedation of patients receiving intensive care, 4,1 i.v infusion, initially 30-300mcg/kg given over 5: minutes, then 30-200mcg/kg/hour; reduce dose (or omit initial dose) in hypovolaemia, vasoconstriction, or hypothermia; low doses may be adequate if opioid analgesic also used; avoid abrupt withdrawal after prolonged administration (safety after more than 14 days not established).
<strong>Drug inter:</strong> Plasma concentration increased by erythromycin, diltiazem and verapamil.  </p>
	        </div><!-- collapsible -->
	  
<div data-role="collapsible"> <!-- collapsible -->
<h3>ANQUIL Tab. General</h3> 
<p>Midazolam 7.5mg & 15mg/tablet. 7.5mg x 30's pack: 240.00 MRP 15mg x 10's pack: 135.00 MRP</p>
</div>

<div data-role="collapsible"> <!-- collapsible -->
<h3>DORMICUM Inj. Roche</h3> 
<p>Midazolam 5mg/5ml ampoule & 15mg/3ml ampoule: injection
5mg (5ml) amp x 10's pack: 1001.25 MRP 15mg (3ml) amp x 5's pack: 900.00 MRP</p>
</div>

<div data-role="collapsible"> <!-- collapsible -->
<h3>DORMICUM Tab. Roche</h3>
<p>Midazolam 7.5mg/tablet.
7.5mg x 30's pack: 360.30 MRP</p>
</div>


<div data-role="collapsible"> <!-- collapsible -->
<h3>HYPNOFAST Tab. Incepta</h3> 
<p>Midazolam 7.5mg & 15mg/tablet.
7.5mg x 30's pack: 240.00 MRP
15mg x 10's pack: 150.00 MRP Ùè∞ÄHYPNOFAST Inj. Incepta Midazolam 15mg/3ml ampoule: injection
15mg (3ml) amp x l's pack: 75.00 MRP</p>
</div>


<div data-role="collapsible"> <!-- collapsible -->
<h3>MILAM Tab. SK+F</h3> 
<p>Midazolam 7.5mg & 15mg/tablet. 7.5mg x 30's pack: 240.00 MRP 15mg x 10's pack: 150.00 MRP </p>
</div>

<div data-role="collapsible"> <!-- collapsible -->
<h3>MIZOLAM Tab. Acme</h3> 
<p>Midazolam 7.5mg/tablet.
 7.5mg x 30's pack: 240.00 MRP</p> 
</div>

<div data-role="collapsible"> <!-- collapsible -->
<h3>SEDAQUIL Tab. Rangs Pharma</h3> 
<p>Midazolam 7.5mg/tablet.
7.5mg x 30's pack: 240.00 MRP</p>
</div>



      </div><!-- collapsible-set -->



       <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> NITRAZEPAM  </h3>
	          <p>  NITRAZEPAM: Tablet/Capsule<br><br>
<strong>Ind:</strong> Short-term treatment of insomnia
where day time sedation is acceptable; insomnia with early morning wakening.<br><br>

<strong>C/I:</strong> Acute pulmonary insufficiency, respiratory depression, chronic psychosis.<br><br>

<strong>S/E:</strong> Hangover on the following day with drowsiness, dizziness, ataxia (particularly in elderly), confusion, dry mouth; GA. disturbances; hypersensitivity reactions; visual disturbances; skin rashes; urinary retention; change in libido.Risk of dependence increases the higher the dose and the longer term treatment.<br><br>

<strong>Caution:</strong> Chronic pulmonary insufficiency, ch. renal or hepatic disease, the elderly, pregnancy, labour and lactation. Avoid long term use; withdraw gradually.<br><br>

<strong>Dosage: Adult:</strong> Elderly, 2.5-5mg at bedtime; Others, 5-10mg at bedtime.
Child: Not recommended.  </p>
	        </div><!-- collapsible -->
	  
<div data-role="collapsible">
<h3>AMOCTIN Tab. Skylab</h3>
<p>Nitrazepam 5mg/tablet. 100's pack: 60.00 MRP</p>
</div>

<div data-role="collapsible">
<h3>EPAM Tab. Opsonin </h3>
<p>Nitrazepam 5mg/tablet. 100's pack: 75.00 MRP</p>
</div>

<div data-role="collapsible">
<h3>NOCTIN Tab. Ambee </h3>
<p>Nitrazepam 5mg/tablet. 100's pack: 69.00 MRP</p>
</div>

<div data-role="collapsible">
<h3>OCTON-5 Tab. Gaco </h3>
<p>Nitrazepam 5mg/tablet. 100's pack: 100.70 MRP</p>
</div>


      </div><!-- collapsible-set -->




       <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> ZALEPLON  </h3>
	          <p> ZALEPLON: Capsule
Zaleplon is a newer hypnotic with short-acting and rapid onset of action. It is a benzodiazepine receptor agonist, possessing the shortest half-life among available agents. It is effective in improving sleep latency, duration & sleep quality. <br><br>

<strong>Ind:</strong> Short-term treatment of insomnia.<br><br>

<strong>C/I:</strong> Obstructive sleep apnoea, acute pulmonary insufficiency, respiratory depression, myasthenia gravis, severe hepatic impairment, psychotic illness.<br><br>

<strong>S/E:</strong> Adverse effects of zaleplon appear to be dose related, so it is important to use the lowest possible effective dose, specially in the elderly. The side-effects are usually mild & transient, the most common are diarrhea, nausea, vomiting, vertigo, headache, asthenia, nightmares etc. <br><br>

<strong>Precautions:</strong> Zaleplon should be taken immediately before bedtime or after the patient has gone to bed & has experienced difficulty falling asleep.Elderly patients with impaired motor performance, a dose of 5mg is recommeded to decrease the possibility of side-effects. Elderly and/or debilitated patients should be monitored closely. Clinical experience with zaleplon in patients with concomitant systemic illness is limited. Zaleplon should be used with caution in patients with disease or conditions that could affect metabolism or hemodynamic responses. Patients with compromised respiration due to preexisting illness should be monitored carefully. In mild to moderate hepatic impairment, zaleplon dose should be reduced to 5mg. No dose adjustment is necessary in patients with mild to moderate renal impairment.<br><br>

<strong>Pregnancy & Lactation:</strong> Zaleplon is not recomm- ended for pregnant woman & nursing mother. <br><br>

<strong>Dosage & Admin:</strong> The dose of zaleplon should be individualized.
The recommended dose of zaleplon for most non-elderly adults is 10mg. For certain low
weight individuals, 5mg may be a sufficient dose. Although the risk of certain adverse events associated with the use of zaleplon appears to be dose dependent, the 20mg dose has been shown to be adequately tolerated and may be considered for the occasional patient who does not benefit from a trial of lower dose. Doses above 20mg are not recommended. Zaleplon should be taken immediately before bedtime or after the patient has gone to bed and has experienced difficulty falling asleep. Taking zaleplon with or immediately after a heavy, high-fat meal results in slower absorption and would be expected to reduce the effect of zaleplon on sleep latency.<br><br>

<strong>Drug Inter:</strong> Zaleplon has been shown to have minimal effects on the kinetics of warfarin, imipramine, ethanol, ibuprofen, diphenhydramine, thioridazine, and digoxin.   </p>
	        </div><!-- collapsible -->
	  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>EPLON Cap. Beximco</h3>
    <p>Zaleplon INN 5mg & 10mg/capsule. 5mg x 30's pack: 180.00 IP 10mg x 30's pack: 300.00 IP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->


   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Barbiturates" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Barbiturates & <br> Trichloroethanol derivatives   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  Barbiturates </h3>
          <p>  PHENOBARBITONE
PHENOBARBITONE: Tablet/Elixir/ Injection. <br>

Ind: Insomnia; (anti-epileptic, see in the respective section).<br>
C/I; S/E; Caution: See under anti-epileptic
drugs.<br>
<strong>Dosage & admin:</strong> Adult: 15-30mg 2 or 3 times daily. Maximum, 600mg in 24 hours.<br>
Child: up to 1 year, 15-30mg daily; 1-12 years, 30-60mg daily.
Prepns: See under anti-epileptic drugs.  </p>
        </div><!-- collapsible -->
  

      </div><!-- collapsible-set -->

      <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>Trichloroethanol derivatives   </h3>
          <p>CHLORAL HYDRATE21
CHLORAL HYDRATE: Capsule/Elixir/Mixture<br>
Chloral hydrate 500mg/5ml, 200mg/5ml in paediatric elixir, & 500mg./1 capsule.<br>
Ind: Insomnia, sedation in children and elderly; pre-operative sedative; adjunct to opiates and analgesics; and in first stage of labour (it induces sleep in about half an hour lasting 6-8 hours). <br>

<strong>C/I:</strong> Severe hepatic, renal or cardiac disease; Gastritis.<br>
<strong>S/E:</strong> Gastro-intestinal distrubances, skin rashes may occur, little hangover on the following day with drowsiness, dizziness, ataxia, headache, excitement & delirium; ketonuria.<br>
Caution: Little hangover may affect patient's ability to drive or operate machinery judgement and dexterity may be impaired, patients should be warned of these effects. Doses are taken well diluted to minimise g.i. disturbances. Contact with skin and mucous membrane should be avoided. Dosage: Adult: Insomnia, 500 mg-1 gm taken with water 15-30 mins. before bedtime or 1-2 hours before surgery. Max. 2gm daily. Sedation, 250mg 3 times daily with water. Child: 30-50mg/kg upto a max. single dose of 1gm. Prepn: May not be available.</p>
        </div><!-- collapsible -->
  

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Misc. Hypnotics" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Misc. Hypnotics   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  PROMETHAZINE </h3>
          <p>  PROMETHAZINE HCl : Tablet/Elixir/
Injection.<br><br>


<strong>Ind:</strong> Sedation in children and adults, nasal allergy, urticaria and other allergic disorders.<br><br>

<strong>S/E:</strong> Drowsiness, dryness of mouth, g.i. disturbances. Caution: As patient is affected with sedation and drowsiness, should not drive or operate machinery requiring alertness. Alcohol and other CNS depressants can potentiate the sedative effect of antihistaminics and patient should be warned of these effects.<br><br>

<strong>Dosage & admin: Adult:</strong> By mouth, 10-20mg, 2 or 3 times daily. By injection 25-50mg. by deep i.m. or slow i.v. inj. after dilution.
<br><br>

<strong>Child:</strong> By mouth, under 6 months, not recommended; 6 months-1 year, 5-10mg, 1-5 yrs. 5 to 15mg; over 5yrs. 10-25mg. If two doses in 24 hrs are reqd. use lower amount stated. By injection, under 5 yrs not recommended; over 5 yrs. 6.25-12.50mg by deep i.m. injection.<br><br>

<strong>Prepn:</strong> See in the section of anti-allergic drugs.  </p>
        </div><!-- collapsible -->
  

      </div><!-- collapsible-set -->

          <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ZOPICLONE  </h3>
          <p>ZOPICLONE: Tablet
Zopiclone is a cyclopyrrolone product.<br><br>

<strong>Mode of action:</strong> Zopiclone exhibits
anticonvulsant, muscle relaxant and
hypnosedative properties in animals. It recognizes specifically, and with high affinity, binding sites that belong to the GABAA - benzodiazepine chloride channel macromolecular receptor complex and increases the chloride ion secretion. Ind: Short-term use for the treatment of insomnia (no longer than four weeks duration). As with other hypnotics, long-term continuous treatment is not recommended.<br><br>

<strong>C/I:</strong> Use in pregnancy should be avoided if a safer alternative is known. Zopiclone is excreted in breast milk, so use in nursing mother must be avoided.<br><br>

<strong>Caution:</strong> Hepatic impairment; pregnancy and breast-feeding; elderly; history of drug abuse, psychiatric illness; avoid prolonged use (and abrupt withdrawal thereafter).
Driving- drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.
<br><br>

<strong>S/E:</strong> Bitter or metallic taste; gastro-intestinal disturbances including nausea and vomiting; irritability, confusion, depressed mood; drowsiness, dizziness, lightheadedness, and incoordination on next day; dependence; rarely urticaria and rashes; hallucinations, amnesia, and behavioural disturbances (including aggression) reported.<br><br>

<strong>Dosage:</strong> 7.5mg at bedtime increased to 15mg in severe insomnia; Elderly, initially 3.75mg at bedtime; Child not recommended. <br><br>

<strong>Drug Inter:</strong> Patients should be cautioned against the simultaneous ingestion of zopiclone and alcohol or other CNS depressant drugs because of possible additive effects.</p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>IMOVANE Tab. Sanofi Aventis</h3>
    <p>Zopiclone 7.5mg/tablet. 30's pack: 227.70 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->

          <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ESZOPICLONE  </h3>
          <p>  ESZOPICLONE: Tablet
Eszopiclone is a nonbenzodiazepine hypnotic, a
pyrrolopyrazine derivative of the cyclopyrrolone class with a chemical structure unrelated to pyrazolopyrimidines, imidazopyridines, benzodiazepines, barbiturates, or other drugs with known hypnotic properties. It is available as eszopiclone INN 1mg & 2mg film-coated tablet. Mode of action: The precise mechanism of action of eszopiclone as a hypnotic is unknown, but its effect is believed to result from its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.<br><br>

<strong>Ind:</strong> Eszopiclone is used for the treatment of insomnia (chronic insomnia, transient insomnia) characterized by difficulty falling asleep and/or difficulty maintaining sleep during the night and early morning.<br><br>

<strong>C/I:</strong> Known case of hypersensitivity to eszopiclone.<br><br>

 <strong>S/E:</strong> The most common side effects are: drowsiness, dizziness, lightheadedness, difficulty with coordination.<br><br>

<strong>Precautions:</strong> No need of specific precaution to be exercised.<br><br>

<strong>Pregnancy & lactation:</strong> There are no adequate and well-controlled studies of eszopiclone in pregnant women. So, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether eszopiclone is excreted in human milk. So, caution should be exercised when eszopiclone is administered to a nursing woman. <br>

<strong>Dosage & admin: </strong>The recommended starting dose of eszopiclone for most non-elderly adults is 2mg immediately before bedtime. Dosing can be initiated at or raised to 3mg if clinically indicated. The recommended starting dose of eszopiclone for elderly patients whose primary complaint is difficulty falling asleep is 1mg immediately before bedtime. In these patients, the dose may be increased to 2mg if clinically indicated. For elderly patients whose primary complaint is difficulty staying asleep, the recommended dose is 2mg immediately before bedtime. Or, as directed by the physician.<br><br>

 <strong>Drug inter:</strong> Alcohol (which causes sedation) and drugs that have sedating effects should not be used with eszopiclone since their sedating effects, when added to those of eszopiclone, may cause excessive sedation.  </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ESZO Tab. Apex</h3>
    <p>Eszopiclone INN 1mg & 2mg/tablet (f.c). 1mg x 50's pack: 100.00 MRP 2mg x 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>S-CLON Tab. Beximco</h3>
    <p>Eszopiclone INN 1mg & 2mg/tablet (f.c). 1mg x 60's pack: 120.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SLEEPIL Tab. Aristopharma</h3>
    <p>Eszopiclone INN 1mg & 2mg/tablet (f.c). 1mg x 50's pack: 100.00 MRP 2mg x 30's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SLEEPON Tab. Silva</h3>
    <p>Eszopiclone INN 1mg & 2mg/tablet (f.c). 1mg x 50's pack: 100.00 MRP 2mg x 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SLEEPWEL Tab. Popular</h3>
    <p>Eszopiclone INN 1mg & 2mg/tablet (f.c). 1mg x 30's pack: 60.00 IP
2mg x 30's pack: 90.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SOMINEX Tab. SK+F</h3>
    <p>Eszopiclone INN 1mg & 2mg/tablet (f.c). 1mg x 50's pack: 100.00 MRP
2mg x 30's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SONO Tab. Acme</h3>
    <p>Eszopiclone INN 1mg & 2mg/tablet (f.c). 1mg x 30's pack: 60.00 MRP
2mg x 30's pack: 90.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZOPILONE Tab. Incepta</h3>
    <p>Eszopiclone INN 1mg & 2mg/tablet (f.c).
1mg x 50's pack: 100.00 MRP 2mg x 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->



      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Sedative" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Sedative & Tranquillisers: Anxiolytics  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

<ul data-role="listview" data-inset="true" data-theme="b">        
     
       
        <li><a href="#DIAZEPAM">DIAZEPAM</a></li> 
        <li><a href="#ALPRAZOLAM">ALPRAZOLAM</a></li> 
        <li><a href="#BROMAZEPAM">BROMAZEPAM</a></li> 
        <li><a href="#CLOBAZAM">CLOBAZAM</a></li>
        <li><a href="#LORAZEPAM">LORAZEPAM</a></li>
          
</ul>
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="DIAZEPAM" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> DIAZEPAM   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> DIAZEPAM  </h3>
          <p> DIAZEPAM: Tablet/Syrup/Injection/Suppository. Ind: Anxiety, insomnia, night terrors in children; adjunctive treatement of acute alcohol withdrawal; epilepsy & other convulsions.<br><br>

<strong>C/I:</strong> Acute pulmonary insufficiency, respiratory depression.<br>

<strong>S/E:</strong> Drowsiness, dizziness, ataxia (particularly in elderly) occasionally confusion, dry mouth; resp. depression on i.v.inj. Pain & Thrombophlebitis. Caution: Neuromuscular disorders, closed angle glaucoma, resp. disease, late pregnancy, nursing mothers; reduce dosages in elderly & debiliated patients, liver disease, renal impairment; patient's ability to avoid alcohol & other CNS depressants; avoid abrupt withdrawal.<br>

<strong>Dosage & admin:</strong> By mouth: Anxiety, 2mg, 3 times daily, increased in severe anxiety to 15- 30mg. daily in divided doses. Child, 1-5mg. daily in divided doses. Insomnia, 5-30 mg. at bedtime.
By i.m or slow i.v injection: For severe anxiety, control of acute panic attack and acute alcoholic withdrawal, 10mg (at a rate of not more than 5mg/min.) repeat if necessary 4 hourly. In epilepsy- see under anticonvulsant drugs.
By rectum as suppositories: When oral route not appropriate, apply 10mg suppository 1 to 3 times daily.   </p>
        </div><!-- collapsible -->
  
    <div data-role="collapsible"> <!-- collapsible -->
          <h3>  DIAZIMET Tab. Medimet </h3>
          <p> Diazepam 5mg/tablet. 100's pack: 22.00 MRP   </p>
    </div><!-- collapsible -->  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EASIUM Tab. Opsonin</h3>
    <p>Diazepam 5mg/tablet. 100's pack: 21.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EASIUM Inj. Opsonin</h3>
    <p>Diazepam 10mg in 2m1 ampoule: injection 5 amps pack: 15.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EASIUM Suppo. Opsonin</h3>
    <p>Diazepam 10mg/suppository.
10's pack: 30.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EVALIN Tab. Aristopharma</h3>
    <p>Diazepam 5mg/tablet 500's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>G-DIAZEPAM Tab. Gonoshasthaya</h3>
    <p>Diazepam 5mg/tablet. 100's pot: 12.00 MRP 100's strip: 20.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>G-DIAZEPAM Inj. Gonoshasthaya</h3>
    <p>Diazepam 10mg in 2m1 ampoule: injection 10 amps pack: 36.70 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ORINIL Tab. Doctors</h3>
    <p>Diazepam 5mg/tablet 100's pack: 21.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PHARMAPAM Tab. Pharmadesh</h3>
    <p>Diazepam 5mg/tablet 250's pack: 62.50 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>RELAXEN Tab. Sonear</h3>
    <p>Diazepam 5mg/tablet 100's pack: 22.00 MRP
500's pack: 110.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ROZAM Tab. Navana</h3>
    <p>Diazepam 5mg/tablet. 200's pack: 42.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDAPEN Tab. Amico</h3>
    <p>Diazepam 5mg/tablet. 100's pack: 21.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDATAB Tab. Supreme</h3>
    <p>Diazepam 5mg/tablet. 100's pack: 22.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDEX Tab. Jalalabad</h3>
    <p>Diazepam 5mg/tablet. 100's pack: 21.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDIL Tab. Square</h3>
    <p>Diazepam 5mg/tablet 500's pack: 110.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDIL Inj. Square Diazepam</h3>
    <p>10mg in 2ml ampoule: injection 10 amps pack: 30.30 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDIUM Tab. Salton</h3>
    <p>Diazepam 5mg/tablet 100's pack: 21.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDULIN Tab. Jayson</h3>
    <p>Diazepam 5mg/tablet 100's pack: 21.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDUXEN Tab. Ambee</h3>
    <p>Diazepam 5mg/tablet 200's pack: 44.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEDUXEN Inj. Ambee</h3>
    <p>Diazepam 10mg in 2m1 ampoule: injection 10 amps pack: 35.90 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="ALPRAZOLAM" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> ALPRAZOLAM   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ALPRAZOLAM: Tablet  </h3>
          <p>  It is a drug of benzodiazepine group, used as an anxiolytic.<br><br>

<strong>Ind:</strong> Alprazolam has antianxiety properties, effective in treatment of generalized anxiety disorders, panic anxiety, agoraphobia, situational anxiety, anxiety depression syndrome, cardiac neurosis & anxiety associated with medical conditions & depressive disorders.<br><br>

<strong>C/I:</strong> Sensitivity to the drug; acute narrow angle glaucoma; pregnancy & lactation.<br><br>

<strong>Warning:</strong> Patients should avoid- driving & operation machinery or doing jobs requiring complete mental alertness, simultaneous ingestion of alcohol & other CNS depressant drugs like psychotropics, anticonvulsants etc.<br><br>

<strong>Precautions:</strong> The dosage of alprazolam tablets should be withdrawn gradually, since withdrawal seizures have been reported upon abrupt withdrawal. Addiction-prone individuals should be under careful surveillance.<br><br>

<strong>S/E:</strong> Side effects are generally observed at the beginning of therapy & usually disappear with continued medication
In usual course, the common side effects are an extension of the pharmacological activity e.g drowsiness, light headedness & dry mouth, nausea, vomiting, allergy,
tachycardia. Paradoxical reactions such as agitation may rarely occur.<br><br>

<strong>Dosage & admin:</strong> For anxiety- 0.25-0.5mg 3 times daily (maximum dose 4mg daily).
For panic disorder of agoraphobia- 0.5mg 3 times daily after meals for 2 days and then the dose may be increased by adding 0.5mg to 1mg of the existing dose every 2-3 days until 2mg thrice daily is given; usual dose 3-6mg daily.
Dosage equivalence- 0.5mg of alprazolam is equivalent to 5mg of diazepam.  </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ALPAM Tab. Asiatic</h3>
    <p>Alprazolam 0.25mg & 0.5mg/tablet. 0.25mg x 100's pack: 100.00 MRP 0.5mg x 50's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ALPRAX Tab. Opsonin</h3>
    <p>Alprazolam 0.25mg & 0.5mg/tablet. 0.25mg x 100's pack: 100.00 MRP 0.5mg x 100's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>XANAX Tab. Navana</h3>
    <p>Alprazolam 0.25mg & 0.5mg/tablet. 0.25mg x 100's pack: 100.00 IP 0.5mg x 50's pack: 100.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZOLAX Tab. Beximco</h3>
    <p>Alprazolam 0.25mg & 0.5mg/tablet. 0.25mg x 100's pack: 100.00 IP 0.5mg x 100's pack: 175.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZOLIUM Tab. Incepta</h3>
    <p>Alprazolam 0.25mg & 0.5mg/tablet. 0.25mg x 100's pack: 100.00 MRP 0.5mg x 100's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="BROMAZEPAM" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> BROMAZEPAM   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> BROMAZEPAM  </h3>
          <p>  BROMAZEPAM: Tablet
Ind: Anxiety (short-term use).<br>
C/I; S/E; Caution: See under diazepam.<br>
<strong>Dosage & admin:</strong> Adult: 3-18mg daily in divided doses; elderly (or debilitated) half adult dose; max. (in exceptional circumstances in hospital patients) 60mg daily in divided doses. Child, not recommended.  </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANCOTIL Tab. Rangs Pharma</h3>
    <p>Bromazepam 3mg/tablet 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANXOPAM Tab. Popular</h3>
    <p>Bromazepam 3mg/tablet 30's pack: 90.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>BOPAM Tab. Opsonin </h3>
    <p>Bromazepam 3mg/tablet 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>BROMAZEP Tab. Orion</h3>
    <p>Bromazepam 3mg/tablet 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>BRONIUM Tab. Doctor's</h3>
    <p>Bromazepam 3mg/tablet 50's pack: 125.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>BROZEP Tab. Alco Pharma</h3>
    <p>Bromazepam 3mg/tablet 100's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LATEN Tab. Supreme</h3>
    <p>Bromazepam 3mg/tablet 30's pack: 75.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LAXONIL Tab. Rephco</h3>
    <p>Bromazepam 3mg/tablet 30's pack: 60.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LAXYL Tab. Square</h3>
    <p>Bromazepam 3mg/tablet 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LEXOTANIL Tab. Roche</h3>
    <p>Bromazepam 3mg/tablet 50's pack: 275.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MAPEZ Tab. Kumudini</h3>
    <p>Bromazepam 3mg/tablet 50's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NIGHTUS Tab. Beximco</h3>
    <p>Bromazepam 3mg/tablet 100's pack: 300.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NORRY Tab. Renata</h3>
    <p>Bromazepam 3mg/tablet 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="CLOBAZAM" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> CLOBAZAM   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CLOBAZAM  </h3>
          <p> CLOBAZAM: Tablet/Capsule<br>
Ind: Anxiety, tension, agitation.<br>
C/I; S/E; Caution: See under Diazepam. Adult: Elderly, 20mg; others, 20-30mg. Both daily in divided doses or as a single dose at night. Max. 60mg daily.<br>
Child: Under 3 years, not rcommended; 3-12 years, upto half adult dose.   </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>EBAZAM Tab. Edruc</h3>
    <p>Clobazam 10mg/tablet 100's pack: 270.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EPSON Tab. Zenith</h3>
    <p>Clobazam 10mg/tablet 100's pack:280.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FRISIUM Tab. Sanofi Aventis</h3>
    <p>Clobazam 10mg/tablet 100's pack: 354.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>KEOLAX Tab. Beximco</h3>
    <p>Clobazam 10mg/tablet. 100's pack: 275.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NEBIUM Tab. Globe</h3>
    <p>Clobazam 10mg/tablet. 100's pack: 255.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NOANXIT Tab. Rephco</h3>
    <p>Clobazam 10mg/tablet. 50's pack: 160.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PREZIUM Tab. Nipa</h3>
    <p>Clobazam 10mg/tablet. 100's pack: 250.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PROCALM Tab. Chemico</h3>
    <p>Clobazam 10mg/tablet. 100's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ROBAZAM Tab. Rasa</h3>
    <p>Clobazam 10mg/tablet. 100's pack: 280.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TENSNIL Tab. Alco Pharma</h3>
    <p>Clobazam 10mg/tablet. 100's pack: 255.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TRANQUIL Tab. Ibn Sina</h3>
    <p>Clobazam 10mg/tablet. 100's pack: 253.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>VENIUM Tab. Hudson</h3>
    <p>Clobazam 10mg/tablet. 100's pack: 270.00 MRP</p>   
</div><!-- collapsible -->



      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="LORAZEPAM" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> LORAZEPAM   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> LORAZEPAM  </h3>
          <p> LOZICUM Tab. Incepta Lorazepam USP 1mg/tablet.<br><br>

<strong>Mode of action:</strong> It is a short-acting tranqulizer anxiolytic drug belonging to
benzodiazepine group. It is an agonist at benzodiazepine receptors in the CNS. It exerts a depressant action on the CNS. which may be mediated by potentiating the inhibitory actions of GABA (gamma amino butyric acid) in the CNS. This will result in diminution of the ascending activating systems, particularly the serotonergic and noradrenergic pathway from brain stem or the mid-brain to the cerebral cortex.<br><br>

<strong>Ind:</strong> Lorazepam is used for the treatment of anxiety states, including anxiety associated with phobic & obsessional states, psychosomatic, organic or psychotic illness, insomnia associated with anxiety, nervousness, restlessness, nausea and vomiting related to chemotherapy and anticonvulsants, and as a premedicant before dental or general surgery or prior to investigative procedures where there may be discomfort.<br><br>

<strong>C/I; S/E; Caution:</strong> See under Diazepam. <br><br><strong></strong>

<strong>Dosage & admin:</strong> Lorazepma is administered orally.
For optimal result dose, frequency of administration and duration of therapy should be individualized according to patient's response.
The usual range of dosage is 2-7mg/day given in divided doses; the largest dose being taken before bedtime, but the largest dosage may vary from 1 to 10mg/day. For anxiety, most patients require an initial dose of 2-3mg/day given b.i.d. or t.i.d.
For elderly or debilitated patients, an initial dosage of 1-2mg/day in divided doses is recommended, to be adjusted as needed and tolerated. For insomnia 1-2mg before bedtime and as premedicant 1-2mg the night before surgery and 1 to 2 hour before surgery. Lorazepma is not recommended in anxiety states in children but may be used as premedicant before surgery at a dose of 0.05mg/kg in children aged 5 to 13 years. When needed, the dosage of lorazepam should be increased gradually to avoid adverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime. 1mg x 100's pack: 200.00 MRP   </p>
        </div><!-- collapsible -->
  

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->





<!-- /................page............................ -->



<div data-role="page" id="Antipsychotic drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>Antipsychotic drugs    </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      
<ul data-role="listview" data-inset="true" data-theme="b">        
     
       
    <li><a href="#Phenothiazine">Phenothiazine derivatives</a></li> 
    <li><a href="#related drugs">Phenothiazine related drugs</a></li>
    <li><a href="#Butyrophenone">Butyrophenone: Haloperidol</a></li>
          
</ul>
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="Phenothiazine" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Phenothiazine derivatives  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CHLORPROMAZINE HCl  </h3>
          <p> CHLORPROMAZINE HCI: Tablet/
Syrup/Injection/Suppository.<br>

<strong>Ind:</strong> Schizophrenia and related psychoses, tranquillization and emergency control in behavioral disturbances, psychoneuroses; induction of hypothermia; emesis & intractable hiccup; adjunctive treatment of alcohol or drug withdrawal or terminal disease.
<br><br>

<strong>C/I:</strong> Comatose state; poisoning caused by CNS depressants; bone-marrow depression.<br><br>

<strong>S/E:</strong> Extrapyramidal symptoms (which can be reversed by dose reduction or anticholinergic agents) and on, prolonged administration, occasionally tardive dyskinesia; hypothermia, drowsiness, apathy, pallor, nightmares, insomnia, depression and more rarely agitation; anticholinergic symptoms e.g. dry mouth, constipation, difficulty with micturition and blurred vision; hypotension, cardiac arrhythmias. <br><br>

<strong>Cautions:</strong> Liver and renal dysfunction; cardiovascular disease; parkinsonism, epilepsy; pregnancy, lactation; concurrent admn. of CNS depressants & guanethi-dine; past history of jaundice, leucopenia.<br><br>

<strong>Dosage & admin:</strong> Adult, initially 25mg 3 times daily increasing if necessary by 25mg daily. Maintenance, usually 75-300mg daily. Child, upto 5 years 5-10mg 3 times daily; 5-12 yrs. third to half adult dose.<br>
<strong>By injection:</strong> Adult, 25-50mg i.m. as a single dose or repeated if necessary 6 to 8 hourly. Follow as soon as possible by oral therapy. Child, severe cases only, use equv. oral dose by i.m. injection.   </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LARGACTIL Tab. Sanofi Aventis</h3>
    <p>Chlorpromazine hydrochlor. 25mg, 50mg & 100mg/tablet.25mg x 500's pack: 205.00 MRP100mg x 100's pack: 101.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LARGACTIL Inj. Sanofi Aventis</h3>
    <p>Chlorpromazine hydrochlor. 50mg in 2m1 ampoule: injection 10 amps pack: 41.20 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OPSONIL Tab. Opsonin</h3>
    <p>Chlorpromazine hydrochlor. 50mg & 100mg/tablet. 50mg x 100's pack: 60.00 MRP 100mg x 100's pack: 100.00 MRP</p>   
</div><!-- collapsible -->
</div><!-- collapsible-set -->



  <div data-role="collapsible-set" data-theme="a">
    <div data-role="collapsible"> <!-- collapsible -->
      <h3> FLUPHENAZINE  </h3>
      <p>  FLUPHENAZINE DECANOATE: Injection <br><br>

     <strong> Ind:</strong> Maintenance treatement of psychotic disorders particularly schizophrenia.<br><br>

      <strong>C/I:</strong> Phaeochromocytoma; marked cerebral atherosclerosis; renal or hepatic failure; cardiac insufficiency; anxiety & tension states or geriatric confusion and agitation.<br><br>

      <strong>S/E:</strong> Extrapyramidal symptoms occur more frequently (particularly in elderly females) usually a few hours after dose has been adminstered and continued for 2 days. See also under clopenthixol.<br><br>

      <strong>Cautions:</strong> Hepatic, respiratory and cardiac diseases, cardiac arrhythmias, thyrotoxicosis, epilepsy, glaucoma, hypothyroidism, myasthenia gravis, prostatic hypertrophy, pregnancy lactation. 

      <strong>Dosage & admin: Adult:</strong> Initially 12.5mg (6.25mg elderly) by deep i.m. inj. into gluteal region to test susceptibility to extrapyramidal reactions, then adjust dose according to response. Usual dosage range, 12.5mg-100mg every 2-5 weeks, starting 4 to 7 days after test. Child: Not recommended.  </p>
    </div><!-- collapsible -->
  

    <div data-role="collapsible"> 
      <h3>FLUPHENAZINE DECANOATE-Rotex Inj. Rotex Medica/City Overseas</h3>
      <p>Fluphenazine decanoate 25mg/ml: 1m1 ampoule & 10m1 vial: injection.
      1m1 amp x 10's pack: 960.00 TP
      10ml vial x l's pack: 645.00 TP</p>
    </div>

      <div data-role="collapsible"> <!-- collapsible -->
          <h3>MODECATE Inj. Squibb/Kapricorn</h3>
          <p>Fluphenazine decanoate 25mg/1ml ampoule: injection.
          1m1 amp: 116.55 MRP</p>   
      </div><!-- collapsible -->
  </div><!-- collapsible-set -->



<div data-role="collapsible-set" data-theme="b">
    <div data-role="collapsible"> <!-- collapsible -->
      <h3>  TRIFLUOPERAZINE </h3>
      <p>  TRIFLUOPERAZINE: Tablet/Syrup/ Injection <br><br>

      <strong>Ind:</strong> Schizophrenia, psychoses due to organic brain damage, behavioral disorder and toxic psychoses. Anxiety, depressive symptoms secondary to anxiety. Senile agitation and confusion. Nausea & vomiting.<br><br>

<strong>C/I; S/E; Caution:</strong> See under haloperidol. <br><br>

<strong>Dose:</strong> By mouth: Adult, Psychoses- initially
10mg daily in single or divided doses increasing after 7 days to 15mg daily. If reqd. increase further by 5mg at 3 day intervals, then reduce to maintenance dose 10mg daily. Anxiety (Psychoneuroses)- 2 to 6mg daily in divided or single doses. Child, Psychoses- under 12 yrs. upto 5mg in divided doses, then adjust according to the response. Anxiety- under 3 yrs. not recommended; 3-5 yrs. 1 mg daily in divided doses ( as syp.); 6-12 yrs. upto 4mg daily (as syp.) in divided doses.
By Injection: Adult, 1-3mg daily by i.m. inj. max. 6mg daily. Child, 1mg/20kg body-wt. daily by i.m. inj. in divided doses.  </p>
    </div><!-- collapsible -->
      
    <div data-role="collapsible"> <!-- collapsible -->
        <h3>SIZONIL Tab. Healthcare</h3>
        <p>Trifluoperazine dihydrochlor. 1mg & 5mg/tablet 1mg x 100's pack: 175.00 MRP 5mg x 100's pack: 300.00 MRP</p>   
    </div><!-- collapsible -->

    <div data-role="collapsible"> <!-- collapsible -->
        <h3>STELA Tab. Delta</h3>
        <p>Trifluoperazine dihydrochlor. 1mg & 5mg/tablet 1mg x 50's pack: 75.00 MRP
    5mg x 50's pack: 125.00 MRP</p>   
    </div><!-- collapsible -->

    <div data-role="collapsible"> <!-- collapsible -->
        <h3>TELAZINE Tab. SK+F</h3>
        <p>Trifluoperazine dihydrochlor. 1mg & 5mg/tablet 1mg x 100's pack: 150.00 MRP 5mg x 100's pack: 250.00 MRP</p>   
    </div><!-- collapsible -->
</div><!-- collapsible-set -->
   
    
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="related drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Phenothiazine related drugs  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

    <ul data-role="listview" data-inset="true" data-theme="b">        
       
        <li><a href="#CLOZAPINE">CLOZAPINE</a></li> 
        <li><a href="#FLUPENTHIXOL">FLUPENTHIXOL</a></li> 
        <li><a href="#MELITRACIN">FLUPENTHIXOL + MELITRACIN</a></li>
        <li><a href="#ZUCLOPENTHIXOL">ZUCLOPENTHIXOL</a></li>
          
	</ul>
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="CLOZAPINE" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> CLOZAPINE   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>CLOZAPINE   </h3>
          <p>  CLOZAPINE: Tablet<br><br>

<strong>Ind:</strong> Schizophrenia in patients unresponsive to, or intolerant of, conventional antipsychotic drugs. <br><br>

<strong>C/I:</strong> Severe cardiac disease; history of drug- induced neutropenia/ agranulocy-tosis; bone marrow disorders; alcoholic and toxic psychoses; history of circulatory collapse or paralytic ileus; drug intoxication; coma or severe CNS
depression; uncontrolled epilepsy; pregnancy and breast-feeding.<br><br>

<strong>S/E:</strong> See under chlorpromazine hydrochloride but less sedating and high incidence of antimuscarinic symptoms; extrapyramidal symptoms may occur less frequently; neutropenia and potentially fatal agranulocytosis, fever (evaluate to rule out underlying infection or agranulocytosis), headache and dizziness, hypersalivation, urinary incontinence, priapism, pericarditis and myocarditis; and deliruim; hypotension- rarely circulatory collapse with cardiac and respiratory arrest (but hypertension also reported), also nausea and vomiting; hyperglycaemia reported. <br><br>

<strong>Cautions:</strong> See under chlorpromzine hydrochloride; initiation must be in hospital in- patients, and leucocyte and differential blood counts must be normal before treatment and must be monitored weekly for first 18 weeks then at least fortnightly- patients who have received clozapine for a year or more and have stable blood counts may have their blood monitoring reduced to every 4 weeks; avoid drugs which depress leucopoiesis such as co-trimoxazole and carbamaze-pine (and taper off conventional neuroleptic before starting); withdraw treatment if leucocyte count falls below 3000/mm3; patients should report any infections.<br><br>

<strong>Withdrawal:</strong> On planned withdrawal reduce dose gradually over 1-2 weeks to avoid risk of rebound psychosis. If abrupt withdrawal necessary observe patient carefully.<br><br>

<strong>Dosage & admin:</strong> (Close medical supervision on initiation- risk of collapse due to hypotension) 12.5mg once or twice on first day then 25-50mg on second day, then slowly increased (if well tolerated) in steps of 25-50mg over 14-21 days to 300mg daily in divided doses (larger dose at night, up to 200mg daily may be taken as a single dose at bed time); if necessary may be further increased in steps of 50-100mg once (preferably) or twice weekly; usual antipsychotic dose 200-450mg daily (max. 900mg daily); subsequent adjustment to usual maintenance of 150-300mg.<br><br>

<strong>Child not recommended.</strong><br><br>

Elderly and special risk groups: in elderly, 12.5mg once on first day- subsequent adjustments restricted to 25mg daily; in cardiovascular disease, hepatic or
renal impairment or if history of epilepsy, 12.5mg on first day-subsequent adjustments slowly and in small steps (if epileptic seizures- suspend for 24 hours and resume at lower dose); restarting after interval of more than 2 days, 12.5mg once or twice on first day (but may be feasible to increase more quickly than on initiation)- unless previous respiratory or cardiac arrest with initial dosing in which case extreme caution.  </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SENSIPIN Tab. Beximco</h3>
    <p>Clozapine 25mg/tablet.
25mg x 30's pack: 75.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SIZOPIN Tab. Sun Pharma</h3>
    <p>Clozapine 25mg & 100mg/tablet. 25mg x 50's pack: 115.00 MRP 100mg x 50's pack: 421.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->



<div data-role="page" id="FLUPENTHIXOL" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>FLUPENTHIXOL    </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> FLUPENTHIXOL  </h3>
          <p>  FLUPENTHIXOL: Tablet/Injection<br><br>
Flupenthixol- a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses.<br><br>

<strong>Ind:</strong> Psychoses, schizophrenia except manic
phase and psychomotor hyperactivity; maintenance in schizophrenia & related psychoses. Depression.<br><br>

<strong>C/I:</strong> Intolerance to neuroleptic drugs; excitable or over active patient; parkinsonism; severe atherosclerosis; senile confusional state; advanced renal, hepatic or cardiovascular disease.<br><br>

<strong>S/E:</strong> Extrapyramidal symptoms occur frequently (1-3 days after administration & continue for 5 days). Aggregation or agitation may appear (in this stage, should be replaced by another drug). Also see under chlorpromazine.<br><br>

<strong>Caution:</strong> Renal & hepatic impairment; atherosclerosis; pregnancy.<br><br>

<strong>Dosage & admin:</strong>
Flupenthixol decanoate: By i.m injection- initially use test does 20mg; then 100-200mg by deep i.m injection (better gluteal muscle) after 5 to 10 days; repeat usually every 2 to 4 weeks maximum 400mg weekly.<br><br>

<strong>Child:</strong> Not recommended.
Flupenthixol dihydrochloride: Adult, 3-9mg
twice daily; maximum 18mg daily. Child: Not recommended.  </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible">
<h3>FLUANXOL Tab. Lundbeck/Lilac</h3> 
<p>Flupenthixol dihydrochloride 0.5mg & 1mg/tablet. 0.5mg x 100's pack: 418.00 MRP
1mg x 50's pack: 337.00 MRP</p>
</div>

<div data-role="collapsible">
<h3>FLUANXOL Depot Inj. Lundbeck/ Lilac </h3>
<p>Flupenthixol decanoate 20mg/ml & 40mg/2ml ampoule: injection
1ml amp x 10's pack: 2141.00 MRP
2ml amp x 10's pack: 3535.00 MRP</p>
</div>

<div data-role="collapsible">
<h3>LUPENTIL Tab. Healthcare</h3>
<p>Flupenthixol dihydrochloride 1mg/tablet.
1mg x 50's pack: 225.00 MRP</p>
</div>

<div data-role="collapsible">
<h3>SENTIX Tab. SK+F</h3>
<p>Flupenthixol dihydrochloride 0.5mg & 1mg/tablet. 0.5mg x 50's pack: 150.00 MRP
1mg x 30's pack: 150.00 MRP</p>
</div>
      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="MELITRACIN" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> FLUPENTHIXOL + MELITRACIN   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>FLUPENTHIXOL+ MELITRACIN: Tablet   </h3>
          <p>  Flupenthixol- a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and melitracen- a bipolar thymoleptic with activating properties in low doses.
In combination the compounds render a preparation with antidepressant, anxiolytic and activating properties, but does not seem to influence the pharmacokinetic properties of the individual compounds.<br><br>

<strong>Ind:</strong> Psychoses, schizophrenia except manic phase and psychomotor hyperactivity. Maintenance in schizophrenia & related psychoses.
<br><br>

<strong>C/I; S/E; Caution: </strong>See above under the text of 'flupenthixol'.<br><br>

<strong>Dosage & admin:</strong> Flupenthixol + melitracen: Adult, usually 2 tablets daily divided in morning and evening doses. In severe cases, morning dose may be increased to 2 tablets. Elderly, 1 tablet in the morning; maintenance, usually 1 tablet in the morning.<br><br>
<strong>Child: Not recommended.</strong>
  </p>
        </div><!-- collapsible -->
  

   
<div data-role="collapsible"> <!-- collapsible -->
    <h3>ADELAX Tab. ACI</h3>
    <p>Flupenthixol dihydrochloride INN equivalent to 0.5mg flupenthixol & melitracen hydrochloride INN equivalent to 10mg melitracen/tablet. 50's pack: 175.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANFREE Tab. Aristopharma</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANGENTA Tab. Healthcare</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANZET Tab. Popular</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 175.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>BENZIT Tab. Bio-pharma</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.100's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DELETA Tab. General</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DEPRESIL Tab. Rangs Pharma</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 162.50 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DEXIT Tab. UniHealth</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DICONTEN Tab. Drug Inter.</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DORMIR Tab. Somatec</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.
100's pack: 350.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EXUTEN Tab. Pharmadesh</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.
30's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FEMANOL Tab. Chemico</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FLUXIT Tab. Opsonin</h3>
    <p>50's pack: 162.50 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FRENXIT Tab. Beximco</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.
100's pack: 350.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MIXIT Tab. Apex</h3>
    <p>50's pack: 160.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NEOXIT Tab. Novo Healthcare</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.30's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PENXIT Tab. Peoples</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>REMOOD Tab. Ibn Sina</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>RENXIT Tab. Renata Flupenthixol</h3>
    <p>dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet. 50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SENSIT Tab. SK+F Flupenthixol</h3>
    <p>dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet. 50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TENAXIT Tab. Incepta Flupenthixol</h3>
    <p>dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet. 50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TENSA Tab. SAPL Flupenthixol</h3>
    <p>dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet. 50's pack: 175.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>THENXET Tab. Pacific</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.
100's pack: 400.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>U4 Tab. Orion</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.
30's pack: 97.50 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZENXIT Tab. Zenith</h3>
    <p>Flupenthixol dihydrochloride 0.5mg & melitracen hydrochloride 10mg/tablet.
100's pack: 325.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->



    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="ZUCLOPENTHIXOL" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> ZUCLOPENTHIXOL   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CLOPIXOL Tab. Lundbeck/Lilac  </h3>
          <p>  Zuclopenthixol dihydrochloride 10mg/ tablet.<br>
Ind: Psychoses, especially schizophrenia with agitation or aggression.<br>
C/I; S/E; Caution: See under chlorpromazine hydrochloride & flupenthixol; should not be used in apathetic or withdrawn states; avoid in children and in porphyria.<br>
Adult: Initially 20-30mg daily in divided doses. Maintenance, 20-50mg daily; maximum 150mg daily if nacessary.<br>
Child: Not recommended.
100's pack: 980.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  CLOPIXOL Depot Inj. Lundbeck/ Lilac </h3>
          <p>  Zuclopenthixol decanoate 200mg/1ml ampoule: oily injection.<br>
C/I; S/E; Caution: See under Chlorpromazine HCl & Flupenthixol; but less sedating; avoid in children and in porphyria;<br>
Dose: by deep i.m injection into the gluteal muscle, test dose 100mg, then after 7-28 days 100-200mg or more, followed by 200-400mg repeated at intervals of 2-4 weeks, adjusted according to the response; max. 600mg weekly. Child: Not recommended.
1ml amp x 10's pack: 2878.00 MRP  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CLOPIXOL ACUPHASE Inj. Lundbeck  </h3>
          <p>  Zuclopenthixol acetate 50mg/1ml & 100mg/2ml ampoule: injection.<br>
C/I; S/E; Caution: see under Chlorpromazine dihydrochlor. & Flupenthixol; avoid in children and in porphyria; treatment duration should not exceed 2 weeks.<br>
Dose: By deep i.m. injection, 50-150mg (elderly 50-100mg), if necessary repeated after 2-3 days (1 additional dose may be needed 1-2 days after the first injection); max. cumulative dose 400mg per course and max. 4 injections; if
maintenance treatment necessary change to an oral antipsychotic 2-3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate.
1ml amp (50mg) x 5's pack: 970.00 MRP 2ml amp (100mg) x 5's pack:‚Äò 1700.00 MRP  </p>
        </div><!-- collapsible -->
  

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Butyrophenone" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>Butyrophenone: Haloperidol</h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> HALOPERIDOL  </h3>
          <p>   HALOPERIDOL: Tablet/ Liquid/ Injection. <br>
          Ind: Schizophrenia, mania, hypomania. Anxiety. Behavioral disorders in children. Alcohol withdrawlal syndrome & delirium tremens. Nausea, vomiting. Pre-anaesthetic medication. <br>
          <STRONG>C/I; S/E:</STRONG> See under chlorpromazine, but less sedating & fewer antichoinergic or hypotensive symptoms. Rarely blood dyscrasias, alterations in liver function, g.i dsiturbances, and weight loss. Avoid in basal ganglia disease.<br>
Caution: Liver and renal failure, epilepsy, thyrotoxicosis, parkinsonism, pregnancy, severe cardiovascular disease.<br>
By mouth: Adult, Psychoses - initially 0.5-5mg 2 or 3 times daily, increasing gradually as regd. max. 200mg. daily, when control is achieved reduce to maintenance dose (5-10mg daily). Anxiety- 0.5mg twice daily. Child, 0.05mg/ kg body-wt . daily in 2 divided doses.
By injection: Adult, Psychoses - initially 2-30mg i.m, then 5mg 1 to 8 hourly as reqd. Child, as dose by mouth. </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>HALOP Tab. Opsonin</h3>
    <p>Haloperidol 5mg/tablet.
5mg x 50's pack: 25.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>HALOPID Tab. Incepta</h3>
    <p>Haloperidol 5mg/tablet.
5mg x 100's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PELDOL Tab. Gaco</h3>
    <p>Haloperidol 5mg/tablet. 5mg x 100's pack: 50.35 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PERIDOL Tab. Square</h3>
    <p>Haloperidol 5mg/tablet. 5mg x 100's pack: 50.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PERIDOL Inj. Square</h3>
    <p>Haloperidol 5mg/1ml ampoule: injection.
10 amps pack: 108.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PERIGEN Tab. General</h3>
    <p>Haloperidol 5mg/tablet. 5mg x 100's pack: 50.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PEROL Tab. Ambee</h3>
    <p>Haloperidol 5mg/tablet. 5mg x 100's pack: 50.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PEROL Inj. Ambee</h3>
    <p>Haloperidol 5mg/1ml ampoule: injection.
10 amps pack: 100.00 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Atypical antipsychotic drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Atypical antipsychotic drugs  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  ARIPIPRAZOLE </h3>
          <p>  ARIPIPRAZOLE: Tablet
Aripiprazole is an 'atypical antipsychotic drug'. It is available as aripiprazole INN 5mg, 10mg & 15mg film-coated tablet.<br>

Ind: Schizophrenia; acute manic & mixed
episodes associated with bipolar disorder.<br><br>

<strong>C/I:</strong> Aripiprazole is contraindicated in patients with a known hypersensitivity to the product; child, adolescent & breast feeding mothers.<br><br>

<strong>S/E:</strong> Headache, asthenia, fever, nausea, vomiting, constipation, anxiety, insomnia, lightheadedness, somnolence, akathisia, tremor, rhinitis, coughing, rash, postural hypotension, dyspepsia and blurred vision. Neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia and diabetes mellitus have been rarely seen during aripiprazole therapy. <br><br>

<strong>Cautions:</strong> Aripiprazole should be used cautiously in patients at risk of orthostatic hypotension, seizure, patients of cognitive and motor impairment, dysphagia, suicide, patients with concomitant illness, elderly, pregnancy.

 <strong>Pregnancy & lactation:</strong> Aripiprazole should be used in pregnancy only if the potential benefits outweigh the potential risk to the fetus and it is recommended that women receiving aripiprazole should not breast-feed.<br><br>
<strong>Dosage & admin:</strong> Schizophrenia: Usual recommended starting and target dose for aripiprazole is 10mg to 15mg/day administered on a once-a-day schedule without regard to meals. Aripiprazole has been shown to be effective in a dose range of 10mg to 30mg/day. Maximum dosage increase should not be made before 2 weeks.
Acute manic & mixed episodes associated with bipolar disorder: Usual recommended starting dose is 30mg given once a day. Dose may be decreased to 15mg based on assessment of tolerability. Dosage adjustments are not routinely indicated on the basis of age, gender, race or renal or hepatic impairment status. <br><br>

<strong>Drug inter:</strong> Ketoconazole and quinidine increase the AUC of aripiprazole; so, dose should be reduced by half when co-administered with these drugs. Carbamazepine decreases the AUC of aripiprazole; so dose should be doubled while carbamazepine is co-administered.
  </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>ARIPEN Tab. Opsonin</h3>
    <p>Aripiprazole INN 10mg & 15mg/tablet 10mg x 30's pack: 150.00 MRP 15mg x 20's pack: 140.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ARIPRA Tab. Incepta</h3>
    <p>Aripiprazole INN 10mg & 15mg/tablet 10mg x 30's pack: 150.00 MRP
15mg x 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ARIPRAZOLE Tab. General</h3>
    <p>Aripiprazole INN 5mg & 10mg/tablet 5mg x 30's pack: 175.00 MRP 10mg x 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SIZNIL Tab. Orion</h3>
    <p>Aripiprazole INN 10mg/tablet 10mg x 50's pack: 250.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SIZOPRA Tab. Acme</h3>
    <p>Aripiprazole INN 10mg & 15mg/tablet 10mg x 30's pack: 150.00 MRP
15mg x 20's pack: 140.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->

      <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>OLANZAPINE</h3>
          <p>  OLANZAPINE: Tablet
Olanzapine is a thienobenzodiazepine atypical antipsychotic drug.<br><br>

<strong>Mode of action:</strong> Olanzapine is a thienobenzodiazepine atypical antipsychotic drug. It is a competitive antagonist of dopamine, acting by binding to the dopamine receptors (Dl, D2 & D4) in the mesolimbic system of brain. It also has affinity for histamine (H1), serotonin (5-HT2), muscarinic (M1) & adrenergic (al) receptors. <br><br>

<strong>Ind:</strong> Olanzapine is indicated for the management of schizophrenia and other psychotic disorders. It is as effective as haloperidol against positive symptoms & more effective against negative symptoms in short-term & possibly in the long- term.
Olanzapine is also indicated for the short-term treatment of acute manic or mixed episodes of manic depression. It is associated with a relatively low incidence of extrapyramidal disorders and is therefore being used in the treatment of drug- induced psychosis in patients with Parkinson's disease.<br><br>

<strong>C/I:</strong> i. Patients with a known hypersensitivity to the drug ii. Nursing mother iii. Patients with pre- existing CNS depression or coma. iv. Narrow- angle glaucoma v. Paediatric patients (under 18 years of age) vi. Patients with prolactin-dependent tumors.
<br><br>

<strong>S/E:</strong> Frequent (>10%)- somnolence & weight gain. Occasional (1-10%)- dizziness, increased appetite, peripheral oedema, orthostatic hypotension, mild & transient anticholinergic effects like constipation & dry mouth, elevated creatine phosphokinase & hepatic transaminse concentration. Other features are tachycardia, hypertension. Lower incidence- Parkinsonism, akathisia, dystonia. Rare (less than 1%)- photosensitivity, hyper-prolactinaemia, back pain, articular impairment, fever.<br><br>

<strong>Warnings:</strong> Development of neuroleptic malignant syndrome (NMS)- immediate discontinuation of the drug should be considered & development of Tardive Dyskinesia due to long-term use- drug discontinuation or dose reduction should be done. <br><br>

<strong>Precautions:</strong> Patients with known cardiovascular disease (history of myocardial infarction, ischemia, heart failure, conduction abnormalities). Patients with a history of seizure. Patients with hepatic impairment & who are being treated with potentially hepatotoxic drug or in case of elevation of hepatic transaminase. Patients receiving concomitant medication with anticholinergic drugs, being subject to dehydration or exposure to extreme heat. Patients with low leucocyte (neutrophil) count or hypereosinophilic condition. Patient with bone marrow depression/toxicity due to drug, chemotherapy, radiation or illness. Patient with clinically significant prostatic hypertrophy, history of paralytic ileus, diabetes mellitus, hypotension, myasthenia gravis. Patients with impaired kidney function. Elderly patients with dementia.
Patient receiving Olanzapine therapy should be cautious about operating hazardous machinery & motor vehicles.
In pregnancy: When potential benefit justifies the potential risk to the foetus. Patients should notify their physician if they become pregnant or
intend to become pregnant during the therapy (since there is no report to show teratogenicity).<br><br>

 <strong>Dosage & Admin:</strong> Initial dose: 10mg once daily regardless of meal. Daily dosage may subsequently be adjusted on the basis of individual clinical status within the range of 5- 20mg once daily. Doses of 15mg or more daily should be given only after appropriate clinical reassessment.
Metabolism rate of Olanzapine is slower in Female, elderly (over 65 years of age) & non- smokers. So, a lower initial & a more gradual dose schedule should be considered.
Patients with renal impairment- starting dose is 5mg once daily.
Patients with hepatic impairment- starting dose is 5mg once daily & only increased with caution.<br><br>

<strong>Drug Inter:</strong> Drugs which inhibit or act as a substrate to Cytochrome P450 isoenzymes or glucoronyl transferase enzymes (omeprazole, rifampicin, fluvoxamine), Dopamine agonists, antihypertensives & antiarrhythmics (methyl dopa, guanethidine, procainamide, quinidine), tricyclic antidepressants (fluvoxamine. fluoxetine), antiepileptics (phenobarbitone, carbamazepine, phenytoin), Terfenadine.  </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>DEPREX Tab. Square</h3>
    <p>Olanzapine INN 5mg & 10mg/tablet 5mg x 100's pack: 150.00 MRP 10mg x 100's pack: 250.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LOPEZ Tab. General</h3>
    <p>Olanzapine INN 5mg & 10mg/tablet 5mg x 50's pack: 75.00 MRP 10mg x 50's pack: 125.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OLEANZ Tab. Sun Pharma</h3>
    <p>Olanzapine INN 5mg & 10mg/tablet 5mg x 50's pack: 125.00 MRP 10mg x 50's pack: 225.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>XYTREX Tab. ACI</h3>
    <p>Olanzapine INN 10mg/tablet
50's pack: 125.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>QUETIAPINE</h3>
          <p> QUETIAPINE FUMARATE: Tablet
Quetiapine is an atypical psychotropic agent belonging to a chemical class, the dibenzothiazepine derivatives. It is available as quetiapine fumarate INN equivalent to quetiapine 25mg & 100mg/tablet (f.c).<br><br>

<strong>Mode of action:</strong> Quetiapine is an antagonist at multiple neurotransmitter receptors in the brain, such as- serotonin 5HT1A and 5HT2, dopamine D1 and D2, histamine H1, and adrenergic 1 and 2 receptors. Quetiapine has no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors. The actual mechanism of action of quetiapine is unknown. However, it has been proposed that this drug's efficacy in schizophrenia
is mediated through a combination of dopamine D2 and serotonin 5HT2 antagonism. Quetiapine's antagonism of histamine H1 receptors may explain the somnolence and that of adrenergic 1 receptors may explain the orthostatic hypotension observed with this drug.
<br>

<strong>Ind:</strong> Bipolar mania: Quetiapine is indicated for the treatment of acute manic episodes associated with bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex. Schizophrenia: Quetiapine is indicated for the treatment of schizophrenia. <br><br>

<strong>C/I:</strong> Known hypersensitivity to this medication or any of its ingredients.<br><br>


<strong>S/E:</strong> Somnolence, dizziness, dry mouth, constipation, dyspesia, postural hypotension, elevated ALT (SGPT) levels, weight gain. <br><br>

<strong>Precautions:</strong> Neuroleptic malignant syndrome, tardive dyskinesia. Hypotension and syncope, specially during the initial dose titration period. Conduct eye examinations prior to or shortly after starting quetiapine and at 6-month intervals thereafter; doscontinue the drug if clinically significant lens changes are observed. History of seizures. Hypothyroidism. Hyperprolactinemia. Antiemetic effect. Suicide. Use with great caution in moderate or severe hepatic impairments. Renal impairment. Cardiovascular disease. Disruption of body temperature regulation. Hyperglycemia. Lactation (avoid breast-feeding).<br><br>

<strong>Pregnancy & lactation:</strong> Quetiapine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing mothers receiving quetiapine should not breast feed.<br><br>

<strong>Dosage & admin:</strong> Bipolar mania: As monotherapy or as adjunct therapy with other anti-psychotic drugs: 1st day- 50mg twice daily; 2nd day- 100mg twice daily; 3rd day- 150mg twice daily; 4th day- 200mg twice daily; 5th day- 300mg twice daily; 6th day- 400mg twice daily.
Data indicates that the majority of patients responded between 400mg to 800mg/day. The safety of doses above 800mg/day has not been evaluated in clinical trials.<br>

<strong>Schizophrenia:</strong> Usual dose: Quetiapine should generally be administered with an initial dose of 25mg twice daily, with increments of 25- 50mg twice daily or thrice daily on the second and third day, as tolerated, to a target dose range of 300mg to 400mg daily by the 4th day, given twice daily or thrice daily. Further dosage adjustments- if indicated, should generally occur at intervals of not less than 2 days, as steady-state for quetiapine would not be achieved for approximately 1-2 days in the typical patient. When dosage adjustments are necessary, dose increments/decrements of 25- 50mg twice daily are recommended. Most efficacy data with quetiapine were obtained using thrice daily regimens, but in one controlled trial 225mg twice daily was also effective.
Physician who elects to use quetiapine for extended periods should periodically re- evaluate the long-term usefulness of the drug for the individual patient.<br>

<strong>Pediatric use:</strong> The safety and effectiveness of quetiapine in pediatric patients less than 18 years have not been established.
<br><br>

<strong>Drug inter:</strong> May enhance the effects of other centrally acting drugs, certain antihypertensive agents; may antagonize the effects of dopamine agonists ans levodopa. Increased clearance of quetiapine by phenytoin, barbiturates, rifampicin, carbamazepine. Increased concentrations of quetiapine with azole antifungals and macrolide antibiotics.   </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>QUIET Tab. Incepta</h3>
    <p>Quetiapine fumarate INN equivalent to quetiapine 25mg & 100mg/tablet (f.c).
25mg x 50's pack: 150.00 MRP
100mg x 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>QUTIPIN Tab. Sun Pharma</h3>
    <p>Quetiapine fumarate equivalent to quetiapine 25mg & 100mg/tablet (f.c).
25mg x 50's pack: 150.00 MRP
100mg x 50's pack: 425.00 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->

      <div data-role="collapsible-set" data-theme="a	">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>RISPERIDONE   </h3>
          <p>  RISPERIDONE: Tablet<br><br>

Risperidone is an atypical antipsychotic drug. Ind: Schizophrenia including affective symptoms. Other psychotic conditions where positive and/or negative symptoms are prominent. Also, behavioural disturbances in patients with dementia where aggressive symptoms (verbal outbursts, physical violence), activity disturbances (agitation, wandering) or psychotic symptoms are prominent.
<br><br>

<strong>C/I:</strong> Hypersensitivity to the drug.<br><br>

<strong>S/E:</strong> Generally well tolerated. Commonly-
insomnia, agitation, anxiety, headache. Less commonly- somnolence, fatigue, dizziness, impaired concentration, constipation, dyspepsia, nausea/vomiting, abdominal pain, blurred vision, priapism, erectile/ejaculatory dysfunction, orgasmic dysfunction, urinary incontinence, rhinitis, rash, allergic reactions. EPS are usually mild nad reversible. Rarely- neuroleptic malignant syndrome. Occasionally- orthostatic dizziness, hypotension (including orthostatic), tachycardia (including reflex) and hypertension observed. Raised plasma prolactin with associated galactorrhoea, gynaecomastia and menstrual cycle disturbances. Oedema and increased hepatic enzyme levels. A mild fall in neutrophil and/or thrombocyte count has been reported. Rarely- water intoxication with hyponatraemia, tardive dyskinesia, body temperature dysregulation and seizures.<br><br>

<strong>Precautions:</strong> Orthostatic hypotension. Cardiovascular disease. Reduce dose if hypotension. If tardive dyskinesia, consider stopping all antipsychotic durgs. Parkinson's disease. Epilepsy. Advise of potential for weight gain. Advise not to drive or operate machinery if alertness affected.<br><br>

<strong>Pregnancy & lactation:</strong> In pregnancy only if benefits outweigh the risks. In lactation, avoid the drug.
<strong>Dosage: </strong>Adults: Start with 2mg daily in single or two divided doses; may be increased to 4mg/day on the second day. Some patients slower in initiation. Maintain unchanged, or adjust if needed. Most patients benefit from doses of 4-6mg/day, but an optimal response
may be obtained at lower doses. Above 10mg/day may increase extrapyramidal symptoms risk, consider risks vs benefits. Maximum dose 16mg/day.
Elderly, renal & liver disease: Start with 0.5mg b.d; adjust by 0.5mg twice daily to 1-2mg thrice daily.
Behavioural disturbances in patients with dementia: Start with 0.25mg b.d; adjust by 0.25mg b.d every other day. Optimum- 0.5mg b.d; some may benefit from 1mg b.d. Once target is achieved, consider once daily dosing. Review regularly, discontinue if no benefit seen or intolerance occurs. Well tolerated in elderly. Caution in renal and liver disease.<br><br>

<strong>Children:</strong> Not recommended.<br><br>

<strong>Drug inter:</strong> Caution with centrally acting drugs. May antagonise effects of dopamine agonists. If starting or stopping hepatic enzyme-inducing drugs, re-evaluate dose.
Phenothiazines, tricyclic antidepressants and some beta-blockers may increase the plasma concentration of risperidone but not those of the antipsychotic fraction. Fluoxetine may increase the plasma concentration of risperidone but less so of the antipsychotic fraction.  </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>RESCO Tab. Drug Inter.</h3>
    <p>Risperidone INN 1mg & 2mg/tablet. 1mg x 50's pack: 75.00 MRP 2mg x 50's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>RISCORD Tab. General</h3>
    <p>Risperidone INN 2mg & 4mg/tablet. 2mg x 30's pack: 60.00 MRP 4mg x 30's pack: 105.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>RISPA Tab. Orion</h3>
    <p>Risperidone INN 1mg & 2mg/tablet. 1mg x 50's pack: 75.00 MRP
2mg x 50's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>RISPOLUX Tab. Sandoz/Novartis</h3>
    <p>Risperidone INN 1mg, 2mg & 4mg/tablet.
1mg x 100's pack: 300.00 MRP 2mg x 100's pack: 500.00 MRP 4mg x 30's pack: 270.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SIZODON Tab. Sun Pharma</h3>
    <p>Risperidone INN 1mg, 2mg & 4mg/tablet.
1mg x 50's pack: 90.00 MRP 2mg x 50's pack: 150.00 MRP 4mg x 50's pack: 275.00 MRP</p>   
</div><!-- collapsible -->




      </div><!-- collapsible-set -->

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ZIPRASIDONE  </h3>
          <p>  ZIPRASIDONE: Capsule<br><br>

Ziprasidone INN 20mg & 40mg/capsule. Ziprasidone is well absorbed after oral administration; the absorption is increased upto two-fold in the presence of food. Elimination of ziprasidone is mainly via hepatic metabolism. 

<strong>Ind:</strong> Ziprasidone is indicated for the treatment of schizophrenia.<br><br>

<strong>C/I:</strong> Ziprasidone is contraindicated in patients with a known history of QT prolongation, with recent acute myocardial infarction, or with uncompensated heart failure.<br><br>

<strong>S/E:</strong> The most common side effects are rash, asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis and abnormal vision. <br><br>

<strong>Precautions: </strong>Ziprasidone should be used with caution in patients with known cardiovascular disease including those associated with prolongation of QT interval.
<br><br>

<strong>Pregnancy & lactation:</strong> It should be used with caution during pregnancy and only if the expected benefit to the mother is greater than the possible risk to the fetus. It is excreted into breast milk; so, mothers should avoid using ziprasidone while breast-feeding.<br><br>

<strong>Dosage & admin:</strong> Ziprasidone should be administered at an initial dose of 20mg twice daily with food. In some patients, daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80mg twice daily; Or, as directed by the physician.<br><br>

<strong>Drug inter:</strong> Ziprasidone may enhance the effects of certain antihypertensive agents, may antagonize the effects of levodopa and dopamine agonists.  </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZIPRADON Cap. Drug Inter.</h3>
    <p>20mg x 50's pack: 250.00 MRP 40mg x 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ZIPSYDON Cap. Sun Pharma</h3>
    <p>Ziprasidone INN 20mg/capsule. 20mg x 50's pack: 300.00 MRP</p>   
</div><!-- collapsible -->



      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Antimanic drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Antimanic drugs  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> Antimanic drugs: Lithium salt  </h3>
          <p> caution in patients with known cardiovascular
disease including those associated with prolongation of QT interval.<br><br>

<strong>Pregnancy & lactation:</strong> It should be used with caution during pregnancy and only if the expected benefit to the mother is greater than the possible risk to the fetus. It is excreted into breast milk; so, mothers should avoid using ziprasidone while breast-feeding.<br><br>

<strong>Dosage & admin:</strong> Ziprasidone should be administered at an initial dose of 20mg twice daily with food. In some patients, daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80mg twice daily; Or, as directed by the physician.<br><br>

<strong>Drug inter:</strong> Ziprasidone may enhance the effects of certain antihypertensive agents, may antagonize the effects of levodopa and dopamine agonists.<br><br>

Ind: Acute mania; prevention of manic depressive illness (prophylaxis of recurrent effective disorders).<br><br>
<strong>C/I:</strong> Pregnancy, lactation. Addison's disease. Hypothyroidism, renal or cardiac disease. Conditions disturbing sodium balance.<br><br>

<strong>S/E:</strong> Mild gastro-intestinal disturbances, fine tremor, polyuria, polydipsia; also weight gain and oedema.<br><br>
Toxicity: Signs of Lithium intoxications are blurred vision, increasing g.i disturbances (anorexia, vomiting, diarrhoea), increasing CNS disturbances (mild drowsiness & sluggishness increasing to giddiness with ataxia, coarse tremor, lack of co-ordination, disarthria). Require withdrawal of treatment .
With severe overdosage ( blood level 2mmol/L), hyperreflexia and hyper extension of limbs, fits, toxic psychoses, syncope, oliguria, circulatroy failure, coma and occasionlally death.<br><br>
<strong>Cautions:</strong> Treatment should be initiated in hospital. Concurrent admin. of diuretics . Maintain adequate salt and fluid intake . Monitor thyroid function.<br><br>
Adult: Acute mania, 0.25-2gm daily in divided doses, adjust the dose by daily blood tests to maintain a serum lithium level in range 0.6-1.2 mmol/L 12 hours after last dose for 5 to 7 days. Prophylaxis, 0.25-1.2 gm daily in divided doses, adjust the dose to minatiain a serum level in range 0.5-1 mmol/L for first 7 days.
Elderly, usually 0.5-1gm/day given in divided doses.<br><br>
Child: Not recommended.<br><br>
Overdosage: No specific antidote. Elimination of lithium can be facilitated by infusion of sodi- bicarbnonate, acetazolamide, urea or mannitol. Continuous peritoneal dialysis may be effective.   </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>CAMCOLIT Tab. Norgine/Lilac</h3>
    <p>Lithium carbnonate 400mg/tablet. 100's pack: 662.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LITHOSUN SR Tab. Sun Pharma</h3>
    <p>Lithium carbonate 400mg/tablet. (sustained release).
50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Tricyclic & related antidepressants drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Tricyclic & related antidepressants drugs   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> AMITRIPTYLINE  </h3>
          <p>  AMITRIPTYLINE HCI : Tablet/ Capsule/ Syrup/Injection.<br><br>
Ind: Depressive illness particularly with anxiety (where sedation is reqd.), nocturnal enuresis in children.<br><br>
<strong>C/I:</strong> Acute myocardial infarction; heart block; mania; pregnancy, severe liver disease.<br><br>
<strong>S/E:</strong> Dry mouth, blurred vision, constipation, difficulty in micturition; sedation; postural hypotension, tachycardia, syncope partricularly with high doses. Sweating, tremor, rashes; behavioral disturbances (particularly in children); interference with sexual function etc.<br><br>
<strong>Cautions:</strong> Cardiovascular disease, liver disorders, hyperthyroidism, epilepsy,
diabetes; psychoses, patients with suicidal tendencies. Alertness may be impaired. Reduce doses for the elderly; extreme caution in glaucoma.<br><br>
By mouth: Adult, initially 75mg (elderly 10- 50mg) daily in divided doses or as a single dose at night, increasing if reqd. to max. 200mg daily. Usual maintenance, 50-100mg at night. Nocturnal enuresis-child 7-10 years 10-20mg,11-16 years 25-50mg at night for max. 3 months.<br><br>
By inj: by i.m. or i.v. injection 20-30mg 4 times daily.  </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMILIN Tab. Opsonin</h3>
    <p>Amitriptylline hydrochlor. 10mg & 25mg/tablet. 10mg x 100's pack: 50.00 MRP 25mg x 100's pack: 80.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMIT Tab. General</h3>
    <p>Amitriptylline hydrochlor. 10mg & 25mg/tablet. 10mg x 100's pack: 50.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMITRIPTYLINE Tab. Glaxo-SmithKline</h3>
    <p>Amitriptylline hydrochlor. 25mg/tablet. 500's bot: 400.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SAROTEN Retard Cap. Lundbeck/ Lilac</h3>
    <p>25mg x 100's pack: 700.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TRIP 10 Tab. Medicon</h3>
    <p>Amitryptyline 10mg/tablet 10mg x 100's pack: 50.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TRYPTIN Tab. Square</h3>
    <p>Amitryptyline 10mg & 25mg/tablet 10mg x 200's pack: 110.00 MRP 25mg x 200's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  CLOMIPRAMINE </h3>
          <p> CLOMIPRAMINE: Tablet/Capsule/ Syrup/ Injection.<br><br>

Ind: Depression, obsessive compulsive disorder, phobic and obsessional states; adjunctive treatment of cataplexy associated with narcolepsy. C/I; S/E; Caution: See under amitriptyline hydrochloride.<br><br>

Dose: By mouth, initially 10mg daily, increased gradually as necessary to 30-150mg daily in divided doses or as a single dose at bedtime; max. 250mg daily; usual maintenance 30-50mg daily; Elderly initially 10mg daily, increased to 30-50mg daily; Child not recommended. Phobic and obsessional states, initially 25mg daily (elderly 10mg daily) increased over 2 weeks to 100-150mg daily; Child not recommended.<br>
Adjunctive treatment of cataplexy associated with narcolepsy, initially 10mg daily, gradually increased until satisfactory response (range 10- 50mg daily).<br>
By i.m injection, initially 25-50mg daily, increased by 25mg daily to 100-150mg daily; Child not recommended.<br>
By i.v infusion (careful monitoring see caution), initially to assess tolerance, 25-50mg, then increase by 25mg daily to usual dose of 100mg daily for 7-10 days; Child not recommended.   </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANAFRANIL Tab. Novartis</h3>
    <p>Clomipramine hydrochloride 25mg/tablet. 50's pack: 275.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CLOFRANIL Tab. Sun Pharma</h3>
    <p>Clomipramine hydrochloride 25mg/tablet. 50's pack: 225.00 MRP</p>   
</div><!-- collapsible -->



      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> IMIPRAMINE  </h3>
          <p>  IMIPRAMINE: Tablet/ Syrup/ Injection. <br><br>
          Ind: Depression; adjunct in chronic rheumatic pain. Nocturnal enuresis in children.<br><br>
<strong>C/I; S/E; Cautions: </strong>See under Amitriptyline, but less sedative & s/e occurs more frequently.<br><br>
By mouth: Adult, 25mg 3 times daily for 3 days, increasing to 50mg 3 or 4 times daily. Elderly, initially 10mg at night increasing to 10-25mg 3 times daily.<br><br>
Child: (use syrup) under 6 yrs. not recommended; 6-7 yrs. 25mg; 8-11 yrs . 25-50 mg ; over 11 yrs. 50-75mg. All at bedtime for 68 wks . then gradually withdraw therapy.  </p>
        </div><!-- collapsible -->


  <div data-role="collapsible"> <!-- collapsible -->
    <h3>MELIPRAMIN Tab. Egis/Medimpex</h3>
    <p>Imipramine hydrochlor. 25mg/tablet. 1000's pack: 720.00 TP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PINOR Tab. Aristopharma</h3>
    <p>Imipramine hydrochlor. 25mg/tablet. 50's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>Imipramine hydrochlor. 25mg/tablet. 50's pack: 100.00 MRP</h3>
    <p>Imipramine hydrochlor. 25mg/tablet 100's pack: 450.00 MRP</p>   
</div><!-- collapsible -->



      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> MAPROTILINE  </h3>
          <p>  Ind: All forms of depression particularly with anxiety.<br><br>
C/I; S/E ; Caution: See under amitriptylline but less sedating & anticholinergic effects occur less frequently . Rashes commonly occur & there is an increased risk of convulsions at higher dosage. <br><br>
Adult: Initially 25-75mg. daily in one dose (usually at night) or 3 divided doses, adjusting after 1-2 weeks as necessary. Max.150 mg daily Elderly: Initially 30 mg at night or 10mg 3 times daily.<br>
Child: Not recommended.
  </p>
        </div><!-- collapsible -->
  

<div data-role="collapsible"> <!-- collapsible -->
    <h3>LUDIOMIL Tab. Novartis</h3>
    <p>Maprotiline hydrochloride 25mg/tablet 50's pack: 250.00 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->



  <div data-role="collapsible-set" data-theme="b">
    <div data-role="collapsible"> <!-- collapsible -->
      <h3> NORTRIPTYLINE  </h3>
      <p>  NORTRIPTYLINE: Tablet/Capsule/ Syrup. Ind: Depressive illness, nocturnal enuresis in children.<br><br>
      <strong>C/I; S/E; Cautions:</strong> Same as Imipramine. Adult: 20-40mg daily in divided doses increasing if necessary to 100mg daily. Usual maintenance, 30-75mg daily.<br><br>
      Elderly: Initially 10mg 3 times daily. Child: Enuresis, under 6 yrs. not recommended; over 6 yrs.10-35 mg 30mins. before bedtime.  </p>
    </div><!-- collapsible -->

    <div data-role="collapsible"> <!-- collapsible -->
        <h3>NORTIN Cap. Navana</h3>
        <p>Nortriptyline 10mg & 25mg/capsule. 10mg x 100's pack: 62.00 MRP 25mg x 100's pack: 85.00 MRP</p>   
    </div><!-- collapsible -->

    <div data-role="collapsible"> <!-- collapsible -->
        <h3>NORTRILEN Tab. Lundbeck/Lilac</h3>
        <p>Nortriptyline 10mg & 25mg/tablet.10mg x 100's pack: 201.00 MRP 25mg x 100's pack: 327.00 MRP</p>   
    </div><!-- collapsible -->
  </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="a">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> MIANSERIN  </h3>
          <p> MIANSERIN HCI: Tablet
          Prepn: May not be available.</p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Monoamine-oxidase inhibitors (MAOIs)" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Monoamine-oxidase inhibitors (MAOIs)   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

<p>  Monomaine-oxidase inhibitors (MAOIs): These drugs include:
Phenelzine, Isocarboxazid, Tranylcypromine. Reversible MAOIs- such as Moclobemide.
Note: Preparations not yet available in our market. </p>
        
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="SSRIs & related antidepressants" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> SSRIs & related antidepressants   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3>CITALOPRAM   </h3>
	          <p> CITALOPRAM: Tablet<br><br>
Citalopram is an orally administered selective serotonin reuptake inhibitor (SSRI) with a chemical structure unrelated to that of other SSRIs, tricyclic, tetracyclic or other available antidepre-ssant agents.<br><br>

Mode of action: The mechanism of action of citalopram as an antidepressant is presumed to be linked to potentiation of serotonergic activity in central nervous system resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).<br><br>

Ind: Citalopram is indicated for depressive illness and panic disorder. It is also indicated in substance abuse disorders and alcohol dependence. Citalopram has also been given in variety of anxiety disorders including obsessive- compulsive disorder and social phobia. It is also effective in generalized anxiety disorder, post- traumatic stress disorder, premenstrual syndrome, idiopathic Parkinson's disease and eating disorder.<BR><BR>

 <strong>C/I:</strong> Citalopram should not be used if the patient enters a manic phase. Patients taking MAO inhibitors. Hypersensitivity to the drug or any of its ingredients.<br><br>

<strong>S/E:</strong> SSRIs are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants. However, side-effects may be seen, include gastro-intestinal effects, such as nausea, vomiting, dyspepsia, abdominal pain, diarrhea, constipation; anorexia with weight loss, palpitations, tachycardia, postural hypotension, cough, confusion, impaired concentration, amnesia, urinary retention, sweating, movement disorders, urticaria, anaphylaxis, arthralgia, myalgia and
photosensitivity.<br><br>

Precaution: Caution should be taken in patients with epilepsy, concurrent electroconvulsive therapy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, history of bleeding disorders, hepatic and renal impairment. Abrupt withdrawal of citalopram should be avoided.<br><br>

<strong>Pregnancy & lactation:</strong> There are no adequate and well-controlled studies in pregnant women, therefore, citalopram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Citalopram is excreted in human breast milk, so, a decision should be made whether to discontinue nursing or to discontinue citalopram therapy, taking into account the importance of the treatment for the mother.<br><br>

<strong>Dosage & admin:</strong> Depressive illness- 20mg daily as a single dose in the morning or evening; increased if necessary to maximum 60mg daily (elderly, maximum 40mg daily). Panic disorder- initially 10mg daily, increased to 20mg after 7 days; usual dose 20-30mg daily; maximum 60mg daily (elderly, maximum 40mg daily).<br><br>

<strong>Drug inter:</strong> Ketoconazole, itraconazole or macrolide antibiotics and citalopram co- administration decreases the metabolism of the later. Co-administration with omeprazole might decrease the clearance of citalopram.   </p>
	        </div><!-- collapsible -->
  			

 <div data-role="collapsible"> <!-- collapsible -->
    <h3>ARPOLAX Tab. Incepta Citalopram</h3>
    <p>hydrobromide INN equivalent to citalopram 20mg/tablet.20mg x 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CIS-20 Cap. Globe</h3>
    <p>Citalopram hydrobromide INN equivalent to citalopram 20mg/capsule.
20mg x 30's pack: 210.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CITAPRAM Tab. General</h3>
    <p>Citalopram hydrobromide INN equivalent to citalopram 10mg & 20mg/tablet. 10mg x 50's pack: 250.00 MRP 20mg x 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->


       </div><!-- collapsible-set -->

      

      <div data-role="collapsible-set" data-theme="a">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3>ESCITALOPRAM</h3>
	          <p> ESCITALOPRAM: Tablet
Escitalopram oxalate INN 10mg/tablet (film- coated tablet).
Escitalopram oxalate is an orally administered selective serotonin reuptake inhibitor (SSRI). It is the pure s-enantiomer of the recemic bicyclic phthalane derivative of citalopram.<br><br>

Mode of action: The mechanism of antidepressant action of escitalopram is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from its inhibition of CNS neuronal reuptake of serotonin (5HT). Escitalopram is highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. It is at least 100 times more potent than the R-enantiomar with respect to inhibtion of 5- HT reuptake and inhibition of 5-HT neuronal firing rate. Escitalopram has no or very low affinity for serotonergic (5-HT 1-7) or other receptors including alpha- and beta-adrenergic, dopamine (D1-5), histamine (H1-3), muscarinic (M1-5) and benzodiazepine receptors.<br><br>

Ind: Escitalopram oxalate is indicated for the treatment of major depressive disorder and maintenance therapy to prevent people with depression from suffering a relapse. A major depressive episode implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor retardation or agitation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.<br><br>

<strong>C/I:</strong> Concomitant use in patients taking MAO inhibitor is contraindicated. This is contraindicated in patients with known hypersensitivity to escitalopram oxalate or citalopram. If a patient enters a manic phase, escitalopram oxalate should be discontinued. As with all drugs effective in the treatment of major depressive disorder, escitalopram should be used cautiously in patients with a history of mania. Escitalopram oxalate should be used with caution in patients with a history of seizure disorder. Rarely, the occurrence of serotonin syndrome has been reported in patients receiving SSRIs. A combination of symptoms, possibly including agitation, confusion, tremor, myoclonus and hyperthermia, may indicate the development of this condition. The use of citalopram in hepatically impaired patients should be approved with caution and a lower maximum dosage (10mg/day) is recommended. Clinical experience with escitalopram in patients with concomitant systemic illness is limited. Escitalopram should be used with caution in diabetic patients on insulin or other antidiabetic drugs.<br><br>

<strong>S/E:</strong> The following adverse reactions have been reported: agitation or restlessness, blurred vision, diarrhea, indigestion, nausea, increased or decreased appetite, increased sweating, sexual difficulties (decreased sexual ability or desire, ejaculatory delay), taste alterations, tremor (shaking), weight changes.<br><br>

<strong>Pregnancy & lactation:</strong> The safety of escitalopram during pregnancy and lactation has not been established. Therefore, escitalopram should not be used during pregnancy, unless, in the opinion of the concerned physician, the expected benefits to the patient markedly outweigh the possible hazards to the fetus. Escitalopram is excreted in human milk, so, it should not be administered to nursing mothers unless, in the opinion of the treating physician, that the expected benefits to the patient markedly outweigh the possible hazards to the child.<br><br>

<strong>Dosage & admin:</strong> Adults: The initial dose of escitalopram oxalate is 10mg once daily. (A fixed dose trial of escitalopram oxalate demonstrated the effectiveness of both 10mg and 20mg of escitalopram, but failed to demonstrate a greater benefit of 20mg over 10mg). If the dose is increased to 20mg, this should occur after a minimum of one week. Elderly: A single oral dose of 10mg/day is the recommended dose for most elderly patients. No significant differences in safety or effectiveness between the elderly group (age 65 and over) and the younger subjects ware observed, but greater sensitivity of some elderly individuals could not be ruled out. Administering in excess of recommended dose has not been yet established.<br><br>

Children: Safety and effectiveness in children below the age of 18 years have not been established.<br><br>

<strong>Drug inter:</strong> Concomitant use in patients taking MAO inhibitor is contraindicated. Escitalopram should be used with caution in diabetic patients on insulin or other antidiabetic drugs.
   </p>
	        </div><!-- collapsible -->
  


<div data-role="collapsible"> <!-- collapsible -->
    <h3>ESITA Tab. Healthcare</h3>
    <p>Escitalopram oxalate INN equivalent to escitalopram 5mg/tablet (f.c).
5mg x 20's pack: 145.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NEXCITAL Tab. UniHealth</h3>
    <p>Escitalopram oxalate INN equivalent to escitalopram 5mg & 10mg/tablet (f.c). 5mg x 30's pack: 165.00 MRP
10mg x 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NEXITO Tab. Sun Pharma</h3>
    <p>Escitalopram oxalate INN equivalent to escitalopram 10mg/tablet (f.c).
10mg x 30's pack: 270.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OXAPRO Tab. Square</h3>
    <p>Escitalopram oxalate INN equivalent to escitalopram 10mg/tablet (f.c).
10mg x 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->

       </div><!-- collapsible-set -->




       <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3>  DULOXETINE </h3>
	          <p> DULOXETINE HCI: Tablet
Duloxetine hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI). It is available as duloxetine hydrochloride INN equivalent to duloxetine 20mg and 30mg/tablet (enteric-coated).<br><br>

Mode of action: Duloxetine hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI). It is a less potent inhibitor of dopamine reuptake. It has no significant affinity for dopaminergic, adrenergic, cholinergic,
histaminergic, opioid, glutamate, and GABA receptors in vitro. Duloxetine dose not inhibit monoamine oxidase (MAO). Orally administered duloxetine hydrochloride is well absorbed. Elimination of duloxetine is mainly through hepatic metabolism.<br><br>

Ind: <br>

1. Treatment of major depressive disorder (MDD) which is associated with the following symptoms:<br> i. depressed mood,<br> ii. loss of interest in usual activities, <br>iii. significant change in weight and/or appetite, <br>iv. insomnia or hypersomnia, <br>v. psychomotor agitation or retardation, <br>vi. increased fatigue, <br>vii. feelings of guilt or worthlessness,<br>
viii. slowed thinking or impaired concentration, <br>ix. suicide attempt or suicidal ideation.<br><br>
2. Management of neuropathic pain associated
with diabetic peripheral neuropathy.<br><br>

<strong>C/I:</strong> Duloxetine is contraindicated in patients with a known hypersensitivity to this drug or any of the inactive ingredients. Concomitant use in patients taking monoamine oxidase inhibitors (MAOls) is contraindicated. It should be avoided in patinets with uncontrolled narrow-angle glaucoma.<br><br>

<strong>S/E:</strong> The most commonly observed abverse events are- nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. It may slightly increase blood pressure. No clinically significant differences were observed for QT, PR, and QRS intervals between duloxetine-treated and placebo-treated patients.<br><br>

<strong>Precautions:</strong> Blood pressure should be measured prior to initiating treatment with duloxetine hydrochloride and preiodically measured throughout treatment. It should be used cautiously in patients with a history of mania, seizure disorder and controlled narrow-angle glaucoma. Duloxetine hydrochloride should ordinarily not be prescribed to patients with substantial alcohol use.<br><br>

<strong>Pregnancy & lactation:</strong> Duloxetine should be used during pregnancy and labor only if the potential benefit justifies the potential risk to the fetus.It is not known whether duloxetine and/or it's metabolites are excreted into human milk, however, breast feeding is not recommended when the mother is on duloxetine therapy.<br><br>

<strong>Dosage & admin:</strong> Major depressive disorder (MDD): 20-30mg twice daily or 60mg once daily.
Diabetic peripheral neuropathy: A total dose of 60mg given once a day.
Duloxetine hydrochloride can be taken regardless of meals.<br><br>

Children: Safety and efficacy in pediatric patients have not been established.<br><br>

<strong>Drug inter:</strong> Both CYP1A2 and CYP2D6 isozymes are responsible for duloxetine metabolism. When duloxetine was co- administered with fluvoxamine, a potent CYP1A2 inhibitor, the AUC, Cmax and t1/2 of duloxetine was increased. Other durgs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin would be expected to have similar effects and these combinations should be avoided. Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.   </p>
	        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>DELOXI DR Cap. SK+F</h3>
    <p>Duloxetine hydrochloride INN equivalent to duloxetine 20mg & 60mg/capsule (delayed release).
20mg x 36's pack: 252.00 MRP 60mg x 16's pack: 288.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>DUL
OX Tab. Acme</h3>
    <p>Duloxetine hydrochloride INN equivalent to duloxetine 20mg & 30mg/tablet (enteric-coated). 20mg x 10's pack: 70.00 MRP
30mg x 10's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>D
ULOXEN Tab. Incepta</h3>
    <p>Duloxetine hydrochloride INN equivalent to duloxetine 20mg & 30mg/tablet (enteric-coated). 20mg x 30's pack: 210.00 MRP
30mg x 30's pack: 300.00 MRP</p>   
</div><!-- collapsible -->



       </div><!-- collapsible-set -->



       <div data-role="collapsible-set" data-theme="a">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> FLUOXETINE  </h3>
	          <p> FLUOXETINE: Capsule/Tablet/Syrup<br><br>
	          Fluoxetine is a selective serotonin re-uptake inhibitor (SSRI).<br><br>

Mode of action: It acts by selectively inhibiting the re-uptake of serotonin (5- hydroxytryptamine), and considered to be an effective antidepressant preparation.<br><br>

Ind: Depressive ilness, bulimia nervosa, obsessive-compulsive disorder.<br><br>

<strong>C/I:</strong> SSRl preparations should not be given in the patients entering a manic phase.<br><br>

<strong>S/E:</strong> Gastro-intestinal (fairly common- include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation, anorexia with weight loss and possible changes in blood sugar); hypersensitivity reactions (important: see also below); also dry mouth, nervousness, anxiety, headache, insomnia, palpitations, tremor, confusion, dizziness, hypotension, hypomania or mania, drowsiness, asthenia, convulsions, fever, sexual dysfunction, sweating; movement disorders and dyskinesias, neuroleptic malignant sydrome- like event; hyponatraemia (may be due to inappropriate antidiuretic hormone secretion- SIADH), abnormal liver function tests reported; also reported (no causal relationship established)- aplastic anaemia, cerebrovascular accident, ecchymoses, eosinophilic pneumonia, gastro- intestinal haemorrhage, hyperprolactinaemia, haemolytic anaemia, pancreatitis, pancytopenia, suicidal ideation, thrombocytopenia, thrombocytopenic purpura, vaginal bleeding on withdrawal, violent behaviour; hair loss also reported.
Hypersensitivity- angioedema, urticaria, pruritus, and other allergic reactions including anaphylaxis have been reported (discontinue if rash occurs, may be warning of impending serious systemic reaction, possibly associated with vasculitis); pharyngitis and rarely pulmonary inflammation or fibrosis (with dyspnoea only warning sign) also reported; possible hypersensitivity signs associated with other SSRIs include arthralgia, myalgia.
SSR1 preparations should not be given in the patients enter a manic phase.<br><br>

<strong>Cautions:</strong> SSRl preparations should be used with caution in patients with cardiac disease, epilepsy (avoid if poorly controlled, discontinue if convulsions develop), concurrent electroconvulsive therapy (prolonged seizures reported), history of mania, hepatic and renal impairment, pregnancy and breast-feeding, avoid abrupt withdrawal.
Driving- may impair performance of skilled tasks (e.g. driving)<br><br>

<strong>Pregnancy & lactation:</strong> Although no teratogenic effects have been observed SSRI preparations should be used during pregnancy or lactation with caution.<br><br>

<strong>Dosage & admin:</strong> Depressive illness, 20mg daily; Child, not recommended.
Bulimia nervosa, 60mg daily; Child, not recommended. Obsessive-compulsive disorder, initially 20mg daily, dose increase may be considered if no response after several weeks, but may be increased potential for side-effects; max. 60mg daily; Child, not recomme nded.
Long duration of action- account should be taken of the long half-life of fluoxetine when adjusting dosage (or in overdosage)
<br><br>

<strong>Drug inter:</strong> Monoamine oxidase inhibitors- it is prudent to avoid their combined use, experience suggests that the combination may produce a potentially lethal serotonin syndrome.Oral anticoagulants - prothrombin time should be carefully monitored when fluoxetine therapy is initiated or stopped in patients on oral coagulants. CNS-active drugs- hypertension and CNS excitation may occur if used with dopaminergic drugs. Cemetidine- plasma concentration of fluoxetine increased by cemetidine.
   </p>
	        </div><!-- collapsible -->
  


<div data-role="collapsible"> <!-- collapsible -->
    <h3>MODIPRAN Cap. Beximco</h3>
    <p>Fluoxetine hydrochloride 20mg/capsule 100's pack 287.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NODEPRESS Tab. Chemico</h3>
    <p>Fluoxetine hydrochloride 20mg/tablet 50's pack: 130.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>OXETIN Cap. Decent Pharma</h3>
    <p>Fluoxetine hydrochloride 20mg/capsule 50's pack: 144.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PRODEP Cap. Sun Pharma</h3>
    <p>Fluoxetine hydrochloride 20mg/capsule 50's pack: 150.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PROLERT Cap. Square</h3>
    <p>Fluoxetine hydrochloride 20mg/capsule 50's pack: 129.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEREN Cap. Sonear</h3>
    <p>Fluoxetine hydrochloride 20mg/capsule 10's pack 28.00 MRP
30's pack 84.00 MRP</p>   
</div><!-- collapsible -->

       </div><!-- collapsible-set -->



       <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3>  FLUVOXAMINE </h3>
	          <p>  FLUVOXAMINE: Tablet<br>
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI). It is available as fluvoxamine maleate BP 50mg tablet.<br><br>
Ind: Obsessive-compulsive disorder, depressive illness. It is also indicated in panic disorder, eating disorders, chronic tension headache.<br><br>

<strong>C/I:</strong> Fluvoxamine maleate should not be used if the patient enters a manic phase.<br><br>

<strong>S/E:</strong> Gastro-intestinal side effects are- anorexia with weight loss (increased appetite and weight gain also reported), hypersensitivity reactions with rash, urticaria, angioedema, arthralgia, myalgia and photosensitivity. Other side effects include dry mouth, nervousness, anxiety, headache, insomnia and sexual dysfunction, palpitation, tachycardia (may also cause bradycardia), rarely postural hypotension, confusion, ataxia, abnormal liver function tests.<br><br>

<strong>Cautions:</strong> Fluvoxamine maleate should be used vith caution in patients with a history of mania, seizures, suicide, concurrent ECT therapy, cardiac disease, diabetes mellitus, angle-closure glaucoma, history of bleeding disorders (specially gastro-intestinal bleeding), hepatic and renal impairment. Fluvoxamine maleate may also impair preformance of skilled tasks (driving).
<br><br> 

<strong>Pregnancy & lactation:</strong> Fluvoxamine maleate
should be avoided in pregnancy and lactation<br><br>

<strong>Dosage & admin:</strong> Obsessive-compulsive disorder: Initially 50mg in the evening for 3-4 days, increasing if necessary to 300mg daily (over 150mg in divided doses). Child- over 8 years, initially 25mg daily, increased if necessary in steps of 25mg every 3-4 days to maximum 200mg daily in divided doses. Depression: Initially 50-100mg daily in the evening, increased if necessary to 300mg daily (over 150mg in divided doses). Usual maintenance dose 100mg daily. Child- not recommended.<br><br>

<strong>Drug inter:</strong> Fluvoxamine maleate should not be used concurrently with monoamine oxidase inhibitors, warfarin, benzodiazepines, theophylline, aminophylline, tricyclic antidepressants and alcohol.  </p>
	        </div><!-- collapsible -->
  
			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>RELAFIN Tab. General</h3>
			    <p>Fluvoxamine maleate BP 50mg/tablet 30's pack: 450.00 MRP</p>   
			</div><!-- collapsible -->

       </div><!-- collapsible-set -->



       <div data-role="collapsible-set" data-theme="a">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> PAROXETINE  </h3>
	          <p>  PAROXETINE HCI: Tablet.<br>
Paroxetine is a potent selective serotonin re-
uptake inhibitor (SSRI). It is available as paroxetine hydrochloride 20mg tablet.<br><br>

Mode of action: Paroxetine selectively inhibits neuronal re-uptake of serotonin (5-Hydroxy tryptamine, 5-HT), which potentiates serotonergic activity in the central nervous system, which appears to be associated with antidepressant activity. Studies have demonstrated that paroxetine blocks the uptake of serotonin into human platelets. In vitro studies in animals also suggest that paroxetine has only very weak effects on norepinephrine and dopamine neuronal reuptake.<br><br>

Ind: Major depressive disorder, Obsessive compulsive disorder, Panic disorder, Social anxiety disorder, Generalized anxiety disorder & Post-traumatic stress disorder.<br><br>

<strong>C/I:</strong> Known hypersensitivity to paroxetine. Concomitant use in patients taking either monoamine oxidase inhibitors (MAOIs) or thioridazine.<br><br>

<strong>S/E:</strong> Asthenia, sweating, nausea, decreased appetite, somnolence, dizziness, insomnia, tremor, nervousness, ejaculatory disturbance and other male genital disorders.<br><br>

<strong>Cautions:</strong> Caution is advised when treating patients with cardiac conditions, patients with epilepsy (avoid if poorly controlled, discontinue if convulsions develop). Paroxetine should be discontinued in any patients who develops seizures ECT, (incidence of seizures in patients treated with paroxetine is les s than 0.1%). Caution is advised when treating patients with history of mania. Paroxetine may impair performance of skilled tasks (e.g driving).<br><br>

<strong>Pregnancy & lactation:</strong> This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The effect of paroxetine on labor and delivery in humans is unknown. Like many other drugs paroxetine is secreted in human milk and caution should be exercised when administered in a nursing mother. <br><br>

<strong>Dosage & admin:</strong> Major depressive disorder:
Usual initial dose is paroxetine 20mg as a single daily dose with or without food, preferably in the morning. Some patients not responding to 20mg dose may benefit from dose increases in 10mg/day increments up to a maximum of 50mg/day. Dose changes should occur at intervals of at least 1 week. Maintenance therapy: Efficacy of paroxetine hydrochloride is maintained for periods of up to 1 year with doses that averaged about 30mg. Obsessive compulsive disorder (OCD):
Patients should be started on 20mg/day and the dose can be increased weekly in 10mg/day increments. Maintenance therapy: Efficacy of paroxetine hydrochloride is maintained for periods of up to 1 year with doses that
averaged about 30mg.<br><br>

Panic disorder: Usual initial dose is paroxetine 20mg as a single daily dose with or without food, preferably in the morning. The target dose in the treatment of panic disorder is 40mg/day. Dose changes should occur in 10mg/day increments at intervals of at least 1 week. The maximum dosage should not exceed 60mg/day. Maintenance therapy: Dosage adjustments should be made to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment. Social anxiety disorder (SAD): Usual initial dose is paroxetine 20mg as a single daily dose with or without food, preferably in the morning. Dose may be increased after 2 weeks if necessary with an increments of 10mg at weekly intervals to a maximum of 50mg daily. Generalized anxiety disorder (GAD): The recommended starting dosage and the established effective dosage is 20mg/day. Post-traumatic stress disorder (PTSD): The recommended starting dosage and the established effective dosage is 20mg/day. Dose changes, if indicated, should occur in 10mg/day increments at intervals of at least 1 week. Dosage for Elderly or Debilitated and Patients with Severe Renal or Hepatic impairment: The recommended initial dose is 10mg/day for elderly patients, debilitated patients and/or patients with severe renal or hepatic impairment. Increases may be made if indicated. Dosage should not exceed 40mg/day. Druug inter: Tryptophan: An interaction between paroxetine and tryptophan may occur, resulting in a serotonin syndrome suggested by development of agitation, restlessness and gastrointestinal symptoms including diarrhoea. Drug metabolizing enzyme inducers/inhibitors: The metabolism and pharmacokinetics of paroxetine may be affected by drugs, which induce or inhibit hepatic drug metabolizing enzymes. When paroxetine is to be co-administered with a known drug metabolizing inhibitor, consideration should be given to using doses at the lower end of the range. Alcohol: Although paroxetine does not increase the impairment of mental and motor skill caused by alcohol, the concomitant use of paroxetine and alcohol in depressed patients is not advised. Haloperidol/Amylobarbitone/Oxazepam: Paroxetine does not increase the sedation and drowsiness associated with haloperidol, amylobarbitone or oxazepam when given in combination. MAOIs: An interaction between paroxetine and monoamine oxidase (MAO) inhibitors may occur. Treatment with paroxetine should not be started until 2 weeks after stopping an MAGI. Lithium: The concurrent administration of paroxetine and lithium should be undertaken with caution. Lithium levels should be monitored. Phenytoin/Anticonvulsants: Co-administration of paroxetine and phenytoin is associated with an increased incidence of adverse experiences. Warfarin: Preliminary data suggest that there may be a pharmacodynamic, interaction between paroxetine and warfarin, which may result in increased bleeding in the presence of unaltered prothrombin times. Paroxetine should therefore be administered with great caution to patients receiving oral anticoagulants. </p>
	        </div><!-- collapsible -->


			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>MELEV 20 Tab. Beximco</h3>
			    <p>Paroxetine hydrochloride 20mg/tablet 30's pack 285.00 IP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>OXAT 20 Tab. Square</h3>
			    <p>Paroxetine hydrochloride 20mg/tablet 30's pack 285.00 MRP</p>   
			</div><!-- collapsible -->


       </div><!-- collapsible-set -->



       <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> SERTRALINE  </h3>
	          <p> Sertraline is a selective serotonin re-uptake inhibitor (SSRI). Therefore, it acts by selectively inhibiting the re-uptake of serotonin (5- hydroxytryptamine), and considered to be an effective antidepressant preparation.<br><br>

Ind: Depressive illness; management of obsessive-compulsive disorder; panic disorder. <br><br>

<strong>C/I; S/E; Cautions:</strong> See notes above under fluoxetine.<br><br>
<strong>Pregnancy & lactation:</strong> See notes above under fluoxetine.<br><br>
<strong>Dosage & admin:</strong> Depression- initially 50mg daily, increased if necessary by 50mg over several weeks to max. 200mg daily; then reduced to usual maintenance dose 50mg daily. Obsessive-compulsive disorder- initially 50mg daily, increased if necessary by 50mg over several weeks; usual dose range 50-200mg daily. Panic disorder- 25mg once daily; after one week the dose should be increased to 50mg once daily. Child: Not recommended.<br><br>
<strong>Drug inter:</strong> See notes above under fluoxetine.   </p>
	        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANDEP Tab. Healthcare Sertraline</h3>
    <p>hydrochlor INN 50mg & 100mg/tablet 50mg x 50's pack: 275.00 IP 100mg x 30's pack: 300.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ATRALIN Tab. Beximco</h3>
    <p>Sertraline hydrochloride INN 50mg/tablet
50mg x 50's pack: 250.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>CHEAR Tab. ACI</h3>
    <p>Sertraline hydrochloride INN 25mg & 50mg/tablet 25mg x 100's pack: 250.00 MRP 50mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>REPOSE Tab. Incepta Sertraline</h3>
    <p>hydrochloride INN 25mg, 50mg & 100mg/tablet
25mg x 50's pack: 150.00 MRP 50mg x 50's pack: 250.00MRP 100mg x 30's pack: 285.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SARTRA Tab. Pacific Sertraline</h3>
    <p>hydrochloride INN 50mg/tablet
50mg x 50's pack: 300.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SERA Tab. Ambee</h3>
    <p>Sertraline hydrochloride INN 50mg/tablet
50mg x 50's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SEROLUX Tab. Sandoz/Novartis</h3>
    <p>Sertraline hydrochloride INN 50mg & 100mg/tablet
50mg x 50's pack: 250.00 IP 100mg x 30's pack: 300.00 IP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SERTAL Tab. Drug Inter.</h3>
    <p>Sertraline hydrochloride INN 50mg/tablet
50mg x 50's pack: 250.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SETRA Tab. General</h3>
    <p>Sertraline hydrochloride INN 25mg, 50mg & 100mg/tablet
25mg x 50's pack: 150.00 MRP 50mg x 50's pack: 300.00 MRP 100mg x 30's pack: 285.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TRALIN Tab. Silva</h3>
    <p>Sertraline hydrochloride INN 25mg, 50mg & 100mg/tablet
25mg x 100's pack: 250.00 MRP 50mg x 50's pack: 200.00 MRP 100mg x 50's pack: 350.00 MRP</p>   
</div><!-- collapsible -->

      </div><!-- collapsible-set -->

   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Misc. Antidepressants" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Misc. Antidepressants  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b	">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> BUPROPION  </h3>
          <p>  BUPROPION HCI: Tablet<br>
Bupropion hydrochloride is an antidepressant of the aminoketone class, chemically unrelated to tricyclic, tetracyclic, or other known antidepre- ssants. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. Mode of action: Bupropion inhibits reuptake of dopamine, noradrenaline, and serotonin in the central nervous system, is a non-competitive nicotine receptor antagonist.<br><br>

Ind: Bupropion hydrochloride is indicated in the treatment of depression. It is also indicated in smoking cessation.<br><br>

<strong>C/I:</strong> Bupropion hydrochloride is contraindicated in patients with a seizure disorder, such as, patients with epilepsy. Bupropion hydrochloride is contraindicated in patients treated with other medications that contain bupropion because the incidence of seizure is dose-dependent. It is also contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of a higher incidence of seizures noted in such patients treated for bulimia with bupropion hydrochloride. The concurrent administration of bupropion hydrochloride and a monoamine oxidase (MAO) inhibitors is contraindicated. At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with bupropion hydrochloride. Bupropion hydrochloride is contraindicated in patients who have shown an allergic response to bupropion or other ingredients of the preparation. <br><br>

<strong>S/E:</strong> Agitation, anxiety, and insomnia often occur during the initial stages of bupropion therapy. Other relatively common side effects reported are- fever, dry mouth, headache or migraine, dizziness, nausea and vomiting, constipation, tremor, sweating, and skin rashes. Hypersensitivity reactions, ranging from pruritus and urticaria, less commonly angioedema, dyspnea, and anaphylactoid reactions have occurred. <br><br>

<strong>Cautions:</strong> As bupropion is contraindicated in patients with a history of seizure disorders, it should be used with extreme caution in patient with other predisposing factors for seizures, such as severe hepatic cirrhosis or CNS tumour, and in those undergoing abrupt withdrawal from alcohol or benzodiazepines. The use of bupropion in patients with other risk factors for seizures (e.g alcohol abuse, a history of head trauma, diabetes, and drugs known to lower the seizure threshold) should only be under taken when there are compelling clinical reasons. Bupropion should be used with caution in patients with bipolar depression or psychoses and in patients with a recent history of myocardial infarction or unstable heart diesease and in hepatic or renal impairment.<br><br>

 <strong>Pregnancy & lactation:</strong> There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Like many other drugs, bupropion and its metabolites are secreted in human milk, because of the potential for serious adverse reactions in nursing infants from bupropion, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.<br><br>

<strong>Dosage & admin:</strong> Depression: The usual adult target dose for bupropion is 300mg/day, given as 150mg twice daily. Treatment should begin at 150mg/day given as a single daily dose in the morning. If the 150mg initial dose is adequately tolerated, an increase to the 300mg/day target dose, given as 150mg twiee daily, may be made as early as fourth day of therapy. There should be an interval of at least 8 hours between successive doses. Increasing the dosage above 300mg/day: As with other antidepressants, the full antidepressant effect of bupropion hydrochloride may not be evident until 4 weeks of treatment or longer. An increase in dosage to the maximum of 400mg/ day, given as 200mg twice daily, may be considered for patients in whom no clinical improvement is noted after several weeks of treatment at 300mg/day. Bupropion should be discontinued in patients who do not demonstrate an adequate response after an appropriate period of treatment at 450mg/day. Maintenance: The lowest dose that maintains remission is recommended. Although it is not known how long the patients should remain on bupropion hydrochloride, it is generally recognized that acute episodes of depression require several months or longer of anti- depressant drug treatment.<br><br>

Child & adolescent under 18 years: Not recommended.<br><br>

<strong>Drug inter:</strong> Bupropion should not be given concurrently with or within 14 days of stopping an MAO inhibitor. The use of alcohol should be minimised or avoided completely because it may alter the seizure threshold. Similarly, other drugs that lower the seizure threshold, such as other antidepressants, antimalarials, antipsychotics, sedating antihistamines, quinolones, tramadol, theophylline, or systemic corticosteroids, should be used with extreme caution together with bupropion. Carbamazepine, phenobarbital, or phenytoin may induce the metabolism of bupropion while other drugs such as cimetidine or ritonavir may inhibit its metabolism. Interaction may occur between bupropion and orphenadrine, cyclophosphamide, and ifosfamide. Caution should be excercised when it is given with drugs such as some antidepressants, antipsychotics, beta-blockers, and type 1C antiarrhythmics.
ÔøºÔøº  </p>
        </div><!-- collapsible -->


  <div data-role="collapsible"> <!-- collapsible -->
    <h3>ZYBEX SR Tab. Beximco</h3>
    <p>Bupropion hydrochloride USP 150mg/tablet (sustained release)
150mg x 30's pack: 300.00 IP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> FLUPENTHIXOL & FLUPENTHIXOL + MELITRACIN  </h3>
          <p>  FLUPENTHIXOL+ MELIT RACIN: Tablet/ Injection<br><br>
Mode of action: Flupenthixol- a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and melitracen- a bipolar thymoleptic with activating properties in low doses.In combination the compounds render a
preparation with antidepressant, anxiolytic and activating properties, but does not seem to influence the pharmacokinetic properties of the individual compounds.<br><br>

Ind: Depressive illness with anxiety, masked depression, asthenia & long lasting myogenic headache, migraine; psychosomatic affections with anxiety & asthenia. Dysphoria & depression in alcoholic and drug addicts.<br><br>

<strong>C/I:</strong> Intolerance to neuroleptic drugs; excitable or over active patient; parkinsonism; severe atherosclerosis; senile confusional state; advanced renal, hepatic or cardiovascular disease.<br><br>
<br><br>

<strong>S/E:</strong> Extrapyramidal symptoms occur frequently (1-3 days after admn. & continue for 5 days). Aggregation or agitation may appear (in this stage, should be replaced by another drug). Also see under chlorpromazine.<br><br>

Caution: Renal & hepatic impairment; atherosclerosis; pregnancy.<br><br>
<strong>Dosage & admin:</strong><br>
Flupenthixol decanoate: See below under the individual preparation.<br>
Flupenthixol dihydrochloride: See below under the individual preparation.<br>
Flupenthixol + melitracen: Adult, usually 2 tablets daily divided in morning and evening doses. In severe cases, morning dose may be increased to 2 tablets. Elderly, 1 tablet in the morning; maintenance, usually 1 tablet in the morning.<br>
Child: Not recommended.<br>
Prepns: See above under antipsychotic drugs.

  </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->
   



 		<div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> MIRTAZAPINE </h3>
          <p>  MIRTAZAPINE: Tablet<br>
Mirtazapine is an antidepressant drug, belonging to miscellaneous group.<br><br>
Ind: Mirtazapine is indicated for the treatment of depression.<br><br>
<strong>C/I:</strong> Known case of hypersensitivity to
mirtazapine.<br><br>
<strong>S/E:</strong> Increased appetite and weight gain, sedation; less commonly oedema, dizziness, headache, rarely postural hypotension, abnormal dreams, mania, convulsions, tremor, myoclonus, paraesthesia, arthralgia, my algia, restless legs, exanthema, reversible agranulocytosis. <br><br>

<strong>Cautions:</strong>re Epilepsy, hepatic or renal impairment, cardiac disorders, hypotension, history of urinary retention, angle-closure glaucoma, diabetes mellitus, psychoses (may aggravate psychotic symptoms), history of bipolar depression; avoid abrupt withdrawal.<br><br>
<strong>Pregnancy & lactation:</strong> There are no adequate and well-controlled studies in pregnant women and lactating mother. So, it should not be used in pregnancy and nursing mother.<br><br>
<strong>Dosage & admin:</strong> Adults: Initially 15mg daily at bedtime. The dosage may need to be increased to obtain an optimal clinical response. The effective daily dose is usually between 15 and 45mg as a single or 2 divided doses.<br>
Children: Not recommended.<br>
Overdose: Depression of the central nervous system with disorientation and prolong sedation, together with tachycardia and mild hyper- or hypotension have been reported with mirtazapine overdose. These patients should be treated by gastric lavage with appropriate symptomatic and supportive therapy.<br><br>
<strong>Drug inter:</strong> Mirtazapine should not be used concomitantly with or within two weeks of discontinuing an MAOIs; at least two weeks should elapse between discontinuation of an MAOIs and initiation of mirtazapine therapy. Administration of mirtazapine concurrently with alcohol, anxiolytic or hypnotics may potentiate sedation effect.  </p>
        </div><!-- collapsible -->
  
  <div data-role="collapsible"> <!-- collapsible -->
    <h3>MIRTAZ Tab. Sun Pharma</h3>
    <p>Mirtazapine INN 15mg/tablet. 30's pack: 225.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MITRAZIN Tab. General</h3>
    <p>Mirtazapine INN 15mg/tablet. 30's pack: 240.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  VENLAFAXINE </h3>
          <p>  VENLAFAXINE HC1: Tablet<br>
Venlafaxine hydrochloride is an antidepressant drug belonging to miscellaneous group.<br><br>
Mode of action: Venlafaxine is a 'serotonin and noradrenaline reuptake inhibitor (SNRI)' having antidepressant effect, but it lacks of sedative and antimuscarinic action of typical tricyclic antidepressants.<br><br>
Ind: It is indicated in depressive illness & generalised anxiety disorder.<br><br>
<strong>Dosage & admin:</strong> Depression- initially 75mg (1 tablet) in 2 divided doses, and can be increased if necessary after several weeks to 150mg daily
in 2 divided doses.
Severely depressed or hospitalized patients- initially 150mg daily in 2 divided doses, and can be increased if necessary in steps of up to 75mg every 2-3 days to max. 375mg daily then gradually reduced. Generalised anxiety disorder- 75mg daily as a single dose.
<br><br>

<strong>C/I:</strong> Venlafaxine is contraindicated in severe hepatic or renal impairment, & during pregnancy and breast feeding.<br><br>

<strong>S/E:</strong> Most frequently reported side-effects include nausea, headache insomnia, dry mouth, dizziness, constipation, sweating, nervousness, asthenia. Other side-effects reported include anorexia, dyspepsia, abdominal pain, anxiety, sexual dysfunction, visual disturbances, vasodilatation, vomiting, tremor, chills, palpitations, sgitation, rashes, convulsion, hypertension. Orthostatic hypotension has been seen occasionally.<br><br>

<strong>Cautions:</strong> Patient should be treated very cautiously in case of history of myocardial infarction or unstable heart disease, blood pressure monitoring advisable if dose exceeds 200mg daily; history of epilepsy, mania, hepatic or renal impairment. Avoid abrupt withdrawal (if taken for more than 1 week, withdraw over at least 1 week). Glaucoma.<br><br>

<strong>Drug inter:</strong> Venlafaxine should not be used concomitantly with MAOIs. Cimetidine inhibits the hepatic metabolism of venlafaxine.  </p>
        </div><!-- collapsible -->


<div data-role="collapsible">
<h3>VENAX Tab. Renata</h3>
<p>Venlafaxine hydrochloride INN 42.45mg & 84.90mg equivalent to venlafaxine 37.5mg & 75mg per tablet respectively.
37.5mg x 20's pack: 80.00 MRP
75mg x 20's pack: 120.00 MRP</p>
</div>


<div data-role="collapsible">
<h3>VENLAF Tab. Orion</h3>
<p>Venlafaxine hydrochloride INN 28.30mg & 84.90mg equivalent to venlafaxine 25mg & 75mg per tablet respectively.
25mg x 50's pack: 200.00 MRP
75mg x 20's pack: 200.00 MRP</p>
</div>


<div data-role="collapsible">
<h3>VENLAX Tab. General</h3> 
<p>Venlafaxine hydrochloride INN 42.45mg & 84.90mg equivalent to venlafaxine 37.5mg & 75mg per tablet respectively. 37.5mg x 30's pack: 165.00 MRP 75mg x 20's pack: 200.00 MRP</p>
</div>


      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> FLUPHENAZINE + NORTRIPTYLINE  </h3>
          <p>  FLUPHENAZINE + NORTRIPTYLINE: Tablet.<br><br>
Fluphenazine hydrochloride & Nortriptyline hydrochloride combination has been found as an effective preparation for the patients suffering from 'anxiety' or 'depression' or both. Fluphenazine is a potent phenothiazine derivative. Nortriptyline is a tricyclic antidepressant having less sedative action. This combination helps to restore functional ability without developing any drug dependence.<br><br>
Ind: Mild to moderate mixed anxiety/depression, emotional disturbance, sleep disorder, gastric problems. <br><br>
<strong>C/I:</strong> History of grandmal epilepsy or organic brain damage, blood dyscrasias, severe cardiac insufficiency, renal or liver damage, MAO inhibitors, younger children.<br><br>
<strong>S/E:</strong> Dryness of mouth, drowsiness, constipation, tachycardia, nasal congestion, blurred vision and excitement.<br><br>
Caution: Concurrent admin. of CNS depressants. Patients with glaucoma, prostate enlargement, cardiac failure and myocardial infarction. The drug may impair alertness and abilities to drive a car or operating machinery. Safety in human pregnancy has not yet been established. Breast feeding is not recommended.<br><br>
Adult: 1 tab. (Fluphenazine hydrochlor. 0.5mg + Nortriptyline hydrochlor. 10mg per tablet.) 2 to 3 times daily for max. 3 months.
<br><br> Child: Not recommended.  </p>
        </div><!-- collapsible -->

  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMIVAL Tab. Amico</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 80.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>AMIVAL-F Tab. Amico</h3>
    <p>Fluphenazine hydrochloride 1.5mg + nortriptyline hydrochloride 30mg/tablet.
100's pack: 201.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ANFLU Tab. Alco Pharma</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 75.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>APRESIN Tab. Beximco</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 81.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>ATEVAL Tab. Ziska</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 100.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>EUPHOR Tab. Bio-pharma</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 80.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FLUTRIP Tab. General</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 70.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>FRESH Tab. Nipa</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 80.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>INDOR Tab. Jalalabad</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 81.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MONITOL Tab. Skylab</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 80.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MOODON Tab. Ibn Sina</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 81.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>MUDIBAK Tab. Rephco</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 75.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NORFLU Tab. Acme</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.100's pack: 75.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>NORZIN Tab. Airstopharma</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
250's pack: 200.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>PERMIVAL Tab. Opsonin</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 75.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>SANIT Tab. Square</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 80.00 MRP</p>   
</div><!-- collapsible -->

<div data-role="collapsible"> <!-- collapsible -->
    <h3>TRIPNOR Tab. Somatec</h3>
    <p>Fluphenazine hydrochloride 0.5mg + nortriptyline hydrochloride 10mg/tablet.
100's pack: 75.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
     
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="C.N.S Stimulant Drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  C.N.S Stimulant Drugs  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>ATOMOXETINE   </h3>
          <p>  ATOMOXETINE: Capsule
Atomoxetine is a selective norepinephrine re- uptake inhibitor. It is primarily licensed for the management of attention deficit hyperactivity disorder (ADHD) in children. It is available as atomoxetine hydrochloride INN 10mg capsule. Atomoxetine is well-absorbed after oral administration and is minimally affected by food. It has a half-life of about 5 hours. This drug is excreted mainly in the urine (greater than 80%) and to a lesser extent in the feces (less than 17%). Mode of action: The precise mechanism by which atomoxetine produces its therapeutic effects in attention-deficit hyperactivity disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake, and neurotransmitter depletion studies.<br><br>

Ind: Atomoxetine is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD).<BR><BR>

 <strong>C/I:</strong> This drug is contralndicated: 1. In patients with known hypersensitivity to atomoxetine; 2. Administration with an MAOI, or within 2 weeks after discontinuing an MAOI, or, treatment with an MAOI should not be initiated within 2 weeks after discontinuing atomoxetine; 3. Administration with other drugs that affect brain monoamine concentrations; 4. In patients with narrow angle glaucoma.<br><br>

<strong>S/E:</strong> Atomoxetine can increase blood pressure and
heart rate. Although uncommon, it may cause allergic reactions, including angioneurotic edema, urticaria, and rash. Severe liver injury in rare cases. Precaution: Atomoxetine should be used with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease, because it can increase blood pressure and heart rate. Pluse & blood pressure should be measured at baseline, following atomoxetine dose increases, and periodically while on therapy. Postmarketing reports indicate that atomoxetine can cause severe liver injury in rare cases.<br><br>

<strong>Dosage & admin:</strong> Initial treatment: Dosing of children & adolescents up to 70kg body weight: Atomoxetine should be initiated at a total daily dose of approximately 0.5mg/kg & increased after a minimum of 3 days to a target total daily dose of approximately 1.2mg/kg administered either as a single daily dose in the morning or in two divided doses in the
morning and late afternoon/early evening. No additional benefit has been demonstrated for doses higher than 1.2mg/kg/day. The total daily dose in children and adolescents should not exceed 1.4mg/kg or 100mg, whichever is less. Dosing of children & adolescents over 70kg body weight & adults: Atomoxetine should be initiated at a total daily dose of 40mg & increased after a minimum of 3 days to a target total daily dose of approximately 80mg administered either as a single daily dose in the morning or in twodivided doses in the morning & late afternoon/early evening. After 2 to 4 additional weeks, the dose may be increased to a maximum of 100mg in patients who have not achieved an optimal response. The maximum recommended total daily dose in children & adolescents over 70kg and adults is 100mg. There is no data that supprot increased effectiveness at higher doses. Maintenance/Extended treatment: There is no evidence available from controlled trials to indicate how long the patient with ADHD should be treated with atomoxetine. It is generally agreed, however, that pharmacological treatment of ADHD may be needed for extended periods. Nevertheless, the physicians who choose to use atomoxetine for extended periods should periodically re- evaluate the long-term usefulness of the drug for the individual patient.<br><br>

<strong>Drug inter:</strong> Albuterol: Atomoxetine should be administered with caution to patients being treated with systemically administered (oral or intravenous) albuterol (or other beta2 agonists), because the action of albuterol on the cardiovascular system can be potentiated resulting in increase in heart rate and blood pressure. CYPO2D6 inhibitors: Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4- hydroxyatomoxetine. Dosage adjustment of atomoxetine may be necessary when coadiministered with CYP2D6 inhibitors, e.g paroxetine, fluoxetine, and quinidine, patients treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6 to 8 fold and Cmax is about 3 to 4 fold greater than atomoxetine alone. Pressor agents: Because of possible effects on blood pressure, atomoxetine should be used cautiously with pressor agents.  </p>
        </div><!-- collapsible -->
  
<div data-role="collapsible"> <!-- collapsible -->
    <h3>SUEV 10 Cap. Square</h3>
    <p>Atomoxetine hydrochloride INN 10mg/capsule 30's pack: 150.00 MRP</p>   
</div><!-- collapsible -->


      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Meniere's disease" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Drugs used in vestibular disorders <br>
	           including Meniere's disease   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

     <div data-role="collapsible-set" data-theme="b">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> CINNARIZINE  </h3>
	          <p>  CINNARIZINE: Tablet<br><br>
Ind: Nausea, vertigo, labyrinthine disorders, motion sickness, Meniere's disease, peripheral vascular disease, Raynaud's syndrome.
<br><br>
<strong>S/E; Cautions:</strong> See under the peripheral vasodilator drugs.<br><br>
<strong>Dosage & admin:</strong> Adult: Nausea, 15-30mg 3 times daily. Vestibular disorder, 25- 30 mg 3 times daily. Motion sickness, 30mg 2 hours before, then 15mg 8 hourly during journey . Child: Under 5 yrs. not recommen ded; 5-12 yrs. half adult dose.  </p>
	        </div><!-- collapsible -->
  				

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>CINARIN Tab. Nipa</h3>
			    <p>Cinnarizine 15mg/tablet 100's pack: 50.00 MRP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>CINARON Tab. Square</h3>
			    <p>Cinnarizine 15mg/tablet 200's pack: 200.00 MRP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>CINARYL Tab. Opsonin</h3>
			    <p>Cinnarizine 15mg/tablet 100's pack: 100.00 MRP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>CINARZIN Tab. Ibn Sina</h3>
			    <p>Cinnarizine 15mg/tablet 100's pack: 100.00 IP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>CINAZIN Tab. Acme</h3>
			    <p>Cinnarizine 15mg/tablet 100's pack: 70.00 MRP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>CINOMYST Tab. Mystic</h3>
			    <p>Cinnarizine 15mg/tablet 100's pack: 70.00 MRP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>INARZIN Tab. Beximco</h3>
			    <p>Cinnarizine 15mg/tablet 100's pack: 90.00 IP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>NEGARON Tab. Gaco</h3>
			    <p>Cinnarizine 30mg/tablet 100's pack: 50.35 MRP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>SUZARON Tab. Rephco</h3>
			    <p>Cinnarizine 15mg/tablet 100's pack: 45.00 MRP</p>   
			</div><!-- collapsible -->

			<div data-role="collapsible"> <!-- collapsible -->
			    <h3>ZINCIN Tab. Aristopharma</h3>
			    <p>Cinnarizine 15mg/tablet 250's pack: 250.00 MRP</p>   
			</div><!-- collapsible -->
      </div><!-- collapsible-set -->





      <div data-role="collapsible-set" data-theme="a">

	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> MECLIZINE  </h3>
	          <p> MECLIZINE HCI: Tablet
Meclizine is a piperazine-derivative antihistamine, used mainly as an antiemetic. It has antiemetic, anticholinergic, and antihistaminic properties. Mode of action: Meclizine reduces the sensitivity of the labyrinthine apparatus. The action may be mediated through nerve pathways to the vomiting centre (VC) from the chemoreceptor trigger zone (CTZ), peripheral nerve pathways, the VC, or other CNS centres.<br><br>

Ind: Prevention and treatment of nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of the vestibular system (e.g Meniere's syndrome, labyrinthitis and other vestibular disturbances). & morning sickness during pregnancy.<br><br>

<strong>C/I:</strong> Known hypersensitivity to meclizine.<br><br>

 <strong>S/E:</strong> Drowsiness, dry mouth, and on rare occasions, blurred vision have been reported.
<br><br> 

<strong>Cautions:</strong> As meclizine may impair mental
alertness or physical coordination, patients should
be warned regarding operating machinery, driving a motor vehicle, and other hazardous activities. Patients should avoid alcoholic beverages while taking this drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.<br><br>

<strong>Pregnancy & lactation:</strong> Based on available data, meclizine found as an antiemetic with lowest risk of teratogenicity and is the drug of first choice in treating nausea and vomiting during pregnancy. Meclizine may excrete into the milk; although it causes no harm to the nursing babies, safety of meclizine has not been established during breast feeding.
<strong>Dosage & admin:</strong> Meclizine is administered orally.<br><br>

Adult & children, 12 years & over: Nausea and vomiting: 25-50mg daily or as directed by the physician. Motion sickness: Take an initial dose of 25-50mg, 1 hour prior to travel; may repeat the dose every 24 hours for the duration of the journey.
Radiation sickness: 50mg administered 2-12 hours prior to radiation treatment. Vertigo: 25- 100mg daily in divided doses.
Emergency contraception: 25-50mg, 1 hour before first ECP dose; repeat if needed in 24 hours.The safety and efficacy for use in children less than 12 years of age have not been established. <br><br>

<strong>Drug inter:</strong> The CNS depressant effects of meclizine can be potentiated by concurrent use of ethanol or other CNS depressant agents such as benzodiazepines, barbiturates, tricyclic antidepressants, opiate agonists, skeletal muscle relaxants, and antihistamines. Concurrent use of other anticholinergics can potentiate the anticholinergic effects of meclizine. Meclizine can also increase the absorption of digoxin by decreasing gastrointestinal motility.<br><br>

Overdosage: Overdosage of the drug is demonstrated by symptoms, such as extreme excitability, seizures, drowsiness and hallucinations. This can be combated by appropriate supportive and symptomatic treatment. Dialysis may be considered. Storage: Store in a cool and dry place (temperature 15¬∞C-30¬∞C).
   </p>
	        </div><!-- collapsible -->
  				
        	<div data-role="collapsible"> <!-- collapsible -->
        	    <h3>ACLIZ Tab. Aristopharma</h3>
        	    <p>Meclizine hydrochloride 50mg/tablet (f.c). 50's pack: 125.00 MRP</p>   
        	</div><!-- collapsible -->

        	<div data-role="collapsible"> <!-- collapsible -->
        	    <h3>AVERT Tab. Bio-pharma</h3>
        	    <p>Meclizine hydrochloride 50mg/tablet (f.c). 100's pack: 250.00 MRP</p>   
        	</div><!-- collapsible -->

        	<div data-role="collapsible"> <!-- collapsible -->
        	    <h3>CLIZIN Tab. Peoples</h3>
        	    <p>Meclizine hydrochloride 50mg/tablet (f.c). 50's pack: 125.00 MRP
        	100's pack: 250.00 MRP</p>   
        	</div><!-- collapsible -->

        	<div data-role="collapsible"> <!-- collapsible -->
        	    <h3>EMENIL Tab. Incepta</h3>
        	    <p>Meclizine hydrochloride 50mg/tablet (f.c). 100's pack: 250.00 MRP</p>   
        	</div><!-- collapsible -->

        	<div data-role="collapsible"> <!-- collapsible -->
        	    <h3>EMEZIN Tab. SK+F</h3>
        	    <p>Meclizine hydrochloride 50mg/tablet (f.c). 50's pack: 125.00 MRP</p>   
        	</div><!-- collapsible -->

        	<div data-role="collapsible"> <!-- collapsible -->
        	    <h3>NOMOSIC Tab. Drug Inter.</h3>
        	    <p>Meclizine hydrochloride 50mg/tablet (f.c). 50's pack: 125.00 MRP</p>   
        	</div><!-- collapsible -->

        	<div data-role="collapsible"> <!-- collapsible -->
        	    <h3>VERTINA Tab. Square</h3>
        	    <p>Meclizine hydrochloride 50mg/tablet (f.c). 50's pack: 125.00 MRP</p>   
        	</div><!-- collapsible -->

        	<div data-role="collapsible"> <!-- collapsible -->
        	    <h3>VOMEC Tab. Beximco</h3>
        	    <p>Meclizine hydrochloride 50mg/tablet (f.c). 30's pack: 75.00 IP
        	50's pack: 125.00 IP
        	100's pack: 250.00 IP</p>   
        	</div><!-- collapsible -->
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="b">
	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> MECLIZINE + PYRIDOXINE  </h3>
	          <p>  MECLIZINE + PYRIDOXINE: Tablet<br><br>
This is a combination preparation of meclizine &
pyridoxine. Meclizine is a piperazine-derivative antihistamine, used as an antiemetic. Pyridoxine (B6) is a vitamin B component having some antiemetic property.
This combination is available as a film coated tablet containing meclizine hydrochloride BP 25mg & pyridoxine hydrochloride BP 50mg. Mode of action: Meclizine: See above under the text of meclizine
Pyridoxine (B6), either alone or in combination has been used to prevent nausea & vomiting due to its antiemetic property.<br><br>

Ind: For prophylaxis and symptomatic relief of nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of vestibular system (e.g Meniere's syndrome, labyrinthitis & other vestibular disturbances) & morning sickness during pregnancy.<br><br>

<strong>C/I:</strong> Known hypersensitivity to meclizine &/or pyridoxine.<br><br>

<strong>S/E; Precautions:</strong> See above under the text of meclizine preparation.<br><br>

<strong>Pregnancy & lactation:</strong> Meclizine: Large scale human studies have not demonstrated adverse fetal effects. Based on available data, it has been suggested that, meclizine presents the lowest risk of teratogenicity and is the drug of first choice in treating nausea and vomiting during pregnancy. Pyrioxine: Pyridoxine itself is considered safe during pregnancy, and has been used in pregnant women without any evidence of fetal harm. <br><br>

<strong>Dosage & admin:</strong> The fixed dose combination (FDC) is recommended for oral administration. <br>
Nausea & vomiting (including morning sickness in pregnancy): One tablet 1-2 times daily or as required.<br>
Motion sickness: The initial dose is one or two tablets daily, it should be taken one hour prior to journey for protection against motion sickness. Therfore, the dose may be repeated every 24 hours as indicated for the duration of the journey. Vertigo: One tablet two times daily or as required. Labyrinthine and vestibular disturbances: The optimal dosage of meclizine is usually 25-100mg daily in divided doses, depending on the clinical response.<br>
Radiation sickness: 50mg (meclizine)
administered 2-12 hours prior to radiation
treatment.<br>
Dosage in pregnancy: Meclizine: Dosage varies from 25-50mg/day in pregnancy or as required. Not recommended in last 2 weeks of pregnancy due to retrolental fibroplasia risk. Pyridoxine: 75mg/day is FDA-approved for use in
pregnancy. Pregnant and breast feeding women should not take more than 100mg/day without a doctor's supervision.<br><br>
<strong>Drug inter:</strong> See above under the text of
meclizine.<br>
Overdosage: See above under the text of meclizine.<br>
Storage: Store in a cool and dry place (temperature 15¬∞C-30¬∞C).  </p>
	        </div><!-- collapsible -->
  			
  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>DEVOMIT Tab. Silva</h3>
  			    <p>Meclizine hydrochloride BP 25mg + pyridoxine hydrochloride BP 50mg/tablet (film coated). 50's pack: 1125.00 MRP</p>   
  			</div><!-- collapsible -->
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="b">
	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> PROMETHAZINE  </h3>
	          <p>  PROMETHAZINE THEOCLATE: Tablet<br>
Ind: Nausea, vertigo, labyrinthine disorders, motion sickness (acts longer than the promethazine hydrochloride).<br>
<strong>C/I:</strong> Sensitivity to phenothiazine derivatives.<br><br>

 <strong>S/E:</strong> Drowsiness, headache, dry mouth, gastro-intestinal disturbances, blurred vision.<br>
Caution: Hepatic disease, impairment in driving machinery; alcohol increases CNS depression.<br>
 Adult: 25-75 mg daily. For severe nausea & vomiting in pregnancy, 25mg at bedtime, increased if necessary to a max. of 100mg daily. Child: 5-10 years. 12.5-37.5mg daily.</p>
	        </div><!-- collapsible -->
  				
  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>AVOMINE Tab. Sanofi Aventis</h3>
  			    <p>Promethazine theoclate 25mg/tablet. 500's pack: 290.00 MRP</p>   
  			</div><!-- collapsible -->
      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="a">
	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3> PROCHLORPERAZINE  </h3>
	          <p> Ind: Nausea, vomiting, vertigo, labyrinthine disorders, motion sickness, (and acts as anti- histaminic).
	          <br>
            C/I; S/E; Caution: see above i.e as P. theoclate.<br>
             <strong>Dosage & admin:</strong> By mouth: Adult, 25-50mg daily in single or divided doses; Child, daily, upto 1 year 5-10mg; 1-5 yrs. 10-15 mg; 6-12 yrs. 15- 25mg.<br>
            By injection: Deep i.m injection, half oral dose. Prepns: See in the section of antihistaminics.</p>
	        </div><!-- collapsible -->
  			

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>AMETIL Tab. Aristopharma</h3>
  			    <p>Prochlorperazine 5mg/tablet. 250's pack: 72.50 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>AVOTIL Tab. Rephco</h3>
  			    <p>Prochlorperazine 5mg/tablet. 100's pack: 30.00 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>EMITAB Tab. Sonear</h3>
  			    <p>Prochlorperazine 5mg/tablet 100's pack: 30.00 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>MELATIL Tab. Gaco</h3>
  			    <p>Prochlorperazine 5mg/tablet 100's pack: 27.83 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>MELATIL Inj. Gaco Prochlorperazine</h3>
  			    <p>mesylate 12.5mg/ml: injection 1 ampoule: 3.54 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>PROMAT Tab. Navana</h3>
  			    <p>Prochlorperazine maleate 5 mg/tablet. 200's pack : 58.00 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>STEMETIL Tab. Sanofi Aventis</h3>
  			    <p>Prochlorperazine maleate 5mg/tablet. 500's pack: 150.00 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>STEMETIL Inj. Sanofi Aventis</h3>
  			    <p>Prochlorperazine mesylate 12.5mg/ml: injection 1ml amp x 10's pack: 50.00 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>VERGON Tab. Opsonin</h3>
  			    <p>Prochlorperazine maleate 5mg/tablet. 200's pack: 60.00 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>VERGON Inj. Opsonin</h3>
  			    <p>Prochlorperazine mesylate 12.5mg/ml: injection
  			5 amps pack: 25.00 MRP</p>   
  			</div><!-- collapsible -->

  			<div data-role="collapsible"> <!-- collapsible -->
  			    <h3>VERTIGAN Tab. Pharmadesh</h3>
  			    <p>Prochlorperazine maleate 5mg/tablet. 250's pack: 75.00 MRP</p>   
  			</div><!-- collapsible -->
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="b">
	        <div data-role="collapsible"> <!-- collapsible -->
	          <h3>BETAHISTINE-Drugs for Meniere's disease  </h3>
	          <p> BETAHISTINE: Tablet<br><br>
Betahistine is a histamine analog that was developed following successful parenteral use of histamine in patients with Meniere's syndrome.
Betahistine is available as betahistine dihydrochloride & mesylate.<br><br>

Mode of action: Betahistine relieves dizziness & vertigo symptoms by improving circulation in the microvasculature of the inner ear which leads to a pressure reduction on the membranous labyrinth and relives the symptoms of Meniere's disease. Ind: Meniere's disease and Meniere's-like syndromes characterized by attacks of dizziness and feeling of dizziness, vertigo, tinnitus and/or progressive loss of hearing, usually accompanied also by nausea and vomiting.<br><br>

<strong>C/I:</strong> Betahistine is contraindicated in Pheochromocytoma.<br><br>
<strong>S/E:</strong> Betahistine is generally well tolerated and there is no known serious adverse effects. In some circumstances gastrointestinal disturbances (nausea/vomiting), headache, rashes and pruritus have been reported.<br><br>

<strong>Cautions:</strong> Caution should be exercised in patients with- i. bronchial asthma (since betahistine has a histamin-like action, it may cause respiratory tract contraction through the intervention of H1-receptors), ii. and peptic ulceration (since betahistine has a histamin-like action, it may enhance gastric acid secretion through the intervention of H2-receptors). <br><br>

<strong>Pregnancy & lactation:</strong> The safety of Betahistine in human pregnancy has not been completely established, although there is no known teratogenic effects in animals. A careful assessment of potential benefit should be made before prescribing Betahistine in pregnancy. Betahistine is excreted in the breast milk of mursing mother in concentrations similar to those found in plasma. But, toxicity to the neonate at these concentrations is not known.<br><br>

<strong>Dosage & admin:</strong> See below under the individual preparation.<br><br>

<strong>Drug inter:</strong> There are no proven cases of hazardous interactions. Yet there may be a chance of antagonism between Betahistine and antihistamines on a theoretical basis, but no such interactions have been reported.   </p>
	        </div><!-- collapsible -->
  				

  			<div data-role="collapsible">
  			<H3>MENARIL Tab. Incepta</H3>
  			<p>Betahistine dihydrochloride INN 8mg/tablet<br>
  			 Ind; C/I; S/E; Cautions: See above under the
  			text.<br>
  			<strong>C/I:</strong> The usual initial dose is 8mg to 16mg 3 times daily taken preferably with meals; maintenance dosage up to 48mg daily have been recommended.<br>
  			Children: Not recommended for children.100's pack: 200.00 MRP</p>
  			</div>

  			<div data-role="collapsible">

  			<H3>MERISON Tab. Square</H3>
  			<p>Betahistine mesylate INN 6mg/tablet<br>
  			Ind; C/I; S/E; Cautions: See above under the text.<br>
  			<strong>Dosage & admin:</strong> The usual initial dose is 6mg to 12mg 3 times daily taken preferably after meals. The dosage may be adjusted depending on the patient's age and symptoms. Maintenance dosage may be given up to 36mg daily.<br>
  			Children: Not recommended for children.
  			100's pack: 200.00 MRP</p>
  			</div>

      </div><!-- collapsible-set -->
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Symtomatic relief" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>Symptomatic relief of nausea & <br>
      vomiting from underlying diseases    </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  METOCLOPRAMIDE </h3>
          <p>  METOCLOPRAMIDE HCI: Tablet/ Syrup/ Drop/Injection.<br>
Ind: Nausea & vomiting particularly due to gastro-intestinal disorders; Migraine, intolerence to drugs (i.e. vomiting); Congestive heart failure Post-operative conditions; Deep X-ray or cobalt therapy.<br>
<strong>S/E:</strong> Drowsiness, constipation, extra pyra-midal effects ( spcecially in children.)<br>
<strong>Cautions:</strong> Parkinsonism; Children; Concurrent admin. of anti cholinergics, phenothiazines or butyrophenones.<br>
Adult: 15 to 20 years 5-10mg; others, 10mg. Both 3 times daily.<br>
Child: Under 1 yr, 1 mg twice daily; 1-3 yrs. 1mg 2 or 3 times daily ; 3-5 yrs. 2mg 2 or 3 times daily; 5-14 yrs
2.5-5mg 3 times daily. All orally, i.m or i.v. Usual max. doses, all ages 0.5mg/kg body-wt. daily.  </p>
        </div><!-- collapsible -->
  			
  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MAXIL Tab. Nipa</h3>
  		    <p>Metoclopramide hydrochlor. 10mg/tablet. 100's pack: 34.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MAXIL Syp. Nipa</h3>
  		    <p>Metoclopramide 5mg/5ml: syrup
  		100m1 bot: 14.11 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MAXOCOL Tab. Medimet</h3>
  		    <p>Metoclopramide hydrochlor. 10mg/tablet.
  		100's pack: 31.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MAXOCOL Syp. Medimet</h3>
  		    <p>Metoclopramide hydrochloride 5mg/5ml: syrup. 100ml bot: 14.90 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MECLID Tab. Jayson</h3>
  		    <p>Metoclopramide hydrochlor. 10mg/tablet.
  		100's pack: 32.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MECLID Inj. Jayson</h3>
  		    <p>Metoclopramide hydrochloride 10mg/2ml ampoule: injection
  		10 amps pack: 35.40 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>METOCOL Tab. Opsonin</h3>
  		    <p>Metoclopramide hydrochlor. 10mg/tablet
  		100's pack: 32.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>METOCOL Syp. Opsonin</h3>
  		    <p>Metoclopramide hydrochlor. 5mg/5ml: syrup 100m1 hot.: 13.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>METOCOL Drop Opsonin</h3>
  		    <p>Metoclopramide hydrochloride 1mg/1ml: drop 15ml bot: 9.50 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MOTILON Tab. Sanofi Aventis</h3>
  		    <p>Metoclopramide hydrochloride 10mg/tablet 500's pack: 170.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MOTILON Syp. Sanofi Aventis</h3>
  		    <p>Metoclopramide hydrochloride 5mg/5ml: syrup 100ml bot: 15.77 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MOTILON Drop Sanofi Aventis</h3>
  		    <p>Metoclopramide hydrochlor. 1mg/1ml: drop 15ml bot: 9.77 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MOTILON Inj. Sanofi Aventis</h3>
  		    <p>Metoclopramide hydrochloride 10mg/2ml ampoule: injection
  		10 amps. pack: 37.50 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MOVLAN Tab. Gaco</h3>
  		    <p>Metoclopramide hydrochloride 10mg/tablet 100's pack: 30.48 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MOVLAN Syp. Gaco</h3>
  		    <p>Metoclopramide hydrochloride 5mg/5ml: syrup 100m1 bot: 14.11 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>NUTRAMID Tab. Acme</h3>
  		    <p>Metoclopramide hydrochloride 10mg/tablet.100's pack: 34.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>NUTRAMID Syp. Acme</h3>
  		    <p>Metoclopramide hydrochloride 5mg/5ml: syrup 60m1 bot: 10.63 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>NUTRAMID Drop Acme</h3>
  		    <p>Metoclopramide hydrochloride 1mg/1ml : drop 15ml bot: 9.61 MRP</p>   
  		</div><!-- collapsible -->
      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="nausea" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Drugs used in nausea & vomiting induced <br>
		by cytostatic chemotherapy & radiotherapy   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>GRANISETRON  </h3>
          <p>  GRANISETRON HCI: Tablet/Injection<br>
Granisetron is a selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors. It is available as tablet and injection form. Each tablet contains granisetron 1mg as granisetron hydrochloride INN. Each injection ampoule contains granisetron 1mg in 1ml as granisetron hydrochloride INN.<br><br>

Mode of action: Granisetron is a selective 5- hydroxytryptamine 3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-TH1, 5HT1A, 5-HT1B/C, 5-HT4; for alpha1, alpha2, or beta adrenoceptors; for dopamine D2; or for histamine H1; benzodiazepine; picrotoxin; or opioid receptors. Ind: Granisetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy including high dose cisplatin; the prevention and treatment of postoperative nausea and vomiting.Tablet preparation is also indicated for nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high dose cisplatin; nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. <br><br>

<strong>C/I:</strong> Granisetron is contraindicated in patients with known hypersensitivity to this drug.<br><br>
<strong>S/E:</strong> Headache, constipation, asthenia, diarrhea, abdominal pain, dyspepsia, nausea and vomiting, dizziness, insomnia, anxiety.
<br><br>

<strong>Pregnancy & lactation:</strong> No evidence of impaired fertility or harm to the animal fetus have been found. However, this drug may be used in pregnancy only if clearly needed. It is also not known whether granisetron is excreted in human milk, so, caution shoud be exercised when granisetron is administered to a nursing mother. <br><br>

<strong>Dosage & admin:</strong> By Injection:<br>
Prevention of chemotherapy induced nausea & vomiting: Adults- the recommended dosage is 10mcg/kg administered i.v within 30 minutes before initiation of chemotherapy, and only on the day(s) chemotherapy is given; injection may be administered i.v either undiluted over 30 seconds, or diluted with 0.9% sodium chloride or 5% dextrose and infused over 5 minutes. Paediatric patients- the recommended dose in paediatric patients 2-16 years of age is 10mcg/kg; uses of this drug under 2 years of age have not been studied. Geriatric patients, renal failure patients or hepatically impaired patients- no dosage adjustment is required.<br>

Prevention & treatment of postoperative nausea & vomiting: Adults- the recommended dosage for prevention of postoperative nausea and vomiting is, a single dose of 1mg (1mI) of injection should be diluted to 5m1 and administered as a slow i.v injection (over 30 seconds); administration should be completed prior to induction of anesthesia. For the treatment of established post-operative nausea and vomiting in adults, a single dose of 1mg (1m1) of injection should be diluted to 5m1 and administered by slow i.v injection (over 30 seconds). The recommended dosage for the treatment of nausea and/or vomiting after surgery is 1mg (1m1) of injection undiluted, administered i.v over 30 seconds. Paediatric patients- safety and effectiveness of parenteral injection have not been established. Geriatric patients, renal failure patients or hepatically impaired patients- no dosage adjustment is required.<br>
Tablet preparation:<br>
Emetogenic chemotherapy: The recommended adult dosage of oral granisetron is 2mg once daily or 1mg twice daily. In the 2mg once-daily regimen, two 1mg tablets are given up to one hour before chemotherapy; in the 1mg twice- daily regimen, the first 1mg tablet is given up to one hour before chemotherapy, and the second tablet 12 hours after the frist; either regimen is administered only on the day(s) chemotherapy is given. Use in the elderly, renal failure patients or hepatically impaired patients- no dosage adjustment is required. Radiation (either total body irradiation or fractionate abdominal radiation): The recommended adult dosage of oral granisetron is 2mg once daily; two 1mg tablets are taken within one hour of irradiation. Paediatric use- there is no experience with oral granisetron in the prevention of radiation induced nausea and vomiting in paediatric patients.  </p>
        </div><!-- collapsible -->
  
        <div data-role="collapsible"> <!-- collapsible -->
            <h3>KYTRIL Tab. Roche</h3>
            <p>Granisetron hydrochloride INN equivalent to granisetron 1mg/tablet.
        1mg x l's pack: 303.75 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>KYTRIL Inj. Roche</h3>
            <p>Granisetron hydrochloride INN equivalent to granisetron 1mg/1ml ampoule: injection 1mg (1ml) amp x l's pack: 641.25 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NAURIF Tab. Square</h3>
            <p>Granisetron hydrochloride INN equivalent to 1mg x 20's pack: 560.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NAURIF Inj. Square</h3>
            <p>Granisetron hydrochloride INN equivalent to granisetron 1mg/1ml ampoule: injection 1mg (1ml) amp x 5's pack: 240.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ONDANSETRON </h3>
          <p>  ONDANSETRON: Tablet/Injection<br>
Ondansetron hydrochloride dihydrate is a potent, highly selective 5-HT3 (serotonin) receptor antagonist.<br>

Mode of action: Cytostatic chemotherapeutic agents & radiotherapy may cause increase in serotonin level by stimulating the mucous membrane of the stomach & the small intestine. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema located on the floor of the fourth ventricle. Serotonin, by the activation of peripheral vagal afferent fibres containing 5-HT3 receptors initiates vomiting reflex, and also promotes emesis by stimulating 5-HT3 receptors present in the central chemoreceptor trigger zone of the area postrema. Ondansetron due to antagonism of 5-HT3 receptors on neurons located both in the central & peripheral nervous system, inhibits the triggering of vomiting reflex. <br><br>

Ind: Prevention and treatment of nausea nad vomiting induced by cytostatic chemotherapy and radiotherapy and postoperative nausea & vomiting. <br><br>

<strong>C/I:</strong> Hypersensitivity of any component of the preparation; pregnancy and lactation.<br><br>

<strong>S/E:</strong> Headache, sensation of warmth or flushing; occasional alterations in liver enzymes; constipation; on rare occasions hypersensitivity reactions (including anaphylaxis); transient visual disturbance and dizziness (after rapid i.v administra-tion), pain, arrhythmias, bradycardia, hypotension, hiccup.<br><br>

<strong>Dosage & admin:</strong> By mouth:<br>
A. Incaseofmoderatelyemetogenic chemotherapy:<br>
Adult: 8mg orally 1 to 2 hours before
treatment, then followed by 8mg every 12
hours for up to 5 days (or up to 1 to 2 days
after completion of chemotherapy).<br>
Children (4 to 11 years age): The dosage is 4mg given 8 or 12 hourly 2 or 3 times a day for up to 5 days.
B. Severely (highly) emeto genic chemotherapy: Adult: The recommended adult oral dosage is 24mg (3 tablets) to be administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin = 50mg/m2. Then followed by 8mg orally every 12 hours for up to 5 days.
For geriatric patients, same as the general population.
The efficacy of ondansetron in highly emetogenic chemotherapy may be enhanced by addition of a single dose of 20mg dexmaethasone sodium phosphate by i.v injection administered prior to chemotherapy. Children (4 to 11 years age): The dosage is 4mg given 8 or 12 hourly 2 or 3 times a day for up to 5 days.
C. Radiotherapy induced nausea and vomiting:
The recommended oral dosage is one 8mg
tablet given 3 times a day.
i. For total body irradiation, one 8mg tablet should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
ii. For single high-dose fraction radiotherapy to the abdomen, one 8mg tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
iii. For daily fractionated radiotherapy to the abdomen, one 8mg tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given. D. Prevention of postoperative nausea and vomiting:
Adult- 16mg orally 1 hour before anaesthesia or 8mg 1 hour before anaesthesia followed by 8mg at intervals of 8 hours for 2 further doses. By injection:
A. Moderatelyemetogenicchemotherapyor radiotherapy: By i.m or slow i.v injection 8mg immediately before treatment.
B. Severelyemetogenicchemotherapy:Byi.mor slow i.v njection 8mg immediately before treatment, when necessary followed by 8mg at intervals of 2-4 hours for further 2 doses. Children: By slow i.v injection 5mg/m2 immediately before chemotherapy.
C. Prevention and treatment of postoperative nausea and vomiting: By i.m or solw i.v injection 4mg at induction of anaesthesia. Children (over 2 years): By slow i.v injection, 100mcg/kg (maximum 4mg before, during or after induction of anaesthesia.  </p>
        </div><!-- collapsible -->
      	
      	<div data-role="collapsible"> <!-- collapsible -->
      	<h3>EMETRON Inj. Gedeon Richter/City
      	Overseas</h3>
      	<p>Ondansetron hydrochloride dihydrate equivalent to ondansetron 2mg/ml; 4ml ampoule: i.v injection. 4ml amp (8mg) x 5's pack: 286.50 TP</p>   
      	</div><!-- collapsible -->

      	<div data-role="collapsible">
      	<h3>EMISTAT Tab. Healthcare</h3>
      	<p>Ondansetron hydrochloride dihydrate equivalent to ondansetron 8mg/tablet (f.c).
      	8mg x 30's pack: 300.00 MRP</p>
      	</div>

      	<div data-role="collapsible">
      	<h3>EMISTAT Inj. Healthcare</h3>
      	<p>Ondansetron hydrochloride dihydrate BP 2.49mg equivalent to ondansetron 2mg/ml; 4m1 ampoule: i.v injection.
      	4ml amp (8mg) x 5's pack: 150.00 MRP</p>
      	</div>

      	<div data-role="collapsible">
      	<h3>ONASERON Tab. Incepta</h3>
      	<p>Ondansetron hydrochloride dihydrate equivalent to ondansetron 8mg/tablet (f.c).
      	8mg x 30's pack: 300.00 MRP</p>
      	</div>

      	<div data-role="collapsible">
      	<h3>ONASERON Inj. Incepta</h3>
      	<p>Ondansetron hydrochloride dihydrate BP 2.49mg equivalent to ondansetron 2mg/ml; 4ml ampoule: i.v injection.
      	4ml amp (8mg) x 5's pack: 125.00 IP</p>
      	</div>

      	<div data-role="collapsible">
      	<h3>ONSAT 8 Tab. Beximco</h3>
      	<p>Ondansetron hydrochloride dihydrate equivalent to ondansetron 8mg/tablet (f.c).
      	8mg x 30's pack: 300.00 IP</p>
      	</div>

      	<div data-role="collapsible">
      	<h3>SETON 8 Tab. Delta</h3>
      	<p>Ondansetron hydrochloride dihydrate equivalent to ondansetron 8mg/tablet (f.c).
      	8mg x 30's pack: 240.00 MRP</p>
      	</div>

      	<div data-role="collapsible">
      	<h3> ZOFER MD 4 Tab. Sun Pharma</h3> 
      	<p>Ondansetron hydrochloride dihydrate equivalent to ondansetron 4mg/tablet (f.c).
      	4mg x 30's pack: 117.00 MRP<p/>
      	</div>

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


<!-- /................page............................ -->



<div data-role="page" id="Antiepileptic Drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Antiepileptic Drugs  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

     <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CARBAMAZEPINE  </h3>
          <p>  CARBAMAZEPINE: Tablet/Syrup<br>
Ind: Grandmal and temporal lobe epilepsy, trigeminal neuralgia, prophylaxis in manic depressive illness.<br>
<strong>C/I:</strong> Hypersensitivity to carbamazepine, patients on MAO inhibitors or within 2 weeks of MAOI therapy.<br>
<strong>S/E:</strong> Dizziness, drowsiness, visual and g.i disturbances; generalised erythematous rash (3%); leucopenia rarely.<br>
<strong>Cautions:</strong> Renal or hepatic impairment. Blood dyscrasias. Pregnancy . Lactation.<br>
Concurrent admin. of doxycycline, oral anticoagulants and oral contraceptives. Blood
count regularly.<br>
<strong>Dosage & admin:</strong> Adult: Initially 100-200mg once or twice daily increasing slowly to optimum dosage, usually 800mg to 1.2gm daily. Max . 1.6gm daily.<br>
Child: Upto 1 year, 100-200 mg; 1-5 years 200- 400mg; 5-10 years, 400-600mg; 10-15 years 600mg-1gm. All daily in divided doers.  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>CARBAZIN Tab. SK+F</h3>
            <p>Carbamazepine 200mg/tablet
        50's pack: 152.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>CARMAZ Tab. Aristopharma</h3>
            <p>Carbamazepine 200mg/tablet
        50's pack: 200.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>EPILEP Tab. Beximco</h3>
            <p>Carbamazepine 200mg/tablet
        50's pack: 175.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>EPILEP CR Tab. Beximco</h3>
            <p>Carbamazepine 200mg/tablet (controlled release) 50's pack: 225.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TEGRETOL Tab. Novartis</h3>
            <p>Carbamazepine 200mg/tablet
        50's pack: 275.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TEGRETOL CR Tab. Novartis</h3>
            <p>Carbamazepine 200mg/tablet (controlled release) 50's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TEGRETOL Syp. Novartis</h3>
            <p>Carbamazepine 100mg/5ml: syrup
        100ml bot: 340.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ZEPTOL Tab. Sun Pharma</h3>
            <p>Carbamazepine 200mg/tablet
        100's pack: 350.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ZEPTOL CR Tab. Sun Pharma</h3>
            <p>Carbamazepine 200mg/tablet (controlled release) 100's pack: 430.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
           <h3>CLOBAZAM   </h3>
           <p>  CLOBAZAM: Tablet/Capsule<br>
          Ind: adjunct in epilepsy, anxiety<br>
          C/I; S/E; Cautions: See under diazepam in the section of anxiolytic drugs.<br>
          Adult: Anxiety, 20-30mg daily in divided doses; max. 60mg daily. Epilepsy, 20-30mg daily. Child: Under 3 yrs. not recommended; 3-12 yrs. upto half adult dose.<br>
          Preparations: see under Sedative, Tranquillisers & Anxiolytices. </p>
         </div><!-- collapsible -->
       </div><!-- collapsible-set -->


       <div data-role="collapsible-set" data-theme="e">

          <div data-role="collapsible"> <!-- collapsible -->
            <h3> CLONAZEPAM  </h3>
            <p> CLONAZEPAM: Tablet/Drop/Injection <br>
            Ind: All forms of epilepsy;. myoclonus; status epilepticus.<br>
<strong>C/I:</strong> Respiratory depression; acute pulmonary insufficiency.<br>
<strong>S/E:</strong> Drowsiness; fatigue, dizziness, muscle hypotonia, coordination disturbances; hypersalivation in infants, paradoxical aggression, irritability and mental changes; rarely blood disorders, abnormal liver-function tests. Cautions: Respiratory disease, hepatic and renal impairment, elderly and debilitated; pregnancy and breast- feeding; avoid sudden withdrawal; porphyria.<br>
Driving: Drowsiness may affect the performance of driving and other skilled tasks.<br>
<strong>Dosage & admin:</strong> Adult: 1mg (elderly, 0.5mg), initially at night for 4 nights, increased over 24 weeks to a usual maintenance dose of 4-8mg daily in divided doses.<br>
Child, up to 1 year 250mcg increased as above to 0.5-1mg, 1-5 years 250mcg increased to 1- 3mg, 5-12 years 500mcg increased to 3-6mg. Overdosage: See treatment of poisoning.   </p>
          </div><!-- collapsible -->
       		

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>AROTRIL Tab. Aristopharma</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 50's pack: 100.00 MRP 2mg x 30's pack: 120.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>CLONAPIN Tab. Popular</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 30's pack: 60.00 IP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>CLORON Tab. SK+F</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 50's pack: 100.00 MRP 2mg x 30's pack: 120.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>DEPANIL Tab. Rangs</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 50's pack: 100.00 MRP 2mg x 30's pack: 120.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>DISOPAN Tab. Incepta
       		Clonazepam</h3>
       		    <p>0.5mg & 2mg/tablet. 0.5mg x 100's pack: 200.00 MRP 2mg x 50's pack: 200.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>DISOPAN Drop Incepta</h3>
       		    <p>Clonazepam 2.5mg/ml: drop. 10m1 drop: 80.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>EPICLON Tab. General</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 50's pack: 100.00 MRP 2mg x 30's pack: 120.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>EPITRA Tab. Square</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 100's pack: 200.00 MRP 2mg x 50's pack: 200.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>EPNIL Tab. Sandoz/Novartis</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 50's pack: 112.50 MRP 2mg x 30's pack: 135.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>LEPTIC Tab. Acme</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 100's pack: 200.00 MRP 2mg x 50's pack: 200.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>LONAZEP Tab. Sun Pharma</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 50's pack: 101.50 MRP 2mg x 50's pack: 210.50 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>PASE Tab. Opsonin</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 50's pack: 100.00 MRP 2mg x 30's pack: 120.00 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>RIVOTRIL Tab. Roche</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 50's pack: 250.50 MRP 2mg x 30's pack: 300.30 MRP</p>   
       		</div><!-- collapsible -->

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>XETRIL Tab. Beximco</h3>
       		    <p>Clonazepam 0.5mg & 2mg/tablet. 0.5mg x 100's pack: 200.00 IP 2mg x 50's pack: 200.00 IP</p>   
       		</div><!-- collapsible -->
        </div><!-- collapsible-set -->


        <div data-role="collapsible-set" data-theme="b">
           <div data-role="collapsible"> <!-- collapsible -->
             <h3>  DIAZEPAM </h3>
             <p> DIAZEPAM: Injection/Suppositories.
              Ind: Status epilepticus; febrile and other convulsions where rapid effect is reqd.
              C/I; S/E; Cautions: See under Anxiolytic drugs. Adult: 10-20mg i.m or i.v at a rate of 2-5 mg/30 sec. repeated after 30-60 mins. if necessary . Then upto 3mg/ kg body-wt. by i.v inj. over 24 hours.
              Child: 0.2-0.3 mg/kg.
              Diazepam preprs: See under Sedatives & Anxiolytics   </p>
           </div><!-- collapsible -->
         </div><!-- collapsible-set -->



         <div data-role="collapsible-set" data-theme="a">

            <div data-role="collapsible"> <!-- collapsible -->
              <h3> LAMOTRIGINE  </h3>
              <p> LAMOTRIGINE: Tablet<br><br>

Ind: Monotherapy of partial seizures and primary and secondarily generalised tonic-clonic seizures; adjunctive treatment of partial seizure and secondarily generalised tonic-clonic seizures.<br><br>
 
<strong>C/I:</strong> Hepatic impairment.<br><br>

<strong>S/E:</strong> Commonly rashes, fever, malaise, influenza- like symptoms, drowsiness; rarely hepatic dysfunction, lymphadeno-pathy, leucopenia, and thrombocytopenia reported in conjuction with rash; angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis and photosensitivity also reported; diplopia, blurred vision, dizziness drowsiness insomnia, headache, ataxia, tiredness, gastrointestinal disturbances, irriability, aggression, tremor, agitation, confusion; headache, nausea dizziness, diplopia and ataxia in patients also taking carbamazepine usually resolve when dose of either drug reduced. <br><br>

<strong>Cautions:</strong> Closely monitor (including hepatic, renal and clotting parameters) and consider withdrawal if rash, fever, influenza-like symptoms, drowsiness, or worsening of seizure control develops, specially in the first month of treatment. (It is found that lamotrigine given with other antiepileptics has been associated with rapidly progressive illness with status epilepticus, multi-organ dysfunction, disseminated intravascular coagulation & death). Avoid abrupt withdrawal (taper off over 2 weeks or longer). Renal impairment. Pregnancy & breast-feeding. <br><br>

Dose: Important, do not confuse the different combinations:<br>
Monotherapy, initially 25mg daily for 14 days then 50mg daily for further 14 days; usual maintenance as monotherapy, 100-200mg daily in 1-2 divided doses (up to 500mg daily has been required); Elderly not recommended. Adjunctive therapy with valproate- initially 25mg every other day for 14 days then 25mg daily for further 14 days; usual maintenance with valproate 100-200mg daily in 1-2 divided doses; Elderly not be recommended. Adjunctive therapy without valproate- initially 50mg daily for 14 days then 50mg twice daily for further 14 days; usual maintenance without valproate 200-400mg daily in 2 divided doses; Elderly not recommended.
Child: 2-12 years, adjunctive therapy with valproate, initially 200mcg/kg daily for 14 days then 500mcg/kg daily for further 14 days (those weighing less than 25kg may receive 5mg on alternate days for first 14 days); usual maintenance with valproate 1-5mg/kg daily in 1-2 divided doses.<br>

Child: 2-12 years adjunctive therapy without valproate, initially 2mg/kg daily in 2 dividd doses for 14 days then 5mg/kg daily in 2 divided doses for further 14 days; usual maintenance without valproate 5-15mg/kg daily in 2 divided doses.   </p>
            </div><!-- collapsible -->
         	
         	<div data-role="collapsible"> <!-- collapsible -->
         	    <h3>LAMICTAL Tab. GlaxoSmithKline</h3>
         	    <p>Lamotrigine 50mg/tablet 30's pack: 1575.90 MRP</p>
         	</div><!-- collapsible -->

         	<div data-role="collapsible"> <!-- collapsible -->
         	    <h3>LAMITRIN Tab. ACI</h3>
         	    <p>Lamotrigine 50mg/tablet 30's pack: 240.00 MRP</p>   
         	</div><!-- collapsible -->
        </div><!-- collapsible-set -->



          <div data-role="collapsible-set" data-theme="b">

             <div data-role="collapsible"> <!-- collapsible -->
               <h3> OXCARBAZEPINE  </h3>
               <p> OXCARBAZEPINE: Tablet<br>
              Oxcarbazepine 300mg and 600mg/tablet (f.c). Ind: Epilepsy- partial seizures or generalised tonic-clonic seizures.<br>

              <strong>C/I:</strong> Hypersensitivity to oxcarbazepine or any other component of the formulation.<br><br>

              <strong>S/E:</strong> Very common- fatigue, dizziness, headache, somnolence, nausea, vomiting, diplopia. Common- asthenia, agitation, amnesia, apathy, ataxia, impaired concentration, confusion, depression, emotional lability, nystagmus, tremor, constipation, diarrhoea, abdominal pain, asymptomatic hyponatraemia, acne, alopecia, rash, vertigo, vision disorders. Uncommon- leucopenia, increase of liver enzymes, urticaria. Very rare- angioedema, multiorgan hypersensitivity disorders, arrhythmia, thrombocytopenia, hepatitis, symptomatic hyponatraemia, Stevens-Johnson syndrome, systemic lupus erythematosus.<br><br>

              Precautions & warnings: Hypersensitivity to carbamazepine. Pregnancy and lactation. Impaired renal function (creatinine clearance- >30ml/min). Hyponatraemia (specially in patients on sodium- lowering comedication). Patients with pre-existing cardiac insufficiency and secondary heart failure. Hepatitis. Abrupt discontinuation of treatment. Road and machinery users. Alcohol.<br><br>

              Dosage: Adults 600-2400mg/day. Children of 2 years of age and above 8-46mg/kg/day. Administration in two divided doses.<br><br>

              <strong>Drug inter:</strong> Felodipine, oral contraceptives. Antiepileptics (e.g carbamazepine, phenobarbital, phenytoin).<br><br>

              Note: For further information consult full prescribing information.
                 </p>
          </div><!-- collapsible -->
      
             <div data-role="collapsible"> <!-- collapsible -->
                 <h3>LEPTAL Tab. Healthcare</h3>
                 <p>Oxcarbazepine INN 300mg & 600mg/tablet (f.c). 300mg x 30's pack: 540.00 IP</p>   
             </div><!-- collapsible -->

             <div data-role="collapsible"> <!-- collapsible -->
                 <h3>OXETOL Tab. Sun Pharma</h3>
                 <p>Oxcarbazepine 150mg & 300mg/tablet (f.c). 150mg x 50's pack: 250.00 MRP 300mg x 50's pack: 450.00 MRP</p>   
             </div><!-- collapsible -->

             <div data-role="collapsible"> <!-- collapsible -->
                 <h3>TRILEPTAL Tab. Novartis</h3>
                 <p>Oxcarbazepine 300mg and 600mg/tablet (f .c). 300mg x 50's pack: 1250.00 MRP 600mg x 50's pack: 2250.00 MRP</p>   
             </div><!-- collapsible -->
           </div><!-- collapsible-set -->



           <div data-role="collapsible-set" data-theme="e">
              <div data-role="collapsible"> <!-- collapsible -->
                <h3> PHENOBARBITONE  </h3>
                <p> PHENOBARBITONE:Tablet/Injection Ind: All forms of epilepsy, convulsions.<br>

<strong>C/I:</strong> Patients with a history of alcohol or drug abuse, acute intermittent porphyria.<br>
<strong>S/E:</strong> drowsiness, lethargy, ataxia and allergic skin reacitons; paradoxical excitement, restlessness and confusion in the elderly & hyperkinesia in children, megaloblastic anaemia.<br>
<strong>Cautions:</strong> Liver disorder, renal impairment, severe pulmonary insufficiency, the elderly & debilited, pregnancy, lactation. Tolerence and dependence may develop.<br>
By mouth: Adult, 60-180mg at night; child 5- 8mg/kg daily (febrile convulsion, 3-4mg/kg daily).<br>
By i.m or i.v injection: Adult, 50-200mg as a single dose, repeat after 6 hours if necessary, max. 600mg daily; Child, by i.m or i.v injection, upto 1 year 30- 60mg; 1-5 years 90mg; 6-12 years 120mg, or 3-5mg /kg intrmauscularly.
(For i.v. administration, dilute injection 1 in 10 with water before administration).   </p>
              </div><!-- collapsible -->
           		

       		<div data-role="collapsible"> <!-- collapsible -->
       		    <h3>BERDINAL Tab. Gaco</h3>
       		    <p>Phenobarbitone 50mg/tablet 100's pack: 23.85 MRP</p>   
       		</div><!-- collapsible -->
        </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="a">
         <div data-role="collapsible"> <!-- collapsible -->
           <h3>PHENYTOIN   </h3>
           <p> PHENYTOIN: Tablet/ Capsule/ Syrup <br>
           Ind: Grandmal & temporal lobe epilepsy, trigeminal neuralgia, migraine.<br>
          <strong>C/I:</strong> Avoid i. v injection in patients with bradycardia or heart block.<br>

          <strong>S/E:</strong> Nausea, vomiting, mental confusion,dizziness, headache, tremor, transient nervousness, insomnia occur commonly; rarely dyskinesias, peripheral neuropathy; ataxia, slurred speech, nystagmus and blurred vision are signs of overdosage; rashes (discontinue, if mild re- introduce cautiously but discontinue immediately if recurrence), coarse facies, acne and hirsutism, fever and hepatitis; lupus erythematosus,
          erythema multiforme (Stevens- Johnson syndrome), toxic epidermal necrolysis, polyarteritis nodosa; lymphadenopathy; gingival hypertrophy and tenderness; rarely haematological effects, including megaloblastic anaemia may be treated with folic acid), leucopenia, thrombocytopenia, agranulocytosis, and aplastic anaemia; plasma calcium may be lowered (rickets and osteomalacia).<br><br>

          <strong>Cautions:</strong> Liver dysfunction, pregnancy (reduce dose), lactation. Withdraw drug slowly. Concurrent admin. of coumarin anticoagulants, isoniazid, chloramphenicol, sulthiame and oral contraceptives.<br>

          Adult: 200mg daily increased to 400mg daily (max. 600mg/day) in divided doses (2-4 times) according to patients response or 3-4 mg/kg daily in divided doses.<br>

          Child: Upto 1 year 25 mg, 1-5 years 25- 50 mg increasing to 75mg, 6-12 years 50-100mg increasing to 150mg. All twice daily, or 5- 8mg/kg daily in divided doses.   </p>
         </div><!-- collapsible -->

         <div data-role="collapsible"> <!-- collapsible -->
             <h3>DIPHEDAN Tab. Ambee</h3>
             <p>Phenytoin 100mg/tablet. 100's pack: 101.00 MRP</p>   
         </div><!-- collapsible -->

         <div data-role="collapsible"> <!-- collapsible -->
             <h3>DIPHEDAN Susp. Ambee</h3>
             <p>Phenytoin 60mg/5ml: suspension.
             100ml bot: 30.34 MRP</p>   
             </div><!-- collapsible -->
        </div><!-- collapsible-set -->



             <div data-role="collapsible-set" data-theme="b">

                <div data-role="collapsible"> <!-- collapsible -->
                  <h3> SODIUM VALPROATE / VALPROIC ACID  </h3>
                  <p>  SODIUM VALPROATE /VALPROIC ACID: Tablet/Injection<br>
Ind: All forms of epilepsy<br>

<strong>Cautions:</strong> Monitor liver function before therapy and during first 6 months especially in patients most at risk, ensure no undue potential for bleeding before starting and before major surgery; renal impairment; pregnancy; breast-feeding; systemic lupus erythematosus; false-positive urine tests for ketones; avoid sudden withdrawal.<br>

Liver toxicity: Liver dysfunction (including fatal hepatic failure) has occurred in association with valproate (specially in children under 3 years of age and those with metabolic or degenerative disorders, organic brain disease or severe seizure disorders associated with mental retardation) usually in the first 6 months of therapy and usually involving multiple antiepileptic therapy (monotherapy preferred). Raised liver enzymes are not uncommon during valproate treatment and are usually transient but patients should be reassessed clinically and liver function (including prothrombin time) monitored until return to normal-an abnormally prolonged prothrombin time (particularly in association with other relevant abnor-malities) requires discontinuation of treatment. Any concomitant use of salicylates should be stopped.<br>

<strong>C/I:</strong> Active liver disease, family history of severe hepatic dysfunction, porphyria<br>

<strong>S/E:</strong> Gastric irritation, nausea, ataxia and tremor; hyperammonaemia, increased appetite and weight gain; transient hair loss (regrowth may be curly), oedema, thrombocytopenia, and inhibition of platelet aggregation; impaired hepatic function leading rarely to fatal hepatic failure withdraw treatment immediately if vomiting, anorexia, jaundice, drowsiness, or loss of seizure control occurs); rashes; sedation reported (rarely lethargy and confusion associated with too high an initial dose) and also increased alertness (occasionally aggression, hyperactivity and behavioral disturbances); rarely pancreatitis (measure plasma amylase in acute abdominal pain), leucopenia, pancytopenia, red cell hypoplasia, fibrinogen reduction; irregular periods, amenorrhoea, gynaecomastia, hearing loss, Fanconi's syndrome, dementia, toxic epidermal necrolysis, Stevens- Johnson syndrome, and vasculitis also reported.<br><br>

Dose: By mouth- adult, initially, 600mg daily given in 2 divided doses, preferably after food, increasing by 200mg/day at 3-day intervals to a max. of 2.5gm daily in divided doses, usual maintenance 1-2gm daily (20-30 mg/kg daily); Child- up to 20 kg, initially 20mg/kg daily in divided doses, may be increased provided plasma concentrations monitored, (also monitor clinical chemistry and haematological parameters); over 20kg initially 400mg daily in divided doses increased until control (usually in range of 20-30mg/kg daily); max. 35mg/kg daily.
  </p>
                </div><!-- collapsible -->
             	
                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>ENCORATE Tab. Sun Pharma</h3>
                    <p>Sodium valproate 200mg/tablet (enteric coated). 50's pack: 142.50 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>ENCORATE Chrono 300 Tab. Sun Pharma</h3>
                    <p>Sodium valproate + valproic acid 300mg/tablet. 50's pack: 300.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>EPILIM 200 Tab. Sanofi Aventis</h3>
                    <p>Sodium valproate 133.2mg + valproic acid 58mg/tablet.
                50's pack: 200.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>EPILIM 300 Tab. Sanofi Aventis</h3>
                    <p>Sodium valproate 199.8mg + valproic acid 87mg/tablet.
                50's pack: 300.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>EPILIM 500 Tab. Sanofi Aventis</h3>
                    <p>Sodium valproate 333mg + valproic acid 145mg/tablet.
                30's pack: 300.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>EPILIM Syp. Sanofi Aventis</h3>
                    <p>Sodium valproate 200mg/5ml: syrup 100ml bot: 80.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>EPIVAL Tab. Abbott/UniHealth</h3>
                    <p>Valproic acid as divalproex sodium 250mg/tablet Ind: All forms of epilepsy.
                C/I; S/E; Cautions: See above.
                Dose: Adult and child- initially 15mg/kg daily.
                in 2-4 divided doses, gradually increasing in steps of 5-10mg/kg up to 30mg/kg daily. 100's pack: 835.50 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>EPIVAL Syp. Abbott/UniHealth</h3>
                    <p>Valproic acid as sodium valproate 200mg/5ml:60ml bot: 122.18 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>PROVAL Tab. General</h3>
                    <p>Sodium valproate 200mg/tablet. 50's pack: 125.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>PROVAL Syp. General</h3>
                    <p>Valproic acid as sodium valproate 200mg/5ml: syrup100m1 bot: 75.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>VALEPI Tab. Medimet</h3>
                    <p>Sodium valproate 200mg/tablet.
                50's pack: 310.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>VALEX Tab. Incepta</h3>
                    <p>Sodium valproate 200mg/tablet.
                50's pack: 125.00 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>VALEX Syp. Incepta Valproic acid as</h3>
                    <p>sodium valproate 200mg/5ml: syrup
                100ml bot: 75.(X) MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>VALPRO Tab. Somatec</h3>
                    <p>Sodium valproate 200mg/tablet.50's pack: 125110 MRP</p>   
                </div><!-- collapsible -->

                <div data-role="collapsible"> <!-- collapsible -->
                    <h3>VALPRO Syp. Somatec Valproic acid</h3>
                    <p>as sodium valproate 200mg/5m1: syrup
                100m1 bot: 75.00 MRP</p>   
                </div><!-- collapsible -->
              </div><!-- collapsible-set -->



              <div data-role="collapsible-set" data-theme="e">
                 <div data-role="collapsible"> <!-- collapsible -->
                   <h3> Other drugs-GABAPENTIN  </h3>
                   <p> GABAPENTIN: Tablet<br>
Gabapentin is an anti-convulsant drug. It is a structural analog of gamma-amino-butyric-acid (GABA).<br>

Mode of action: Pharmacological actions of gabapentin are due to the activity of its parent compound. It increases brain GABA levels, binds to alpha-2-delta subunit of voltage-gated L-type calcium channel, and inhibit branched chain amino acid transferase and probably inhibits neurotransmitter release of excitatory amino acids. Ind: 1. Neuralgia: (a) pain from diabetic neuropathy, (b) post herpetic neuralgia.
2. Partial seizures: Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with & with-out secondary generalization in patients over 12 years of age with epilepsy.
3. Sleep disturbances and mood disorders.<BR><BR>

 <strong>C/I:</strong> Known hypersensitivity to the drug. <BR><BR>

 <strong>S/E:</strong> Generally gabapentin is well tolerated but a few side effects like fatigue, dizziness, ataxia, weight gain, peripheral edema, dry mouth and somnolence may occur. Rarely, it may cause fulminant hepatic failure, or aplastic anemia. Precautions: Patients should be instructed to take gabapentin only as prescribed.
While using gabapentin patients should be instructed either not to drive a car or to operate other complex machinery until they have gained sufficinet experiences about gabapentin whether or not it affects their mental and/or motor performance adversely.
<br><br>

<strong>Pregnancy & lactation:</strong> Gabapentin is a
pregnancy category-c drug; it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Gabapentin may be secreted through the breast milk like many other drugs, so it should be used in women who are nursing, only if the benefits clearly outweigh the risks.<br><br>

<strong>Dosage & admin:</strong> Neuralgia: The effective dose of gabapentin is 300-1800mg daily in three divided doses; maximum dose is 3600mg daily in 3 divided doses. Seizure: The effective dose of gabapentin is 900-1800mg daily in three divided doses. The starting dose is 300mg three times a day. Doses of 3600mg/day have also been administered to a small number of patients for a relatively short duration, and have been found well tolerated. The maximum time between doses should not exceed 12 hours.
In sleep disorder or mood disorder: 900mg daily in divided doses found effective. <br>

Children: Safety and effectiveness in pediatric patients below the age of 12 years have not been established.
In case of renal impairment gabapentin doses must be reduced:
Creatinine clearance >60ml/min: max. dose 1200mg daily orally in 3 divided doses. Creatinine clearance 30-60ml/min: max. dose 600mg daily orally in 2 divided doses. Creatinine clearance 15-30ml/min: max. dose 300mg daily orally in single dose. Creatinine clearance less than 15ml/min: max. dose 150mg daily orally in single dose or 300mg every alternate day.
For patients on hemodialysis: max. 300mg dose only after each dialysis session.
Gabapentin can be taken orally with or
without food.<br><br>

<strong>Drug inter:</strong> Antacids may reduce the bioavailability of gabapentin by up to 20%. Cimetidine may alter its renal excretion. Gabapentin does not interact with other antiepileptic agent or with oral contraceptive preparation.<br><br>

Overdosage: Overdosage of up to 30gm has been reported. The symptoms consist of drwsiness, dizziness, slurred speech and mild diarrhea. Gabapentin can be removed by hemodialysis.   </p>
                 </div><!-- collapsible -->
              

                 <div data-role="collapsible"> <!-- collapsible -->
                     <h3>EPIPEN Tab. Beximco</h3>
                     <p>Gabapentin INN 300mg/tablet. 300mg x 30's pack: 540.00 IP</p>   
                 </div><!-- collapsible -->

                 <div data-role="collapsible"> <!-- collapsible -->
                     <h3>GABAPEN Tab. Incepta</h3>
                     <p>Gabapentin INN 300mg & 600mg/tablet.
                 300mg x 30's pack: 480.00 MRP 600mg x 20's pack: 600.00 MRP</p>   
                 </div><!-- collapsible -->

                 <div data-role="collapsible"> <!-- collapsible -->
                     <h3>GABANTIN Cap. Sun Pharma</h3>
                     <p>Gabapentin INN 300mg/capsule 300mg x 30's pack: 450.00 MRP</p>   
                 </div><!-- collapsible -->

                 <div data-role="collapsible"> <!-- collapsible -->
                     <h3>GABATIN Tab. UniHealth/UniMed</h3>
                     <p>Gabapentin INN 300mg/tablet. 300mg x 10's pack: 100.00 MRP</p>   
                 </div><!-- collapsible -->

                 <div data-role="collapsible"> <!-- collapsible -->
                     <h3>GABOTON Tab. Sandoz/Novartis</h3>
                     <p>Gabapentin INN 300mg & 600mg/tablet.
                 300mg x 30's pack: 480.00 MRP 600mg x 20's pack: 600.00 MRP</p>   
                 </div><!-- collapsible -->

                 <div data-role="collapsible"> <!-- collapsible -->
                     <h3>NEUROPEN Tab. Drug Inter.</h3>
                     <p>Gabapentin INN 300mg/tablet. 300mg x 30's pack: 480.00 MRP</p>   
                 </div><!-- collapsible -->

                 <div data-role="collapsible"> <!-- collapsible -->
                     <h3>NEUROTIN Tab. Silva</h3>
                     <p>Gabapentin INN 300mg & 600mg/tablet. 300mg x 30's pack: 450.00 MRP
                 600mg x 20's pack: 560.00 MRP</p>   
                 </div><!-- collapsible -->
               </div><!-- collapsible-set -->



       <div data-role="collapsible-set" data-theme="a">
         <div data-role="collapsible"> <!-- collapsible -->
           <h3> Other drugs-PIRACETAM  </h3>
           <p>  Piracetam is indicated & may be used in epileptic
          patients who are suffering from myoclonus of cortical origin.
          Piracetam is mainly a 'nootrope' psychotropic agent, which acts directly on the brain to improve the efficacy of the telencephalon in both normal subjects and those suffering from some functional deficits. This drug has been discussed in this chapter under the 'antiparkinson's drugs'.  </p>
         </div><!-- collapsible -->
       </div><!-- collapsible-set -->


               <div data-role="collapsible-set" data-theme="b">

                 <div data-role="collapsible"> <!-- collapsible -->
                   <h3> Other drugs-TOPIRAMATE  </h3>
                   <p> TOPIRAMATE: Tablet<br>
Topiramate 25mg & 50mg/tablet.<br>
Ind: Topiramate is indicated as monotherapy or<br>
adjunctive therapy for adults and children (2 years and above) with partial onset seizures or generalized tonic-clonic seizures in epilepsy. It is also indicated as adjunctive therapy for the treatment of seizures associated with Lennox- Gastaut syndrome.
<br><br>

<strong>C/I:</strong> History of hypersensitivity to any component of this product.
Adverse effects:
Monotherapy: In a double-blind clinical trial, adverse events that occurred at a frequency greater than or equal to 10% in either treatment group, are- paraesthesia, headache, dizziness, fatigue, somnolence, weight decrease, nausea, and diarrhea. These adverse events with monotherapy were consistent with, but generally less frequent than the adverse events with adjunctive therapy. Adjunctive therapy: Adults: In double-blind trials, adverse events that occurred with a frequency greater than or equal to 5% and with a higher incidence in the topiramate-treated adult patients than in the placebo group. These include- somnolence, dizziness, nervousness, ataxia, fatigue, speech disorders/related speech problems, psychomotor slowing, abnormal vision, difficulty with memory (not otherwise specified), confusion, paraesthesia, diplopia, anorexia, nystagmus, nausea, weight decrease, language problems, difficulty with concentration/attention, depression, abdominal pain, asthenia, and mood problems. Adverse events that occurred more frequently with adjunctive therapy than with monotherapy included somnolence, dizziness, difficulty with memory, psychomotor slowing, confusion, nervousness, ataxia, vision abnormal, diplopia, speech disorders and related speech problems, and nystagmus. Pediatric patients: In double-blind clinical trials, adverse events that occurred at a frequency greater than or equal to 5% and with a higher incidence in the topiramate-treated pediatric patients than in the placebo group. These include- somnolence, anorexia, fatigue, nervousness, personality disorder, difficulty with concentration/attention, aggressive reaction, weight decrease, abnormal gait, mood problems, ataxia, salivation, nausea, difficulty with memory (not otherwise specified), hyperkinesia, dizziness, speech disorders/related speech problems, and
paraesthesia.<br><br>

<strong>Warnings & precautions: </strong>Antiepileptic drugs, including topiramate, should be withdrawn gradually to minimize the potential of increased seizure frequency. In clinical trials, dosages were decreased by 100mg/day at weekly intervals. In some patients withdrawal was accelerated without complications.
The major route of elimination of unchanged topiramate and its metabolites is the kidney. Renal elimination is dependent on renal function and is independent for age. Patients with moderate or severe renal impairment may take 10 to 15 days to reach steady-state plasma concentrations as compared to 4 to 8 days in patients with normal renal function.
In all patients, the titration schedule should be guided by clinical outcome (i.e seizure control, avoidance of side-effects) with the knowledge that subjects with known renal impairment may require a longer time to reach steady-state at each dose. Some patients, specially those with a history of prior stone formation, or family history of nephrolithiasis or hypercalci-uria, are at increased risk for renal stone formation with topiramate therapy. Adequate hydration is recommended to reduce this risk.
In addition, patients taking other medica-tions associated with nephrolithiasis or on a ketogenic diet may be at increased risk. Therefore, while using topiramate, patient should avoid ketogenic diet.
In hepatic impaired patients, topiramate should be administered with caution as the clearnce of topiramate may be decreased.
A dietary supplement or increased food intake may be considered if the patient is losing weight while on this medication.
Effects on ability to drive and use machines: As with all AEDs, patient taking topiramate is potentially in danger while driving a vehicle or operating machinery, particulary until such time as the individual patient's experience with the drug is established.
<br><br>

<strong>Pregnancy & lactation:</strong> There are no studies using topiramate in pregnant women. But, as with other AEDs, topiramate was found teratogenic in mice, rats and rabbits. Therefore, topiramate should only be used during pregnancy, if the potential benefit outweighs the potential risk to the fetus. In lactating women, it is not known whether topiramate is excreted in breast milk. But, as topiramate is excreted in the milk of lactating rats, & as many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. In marketing experience, cases of hypospadias have been reported in male infants exposed in utero to topiramate, with or without other anticonvulsants; however, a causal relationship with topiramate has not been established.
<br><br>

<strong>Dosage & admin:</strong> For optimal seizure control in both adults and children, it is recommended that therapy should be initiated at a low dose followed by titration to an effective dose. Because of the bitter taste, tablets should not be broken.
Monotherapy: When concomitant anti-epileptic drugs (AEDs) are withdrawn to achieve monotherapy with topiramate, consideration
should be given to the effects of this drug, that may have on seizure control. Unless safety concern, an abrupt withdrawal of the concomitant AED is not advised, rather a gradual discontinuation at the rate of approximately one third of the concomitant AED dose every 2 weeks is recommended. When enzyme-inducing drugs are withdrawn, topiramate levels will increase. A decrease in topirmaate dosage may be required if clinically indicated.
<br><br>

Adults: Titration should begin at 25mg nightly for 1 week. The dosage should then be increased at 1- or 2-week intervals by increments of 25mg or 50mg/day, administered in two divided doses. If the patient is unable to tolerate the titration regimen, smaller increments or longer intervals between increments can be considered. Dose and titration rate should be guided by clinical outcome.
The recommended initial target dose range for topirmaate monotherapy in adults is 100mg to 200mg/day and the maximum recommended daily dose is 500mg. Some patients with refractory forms of epilepsy have tolerated topirmaate monotherapy at doses of 1000mg/day. These dosing recommendations can be applied to all adults including the elderly in the absence of underlying renal disease. <br>

Children: Treatment of children
(2 years and above) should begin at 1mg to 3mg/kg nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1mg to 3mg/kg/day, administered in two divided doses. If the child is unable to tolerate the titration regimen, smaller increments or longer intervals between dose increments can be considered. Dose and titration rate should be guided by clinical outcome.<br>

Adjunctive therapy:<br>
Adults: Titration should begin at 25mg nightly for 1 week. Subsequently, at weekly or biweekly intervals, the dose should be increased by 25mg/day and given in two divided doses. Dose titration should be guided
by clinical outcome. Some patients may achieve efficacy with once-a-day dosing.
The usual total daily dose of topiramate as adjunctive therapy is 200mg to 400mg/day in two divided doses. Individual patients have received dosages as high as 1600mg/day. Because topiramate is removed from plasma by hemodialysis, a supplemental dose of topiramate equal to approximately one-half the daily dose should be administered in divided doses at the beginning and completion of the hemodialysis procedure. This supplemental dose may vary based on the characteristics of the dialysis equipment used.
These dosing recommendations can be applied to all adults, including the elderly, in the absence of underlying renal disease.
Children: The recommended total daily dose of topirmaate as adjunctive therapy for seizures in children is approximately 5mg to 9mg/kg/day in 2 divided doses. Titration should begin at 15mg to 25mg (or less based on a range of 1mg to 3mg/kg/day) nightly for the first week. To achieve optimal clinical response, the dosage should then be increased at 1- or 2-week intervals by increments of 1mg to 3mg/kg/day (administered in 2 divided doses). Dose titration should be guided by clinical outcome. Daily doses up to 30mg/kg/day have been studied and were generally well tolerated.<br><br>

<strong>Drug inter:</strong> Effects of topiramate on other antiepileptic drugs: The addition of topiramate to other AEDs (phenytoin, carbamazepine, valproic acid, primidone, phenobarbitone) has no effect on their steady-state plasma concentrations, except in the occasiounal patient, where the addition of topiramate to phenytoin may result in an increase in plsma concentrations of phenytoin. Consequently, any patient on phenytoin showing clinical signs or symptoms of toxicity should have phenytoin levels monitored.
Effects of other antiepileptic drugs on topiramate: Phenytoin and carbamazepine decrease the plasma concentration of topiramate. The addition or withdrawal of phenytoin or cabamazepine to topiramate therapy may require an adjustment in dosage of the latter. This should be done by titrating to clinical effect. The addition or withdrawal of valproic acid does not produce clinically significant changes in plasma concentrations of topiramate and, therefore, does not warrant dose adjustment of topiramate.
Other drug interactions: When topiramate is added or withdrawn in patients on digoxin therapy, careful attention should be given to the routine monitoring of serum digoxin levels. Topiramate is not recommended to use concomitantly with alcohol or other CNS depressant drugs. Patients taking topiramate concomitantly with oral contraceptives should be asked to report any change in their bleeding patterns.   </p>
                 </div><!-- collapsible -->
              	

              	<div data-role="collapsible"> <!-- collapsible -->
              	    <h3>TOPAMAX Tab. Janssen Cilag/ UniHealth</h3>
              	    <p>Topiramate 25mg & 50mg/tablet. 25mg x 60's pack: 1780.80 MRP 50mg x 60's pack: 3249.60 MRP</p>   
              	</div><!-- collapsible -->

              	<div data-role="collapsible"> <!-- collapsible -->
              	    <h3>TOPIRVA Tab. Incepta</h3>
              	    <p>Topiramate INN 25mg & 50mg/tablet. 25mg x 50's pack: 150.00 MRP 50mg x 50's pack: 250.00 MRP</p>   
              	</div><!-- collapsible -->


               </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Dopaminergic drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Dopaminergic drugs   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="a">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  LEVODOPA </h3>
          <p>  LEVODOPA: Tablet/Capsule.<br>
Levodopa, the amino acid precursor of dopamine, acts mainly by replenishing depleted striatal dopamine. It improves bradykinesia and rigidity more than tremor. It is generally administered in conjuction with an extracerebral dopa- decarboxylase inhibitor (please see below).<br><br>

Ind: Parkinsonism (idiopathic , post-encephalitic or arteriosclerotic, but not
drug-induced extrapyramidal symptoms).<br><br>

<strong>C/I:</strong> Severe psychoses, closed or narrow angle glaucoma, history of malignant melanoma. With or within 2 weeks of MAO inhibitors.
<br><br>

<strong>S/E:</strong> Anorexia, nausea; insomnia, agitation; postural hypotension, dizziness, tachycardia, cardiac arrhythmias; polyuria, incontinence, difficulty with micturition, discoloration of urine and other body fluids; rarely hypersensitivity; abdominal pain; abnormal involuntary movements and psychiatric symptoms may be dose-limiting.<br><br>

 <strong>Cautions:</strong> Cardiovascular, hepatic, renal, pulmonary or endocrine diseases. Peptic ulceration, wide angle glaucoma. Pregnancy. Monitor blood values and hepatic, renal & cardiovascular functions.<br><br>

Adult: Initially 250mg daily in divided doses (two) after meals, increasing by 125mg every 3 or 4 days or weekly intervals. Until optimum response obtained, maintenance usually 2.5 - 8gm daily. The total daily dose being given in 4 or 5 divided doses after food. As the patient ages, the maintenance dose may need to be reduced. Child: Not recommended.
Preparations: May not be available.</p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CO-CARELDOPA  </h3>
          <p>  CO-CARELDOPA: Tablet<br>
The combined preparation of carbidopa & levodopa is termed as co-careldopa. This combination is because, levodopa is generally administered in conjuction with an extracerebral dopa-decarboxylase inhibitor, viz. carbidopa (& benserazide) which prevents the peripheral degradation of levodopa to dopamine but, unlike levodopa, it does not cross the blood-brain barrier. So, effective brain concentration of dopamine can be achieved with lower doses of levodopa. The proportion of combination in the co-careldopa is either 10mg of carbidopa for each 100mg of levodopa, or 25mg of carbidopa for each 100mg of levodopa.
The available fixed combinations are: i. Co- careldopa 110 (levodopa 100mg + carbidopa 10mg)/tablet; ii. Co-careldopa 275 (levodopa 250mg + carbidopa 25mg)/tablet.<br><br>

Ind: Parkinsonism (idiopathic, post-encephalitic or arteriosclerotic, but not drug-induced extrapyramidal symptoms).<br><br>
C/I; S/E; Caution: See above under the text of levodopa.<br><br>
<strong>Dosage & admin:</strong> Dosage of Co-careldopa 110 (levodopa 100mg + carbidopa 10mg)/tablet:<br><br>
Adult: Patients not receiving levodopa, initially 1 tablet 3 times daily increasing in small increments to maximum 8 tablets daily. Usual maintenance dose is 212 tablets 3 or 4 times daily after food. As the patient ages, the maintenance dose may need to be reduced. Child: Not recommended.<br><br>
Dosage of Co-careldopa 275 (levodopa 250mg + carbidopa 25mg)/tablet:
This preparation is for the patients already receiving plain levodopa. First discontinue levodopa atleast 12 hours before starting the therapy with this combination. The dose should be approximately 25% of the previous daily dosage of levodopa. When daily levodopa intake is greater than 1500mg, start with this co-careldopa 275 one tablet 3-4 times daily after food.
Maintenance therapy- this should be individualised and adjusted gradually; the patient must be maintained on the optimal therapeutic dosage. When the levodopa requirement is very high, the total dosage may be given as co-careldopa 275 tablets in 3 or 4 doses. As the patient ages, the maintenance dose may need to be reduced.<br>
Child: Not recommended.
  </p>
        </div><!-- collapsible -->
      	

      	 <div data-role="collapsible"> <!-- collapsible -->
      	     <h3>CO-DOPA 110 Tab. UniHealth/UniMed</h3>
      	     <p>Levodopa 100mg + carbidopa 10mg/tablet 30's pack: 105.00 MRP</p>   
      	 </div><!-- collapsible -->

      	 <div data-role="collapsible"> <!-- collapsible -->
      	     <h3>CO-DOPA 275 Tab. UniHealth/UniMed</h3>
      	     <p>Levodopa 250mg + carbidopa 25mg/tablet -30's pack: 225.00 MRP</p>   
      	 </div><!-- collapsible -->

      	 <div data-role="collapsible"> <!-- collapsible -->
      	     <h3>D-DOPA Plus Tab. Drug Inter.</h3>
      	     <p>Levodopa 250mg + carbidopa 25mg/tablet 50's pack: 300.00 MRP</p>   
      	 </div><!-- collapsible -->

      	 <div data-role="collapsible"> <!-- collapsible -->
      	     <h3>SYNDOPA 275 Tab. Sun Pharma</h3>
      	     <p>Levodopa 250mg + carbidopa 25mg/tablet 50's pack: 275.00 MRP</p>   
      	 </div><!-- collapsible -->

      	 <div data-role="collapsible"> <!-- collapsible -->
      	     <h3>ZIMOX Tab. Faran Lab. s.a, Greece/
      	 Maisha Health</h3>
      	     <p>Levodopa 250mg & carbidopa 25mg/tablet 30's pack: 406.00 TP</p>   
      	 </div><!-- collapsible -->


      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> BROMOCRIPTINE  </h3>
          <p>  BROMOCRIPTINE: Tablet<br><br>
Ind: Parkinsonism (but not drug induced extrapyramidal symptoms); Endocrine disorders (Bromocriptine is used for the suppression of lactation when simpler measures fail, for the treatment of galactorrhoea and cyclical benign breast disease, for the treatment of prolactinomas and treatment of acromegaly but success rate is much lower than with prolactinomas).<br><br>

<strong>C/I;S/E; Cautions:</strong> See under levodopa; perform annual gynaecological assessment for women (post-menopausal, every 6 month). Monitor for pituitary enlargement, particularly during pregnancy & for peptic ulceration in acromegalic patients<br><br>

<strong>Dosage & admin:</strong> Adult: Parkinsonism: first week, 1-1.25mg at night, second week, 2-2.5mg at night, third week, 2.5mg twice daily, then 3 times daily increasing by 2.5mg every 3-14 days according to response to a usual range of 10- 40mg daily; taken with food. Prevention/suppression of lactation for medical reasons, 2.5 mg on 1st day (prevention) or daily for 2-3 days (suppression); then 2.5mg twice daily for 14 days. Hypogonadism/galactorrhoea/infertility, initially 1-1.25mg at bedtime, increased gradually; usual dose 7.5mg daily in divided doses, increased if necessary to a max. of 30 mg daily. Usual dose in infertility without hyperprolactinaemia, 2.5 mg twice daily. Cyclical benign breast disease and cyclical menstrual disorders (particularly breast pain), 1-1.25mg at bedtime, increased gradually; usual dose 2.5mg twice daily.
Acromegaly- initially 1-1.25mg at bedtime increase gradually to 5mg every 6 hours. Prolactinoma- initially 1-1.25mg at bedtime; increased gradually to 5mg every 6 hours (occasional patients may require up to 30mg daily).
All doses should be taken during meals. Child: not recommended.
  </p>
        </div><!-- collapsible -->
      

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>BROMOCRIPTINE RICTER Tab. Gedeon</h3>
            <p>Richter/City Overseas
        Bromocriptine mesylate 2.5mg/tablet. 30's pack: 490.00 TP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>BROMERGAN Tab. </h3>
            <p>Sandoz/Novartis Bromocriptine mesylate 2.5mg/tablet. 30's pack: 332.40 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>CRIPTINE Tab. Renata</h3>
            <p>Bromocriptine mesylate 2.5mg/tablet. 100's pack: 1300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MEDOCRIPTINE Tab. Medochemie/</h3>
            <p>Hyeimpex
        Bromocriptine mesylate 2.5mg/tablet. 30's pack: 416.70 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ENTACAPONE  </h3>
          <p>    </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> COMTAN Tab. Novartis</h3>
          <p> Entacapone 200mg/tablet (f.c).
It is a catechol-o-methyl transferase inhibitor.<br>

Ind: Adjunct to levodopa/benserazide or levodopa/carbidopa treatment in patients with Parkinson's disease and end-of dose motor fluctuations, who cannot be stabilised on those combinations.<br><br>

<strong>C/I:</strong> Known hypersensitivity to entacapone or any of the excipients. Pregnancy and breast-feeding. Liver impairment. Phaeochromocytoma. Concomitant use with nonselective monoamine oxidase inbibitors (MAO-A and MAO-B). Concomitant use with a selective MAO-A plus a selective MAO-B inhibitor. History of neuroleptic malignant syndrome (NMS) and/or nontraumatic rhabdomyolysis.<br><br>

A/R: Dyskinesia; gastrointestinal symptoms (e.g nausea, vomiting, abdominal pain, constipation, diarrhoea, dry mouth); discoloration of urine; fatigue, insomnia, paroniria, confusion, hallucinations; dizziness, postural hypotension, vertigo, headache; leg cramps, hyperkinesia, tremor, increased sweating; slight decrease in haemoglobin, erythrocyte count, and haematocrit. Increases in liver enzymes have been reported rarely.<br><br>

Precautions & warnings: Dosage of levodopa and other antiparkinsonian medications (e.g dopamine agonists) may need to be adjusted when entacapone treatment is initiated. Levodopainduced orthostatic hypotension may be
aggravated. Effects of medicinal products metabolised by catechol-o-methyl transferase may be potentiated. Caution when discontinuing entacapone treatment (see full prescribing information).<br><br>

Dosage: 200mg with each levodopa/ dopadecarboxylase inhibitor dose. Maximum recommended daily dose is 2000mg.<br><br>

<strong>Drug inter:</strong> Entacapone and iron preparations should be taken at least 2-3 hours apart.
30's pack: 2006.40 MRP<br>

Note: For further information consult full prescribing information.   </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ROPINIROLE  </h3>
          <p>  ROPINIROLE: Tablet<br>
Ropinirole is an antiparkinson's drug. It is available as ropinirole hydrochloride INN 0.25mg & 2mg film-coated tablets.<br><br>
Ind: 1. Parkinson's disease. 2. Restless legs
syndrome (RLS).
<strong>S/E:</strong> Nausea, somnolence, leg edema, abdominal pain, vomiting, & syncope.<br><br>
Pragnancy & lactation: Ropinirole should not be used during pregnancy. It should also not be used in nursing mothers as it may inhibit lactating.<br><br>
<strong>Dosage & admin:</strong> Parkinson's disease: In all clinical studies, dosage was initiated at a subtherapeutic level & gradually titrated to therapeutic response. The dosage should be increased to achieve a maximum therapeutic effect, balanced against the principal side effects of nausea, dizziness, somnolence, & dyskinesia.
Ascending-dose schedule of ropinirole for Parkinson's disease:
The recommended starting dose for Parkinson's disease is 0.25mg 3 times daily. Based on individual response, dosage should then be titrated with weekly increments as described below:
After week 4, if necessary, daily dosage may be increased by 1.5mg/day on a weekly basis up to a dose of 9mg/day, & then by up to a total dose of 24mg/day. Doses greater than 24mg/day
have not been tested in clinical trials.
When ropinirole is administered as adjunct therapy to L-dopa, the concurrent dose of L- dopa may be decreased gradually as tolerated. L-dopa dosage reduction was allowed during the advanced Parkinson's disease (with L- dopa) study if dyskinesias or other dopaminergic effects occurred.
Ropinirole for Parkinson's disease patients should be discontinued gradually over a 7-day period. The frequency of administration should be reduced from 3 times daily to twice daily for 4 days; for the rest 3 days, the frequency should be reduced to once daily up to complete withdrawal of ropinirole.
Restless legs syndrome: The recommended adult starting dosage for RLS is 0.25mg once daily, 1 to 3 hours before bedtime. After 2 days, the dosage can be increased to 0.5mg once daily & to 1mg once daily at the end of the first week of dosing, then increased as needed to achieve efficacy. For RLS, the safety & effectiveness of doses greater than 4mg once daily have not been established.
In clinical trials of patients being treated for RLS with doses up to 4mg once daily, ropinirole can be discontinued without a taper. Note: For further information please consult manufacturer's literature.  </p>
        </div><!-- collapsible -->
      	

      	<div data-role="collapsible"> <!-- collapsible -->
      	    <h3>PERKIROL Tab. Square</h3>
      	    <p>Ropinirole hydrochloride INN 0.25mg & 2mg/tablet (Lc). 0.25mg x 50's pack: 100.00 MRP
      	2mg x 30's pack: 180.00 MRP</p>   
      	</div><!-- collapsible -->

      	<div data-role="collapsible"> <!-- collapsible -->
      	    <h3>REPITOL Tab. Beximco</h3>
      	    <p>Ropinirole hydrochloride INN 0.25mg & 2mg/tablet (f.c). 0.25mg x 30's pack: 60.00 MRP
      	2mg x 30's pack: 300.00 MRP</p>   
      	</div><!-- collapsible -->

      </div><!-- collapsible-set -->




      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>SELEGILINE</h3>
          <p> SELEGILINE: Tablet/Syrup.<br>
Selegiline is a monoamine-oxidase-B inhibitor used in severe parkinsonism in conjunction with levodopa to reduce 'end-of-dose' deterioration. <br>

Ind: Parkinson's disease or symptomatic parkinsonism (but not drug-induced extrapyramidal symptoms), either used alone (in early disease) or as an adjunct to levodopa therapy.<br>
<strong>S/E:</strong> Hypotension, nausea and vomiting,
confusion, agitation.<br><br>
<strong>Cautions:</strong> Side-effects of levodopa may be increased, concurrent levodopa dosage may need to be reduced by 20-50%; interactions- see Appendix (selegline)<br>
Dose: 10mg in the morning, or 5mg at breakfast and midday.   </p>
        </div><!-- collapsible -->
      	

      	<div data-role="collapsible"> <!-- collapsible -->
      	    <h3>JUMEX Tab. Chinoin/City Overseas</h3>
      	    <p>Selegiline 5mg/tablet 50's pack: 725.00 TP</p>   
      	</div><!-- collapsible -->
      </div><!-- collapsible-set -->

   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Antimuscarinic drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>    </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  PROCYCLIDINE </h3>
          <p> PROCYCLIDINE: Tablet/ Injection<br>
Ind: Parkinsonism; drug-induced extrapyramidal symptoms (but not tardive dyskinesia).<br><br>

<strong>S/E:</strong> Dry mouth, g.i disturbances, dizziness, blurred vision; less commonly urinary retention, tachycardia, hypersensitivity, nervousness and with high doses in susceptible patients, mental confusion, excitement and psychiatric disturbances which may necessitate discontinuation of treatment.<br><br>

 <strong>Cautions:</strong> Urinary retention, closed-angle glaucoma, cardiovascular disease,
hepatic or renal impairment; gastrointestinal obstruction; avoid abrupt discontinuation of treatment; drugs of this type liable to abuse. May affect performance of skilled tasks<br><br>

<strong>Dosage & admin:</strong> Adult: Initially 2.5-5mg 3 times daily increasing at intervals of 2 or 3 days by 2.5-5mg daily; usual max. 30mg daily. Parenteral dose, Adult- 10-20mg daily by i. m or i. v injection.
Acute dystonia- by i.m injection, 5-10mg repeated if necessary after 20 minutes; max. 20mg daily; by i.v. injection 5mg (usually effective within 5 minutes); an occasional patient may need 10 mg or more and may require up to half an hour to obtain relief.<br> Child: Not recommended.   </p>
        </div><!-- collapsible -->
  

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>EXTRANIL Tab. General</h3>
            <p>Procyclidine hydrochloride 5mg/tablet. 100's pack: 75.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>KDRINE Tab. Opsonin</h3>
            <p>Procyclidine hydrochloride 5mg/tablet. 100's pack: 42.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>KEMADRIN Tab. GlaxoSmithKline</h3>
            <p>Procyclidine hydrochloride 5mg/tablet. 100's pack: 186.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PERKINIL Tab. Square</h3>
            <p>Procyclidine hydrochloride 5mg/tablet 200's pack: 150.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PERKINIL Inj. Square</h3>
            <p>Procyclidine hydrochloride 10mg/2ml ampoule: injection.1 amp pack: 30.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="tics" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Drugs used in essential tremor, <br>
 		 chorea, tics & related disorders</a>   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 


    <div data-role="collapsible-set" data-theme="a">
          <div data-role="collapsible"> <!-- collapsible -->
            <h3> HALOPERIDOL  </h3>
            <p>  HALOPERIDOL: Tablet/Syrup/ Injection<br>
             Ind: Motor tics, adjunctive treatment in choreas and Gilles de la Tourette syndrome; (for other indications, see under antipsychotic drugs).<br>
<strong>C/I; S/E; Cautions:</strong> See under antipsychotic
drugs.<br>
Dose: By mouth, 0.5-1.5mg 3 times daily adjusted according to the response; 10mg daily or more may occasionally be necessary in Gilles de la Tourette syndrome; Child, Gilles de la Tourette syndrome up to 10mg daily. Preparations: See under antipsychotic drugs.  </p>
          </div><!-- collapsible -->
    </div><!-- collapsible-set -->



    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> PIRACETAM  </h3>
          <p>  PIRACETAM: Tablet<br>
Piracetam is a 'nootrope', psychotropic agent. 
<br><br>
Mode of action: Piracetam as a psychotropic agent, acts directly on the brain to improve the efficacy of the telencephalon in both normal subjects and those suffering from some functional deficits. This area of the brain is involved in cognition and also has a role to play in learning and memory, in alertness and in consciousness. Piracetam does not cause sedation or stimulation. It acts on the central nervous system in different ways. It can modify neurotransmission within the brain, and can help to improve the metabolic environment essential for good neuronal function. It is also a haemorrheological agent and can improve microcirculation without producing vasodilation. When given as acute or long-term treatment for patients, suffering from a functional CNS deficit, it enhances alertness and increases cognitive function. Piracetam also protects and restores cognitive functional capacity for cerebral trauma, e.g hypoxia or intoxication, and after electroshock therapy. Piracetam may be given alone or in combination with other drugs when treating myoclonia due to anoxia. It reduces the duration of vestibular nystagmus. Piracetam also improves regional oxygen and glucose uptake in the brain in patients suffering from dementia subequent to multiple infarcts, or in those with cerebral ischaemia. Piracetam inhibits the increased aggregation of activated platelets and, in conditions where there is abnormal rigidity of the RBC, it can restore deformability and the ability to pass through the microvasculature.
<br><br>

Ind: 1. Cerebral vascular accidents and cerebral insufficiencies- ischaemic or even haemorrhagic acute accidents, stroke, chronic manifestations of the above accidents of cerebral atherosclerosis.
2. Mental retardation in children- ease of resuming individual contact, sociability and learning, improved intellectual performances and school results.
3. Behaviour and psychotic problems in old age- memory deficits, particularly with regard to fixation and evocation asthenia adoption disorders, disturbed psychomotor reactions. 4. Patients suffering from myoclonus of cortical origin.
<br><br>

<strong>S/E:</strong> The side effects reported include nervousness, agitation, irritability, anxiety and sleep disturbances. The incidence of these during clinical trials was =5% and they were more often noted in the older patients taking >2.4gm daily. In the majority cases, a dose reduction causes disappearance of the symptoms.
Some patients may complain very rarely of fatigue or drowsiness, gastrointestinal problems e.g nausea, vomiting, diarrhoea and stomach pain. Other symptoms e.g vertigo, headache, trembling and sexual stimulation have occasionally been reported.
<br><br>

<strong>C/I & Precautions:</strong> Piracetam is contra-indicated in patients with severe renal insufficiency (creatinine clearance less than 20m1/min), hepatic impairment. As the principal route of elimination for piracetam is via the kidney, special care must be taken when treating patients suffering from renal insufficiency. Monitoring of renal function is recommended in such cases. This is also true for the older patients in whom creatinine clearance is dependent on age.
When the creatinine clearance is less than 60ml/min, or serum creatinine is >1.25mg/100ml, the dosage should be given half of the normal dose; accordingly when the creatinine clearance is less than 40ml/min, or serum creatinine is >1.70mg/100ml, the dosage should be given quarter of the normal dose.<br><br>

<strong>Pregnancy & lactation:</strong> Piracetam should not be prescribed during pregnancy or when breast feeding, except under exceptional circumstances. Piracetam crosses the placental harrier.<br><br>

<strong>Dosage & admin:</strong> Adults, in cerebro-cortical insufficiency disoders, usual dose is 800mg 3 times a day. In myoclonic seizures, a dose of 7.2gm daily, increasing by 4.8gm per day every 3 to 4 days up to maximum of 20gm daily, given in 2 or 3 divided doses.
Children, 50mg/kg of body weight in 3 divided doses. Once the desired results has been obtained, reduce the initial dose by half.
 </p>
        </div><!-- collapsible -->
  		
  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>LUCETAM Tab. Egis/City Overseas</h3>
  		    <p>Piracetam 1200mg/tablet (Lc) 20's Pack: 254.00 TP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MEMOPIL Tab. ACI Piracetam</h3>
  		    <p>INN 800mg & 1200mg/tablet
  		800mg x 50's Pack: 300.00 IP 1200mg x 30's Pack: 270.00 IP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>NEUROLEP Tab. Square</h3>
  		    <p>Piracetam INN 800mg/tablet 40's Pack: 240.00 MRP</p>   
  		</div><!-- collapsible -->
    </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Appetite" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Appetite Suppressants<br>
       / Antiobesity Drugs   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

      	<a href="#" data-role="button" 
      	data-theme="a">Pancreatic lipase inhibitor</a>

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ORLISTAT  </h3>
          <p> ORLISTAT: Capsule<br>
Orlistat is an anti-obesity drug acting on the gastrointestinal tract.<br><br>

Mode of action: It is a pancreatic lipase inhibitor, which reduces the absorption of dietary fat.<br><br>

Ind: For long-term management of obese
and overweight patients, including patients with
risk factors e.g hypercholesterolaemia, noninsulin dependent diabetes mellitus (NIDDM), impaired glucose tolerance, hyperinsulinaemia,
hypertension associated with obesity and in a reduction of visceral fat.<br><br>

<strong>C/I:</strong> Chronic malabsorption syndrome; patients with known hypersensitivity to
orlistat or any of the other components contained in the preparation.<br><br>

A/R: Adverse reactions are largely gastrointestinal in nature. Commonly observed events are oily spotting, flatus with discharge, faecal urgency, fatty or oily stool, oily evacuation, increased defaecation and faecal incontinence. These are generally mild and transient.<br><br>

<strong>Cautions:</strong> The possibility of experiencing gastrointestinal events may increase when orlistat is taken with a diet high in fat.<br>

<strong>Pregnancy & lactation:</strong> The safety of orlistat has not been established in pregnant women. Orlistat should not be taken by breast-feeding women, unless the potential benefit outweighs the potential risk.<br><br>

<strong>Dosage & admin:</strong> Adults, 120mg with each main meal; if a meal is missed or contains no fat, the dose of orlistat may be omitted for that meal. In case of hepatic and renal impairment, dose adjustment is not required.<br>
Children, below the age of 18 years not recommended.<br><br>
<strong>Drug inter:</strong> There are no evidences of interactions with commonly prescribed medications. However, orlistat enhances the bioavailability and lipid lowering effect of pravastin.   </p>
        </div><!-- collapsible -->
  

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ADIPONIL Cap. Incepta</h3>
            <p>Orlistat 120mg/capsule
        10's packs: 400.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>XENICAL Cap. Roche</h3>
            <p>Orlistat 120mg/capsule 84's packs: 4500.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->
   
    

      <div data-role="collapsible-set" data-theme="b">
      	<a href="#" data-role="button" 
      	data-theme="a">Centrally acting <br>
      	appetite suppressants</a>

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> SIBUTRAMINE  </h3>
          <p>  SIBUTRAMINE: Capsule<br>
Sibutramine is an effective anti-obesity drug. It works against obesity- i. by supporting the natural weight-control functions in the body by inhibition of re-uptake of monoamine neurotransmiters & ii. by stimulating metabolic activity.<br><br>

Mode of action: Sibutramine produces its therapeutic effect by inhibition of re-uptake of neural messenger substances viz. norepinephrine, serotonin and dopamine (neurotransmiters) in the brain. Sibutramine and its major pharmacolo- gically active metabolites (M1 and M2) do not act via release of monoamines. Sibutramine exerts its phamacological actions predominantly by its secondary (Ml) and primary (M2) amine metaboliltes. However, prevention of resorption of the aforesaid neurotransmiters in the brain, allowing them to act at higher concentration on the nerve cells. Thus increases the feeling of fullness of stomach. Sibutramine also stimulates thermogenesis (metabolic activity) indirectly by activating the b3-system in brown aolipose tissue. Ind: Sibutramine is used in the management of obesity, including weight loss and management of weight loss when used in conjunction with a reduced caloric diet. Sibutramine is recommended for obese patients with an initial body mass index (BMI) = 30kg/m2 or = 27kg/m2 in the presence of other risk factors (e.g hypertension, diabetes, dyslipidaemia).
(BMI is calculated by taking the patient's weight in kg and dividing by the patient's height, in meters, squared. Metric conversions are as follows: Pounds 2.2=kg; inches x 0.0254=meters.)<br><br>

<strong>C/I:</strong> Patients receiving monoamine oxidase inhibitors (MAOIs); hypersensitivity to sibutramine or any of the active ingredients of sibutramine; patients with anorexia nervosa; patients taking other centrally acting appetite- suppressant drugs.<br><br>

<strong>S/E:</strong> Commonly reported side-effects of sibutramine are dry mouth, headache, insomnia and constipation; diarrhoea, dizziess, drowsiness and rhinitis have also occured. Less frequently reported side-effects include dysmenorrhoea, oedema, influenza-like symptoms, and depression. Abnormal bleeding, acute interstitial nephritis, emotional lability, migraine, seizures and skin rashes have been reported rarely. Clinically significant increase in heart rate and blood pressure may occur. Sibutramine may decrease salivary flow and therefore increase the risk of dental caries, periodontal disease, or other oral disorders. It may also produce mydriasis.
Increases in liver enzyme have been reported.<br><br>

 <strong>Cautions:</strong> Give with caution to those patients with a history of hypertension and do not give to patients with uncontrolled or poorly controlled hypertension. Use with caution when prescribing sibutramine with other agents that may raise blood pressure or heart rate including certain decongestant, cough, cold and allergy medications that contain agents such as phenylpropanolamine. ephedrine or pseudoephedrine.<br><br>

<strong>Pregnancy & lactation:</strong> The use of sibutramine is not recommended during pregnancy, and in nursing mothers.<br>

<strong>Dosage & admin:</strong> The recommended starting dose is 10mg once daily with or without food. If there is inadequate weight loss, the dose may be increased after 4 weeks to a total of 15mg once daily. The 5mg dose should be reserved for patients who do not tolerate 10mg dose. Blood pressure and heart rate changes should be taken into account when making decisions regarding dose titration. Analysis of numerous variables has indicated that 60% of patients who lose at least 4 lbs in the first 4 weeks of treatment with a given dose of sibutramine in combination with a reduced-calorie diet lose at least 5% of their initial body weight by the end fo 6 months to 1 year of treatment on that dose. Conversely, 80% of patients who do not lose at least 4 lbs in the first 4 weeks of treatment with a given dose, do not lose at least 5% of their initial body weight by the end of 6 months to 1 year of treatment on that dose. If a patient has not lost at least 4 lbs in the first 4 weeks of treatment, consider re-evaluation of therapy which may include increasing the dose or discontinuing sibutramine. The safety and efficacy of sibutramine have not been determined beyond 1 year at this time.<br><br>

<strong>Drug inter:</strong> Sibutramine should not be given concurrently with, or within at least two weeks of stopping an MAOI; at least two weeks should elapse between discontinuation of sibutramine and starting therapy with an MAOI. There is a risk of the serotonin syndrome developing if sibutramine is administered together with other serotonergic drug such as selective serotonin reuptake inhibitors (SSRIs), sumatriptan, lithium, pethidine, fentanyl, dextromethorphan and pentazocine. Sibutramine should not be used with other drugs that may increase heart rate or blood pressure such as ephedrine, phenylpropanolamine, and pseudoephedrine (which may be ingredients of some cough and cold remedies). Alcohol should be avoided. Inhibitors of the cytochrome P450 isoenzyme CYP3A4, such as ketoconazole and erythromycin, may increase plasma concentrations of sibutramine.  </p>
        </div><!-- collapsible -->
    	
    	<div data-role="collapsible"> <!-- collapsible -->
    	    <h3>BUTRAMIN Cap. Drug Inter.</h3>
    	    <p>Sibutramine hydrochloride monohydrate INN equivalent to 5mg sibutramine hydrochloride INN/capsule.
    	30's pack: 120.00 MRP</p>   
    	</div><!-- collapsible -->

    	<div data-role="collapsible"> <!-- collapsible -->
    	    <h3>OBENIL Cap. Square</h3>
    	    <p>Sibutramine hydrochloride monohydrate INN equivalent to 5mg sibutramine hydrochloride INN/capsule.
    	30's pack: 150.00 MRP</p>   
    	</div><!-- collapsible -->

    	<div data-role="collapsible"> <!-- collapsible -->
    	    <h3>REDUX Cap. UniHealth</h3>
    	    <p>Sibutramine hydrochloride monohydrate INN equivalent to 5mg sibutramine hydrochloride INN/capsule.
    	30's pack: 150.00 MRP</p>   
    	</div><!-- collapsible -->

    	<div data-role="collapsible"> <!-- collapsible -->
    	    <h3>SIBULIN Cap. Beximco</h3>
    	    <p>Sibutramine hydrochloride monohydrate INN equivalent to 5mg sibutramine hydrochloride INN/capsule.
    	60's pack: 300.00 IP</p>   
    	</div><!-- collapsible -->

    	<div data-role="collapsible"> <!-- collapsible -->
    	    <h3>SIBUTRIN Cap. General</h3>
    	    <p>Sibutramine hydrochloride monohydrate INN equivalent to 5mg & 10mg sibutramine hydrochloride INN/capsule.
    	5mg x 30's pack: 150.00 MRP
    	10mg x 20's pack: 160.00 MRP</p>   
    	</div><!-- collapsible -->

    	<div data-role="collapsible"> <!-- collapsible -->
    	    <h3>SLIM Cap. Rephco</h3>
    	    <p>Sibutramine hydrochloride monohydrate INN equivalent to 5mg sibutramine hydrochloride INN/capsule.
    	30's pack: 150.00 MRP</p>   
    	</div><!-- collapsible -->
      </div><!-- collapsible-set -->
    
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Dementia" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>DRUGS FOR DEMENTIA</h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> DONEPEZIL  </h3>
          <p> DONEPEZIL: Tablet<br>
Donepezil hydrochloride is a centrally acting & reversible anticholinesterase agent.<br><br>

Mode of action: Donepezil hydrochloride binds reversibly & selectively with acetylcholinesterase and inactivates it, thus inhibiting hydrolysis of acetylcholine.
As a result the concentration of acetylcholine increases at cholinergic synapses in the brain. Ind: Symptomatic treatment of mild to moderate dementia of Alzheimer's type.<br><br>

<strong>C/I:</strong> Known hypersensitivity to donepezil hydrochloried or to piperidine derivatives.<br><br>

<strong>S/E:</strong> Generally well tolerated but some patients may experience nausea, vomiting & diarrhoea. These adverse events are of mild intensity and transient, resolving during continued treatment without the need for dose modification. Less frequent side effeccts are insomnia, fatigue, anorexia, muscle cramps, generalized seizure etc. <br><br>

<strong>Precautions: </strong>Caution should be taken in sick sinus syndrome or other supraventricular conduction abnormalities, patients at risk of developing peptic ulcers, asthma, obstructive airway disease and during anaesthetic procedure. <br><br>

<strong>Pregnancy & lactation:</strong> There are no adequate and well controlled studies in pregnant woman. Donepezil should be used durng pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing mother- it is not known whether Donepezil hydrochloride is secreted in human breast milk or not, so it is not advised in nursing mother.<br><br>

<strong>Dosage & admin:</strong> 5mg once daily orally at bed time, for at least one month, in order to allow the earliest clinical response to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. Following a one-month clinical assessment of treatment, the dose can be increased to 10mg/day (once-a-day dosing). Since food does not affect the rate or extent of absorption of donepezil, it can be administered with or without food.<br>
In case of renal & hepatic impairment- a similar dose schedule can be followed for patients with renal or mild to moderate hepatic impairment as clearance of donepezil hydrochloride is not affected by these conditions.
In case of children- Donepezil is not recommended for use in children.<br><br>

<strong>Drug inter:</strong> Drugs with anticholinergic properties and which cross into the brain, such as atropine, benztropine produce the opposite effects of Donepezil and should be avoided during therapy with donepezil. Medication with carbamazepine, dexamethasone, phenobarbital, phenytoin may reduce the effect of donepezil, whereas
ketoconazole, quinidine, cimetidine may increase the effects.   </p>
        </div><!-- collapsible -->
  		
  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>AMELOSS Tab. Incepta</h3>
  		    <p>Donepezil hydrochloride INN 5mg/tablet (f.c). 5mg x 30's pack: 300.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>ELZER Tab. Square</h3>
  		    <p>Donepezil hydrochloride INN 5mg/tablet (f.c). 5mg x 30's pack: 300.00 MRP</p>   
  		</div><!-- collapsible -->

  		<div data-role="collapsible"> <!-- collapsible -->
  		    <h3>MEMORIN Tab. Beximco</h3>
  		    <p>Donepezil hydrochloride INN 5mg/tablet (f.c). 5mg x 30's pack: 300.00 MRP</p>   
  		</div><!-- collapsible -->

      </div><!-- collapsible-set -->


      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> RIVASTIGMINE  </h3>
          <p>  RIVASTIGMINE: Capsule<br>
Rivastigmine is a centrally acting, reversible non- competitive acetylcholinesterase inhibitor, introduced as the specific drug therapy for Alzheimer's patients to improve their functional ability & preserve cognitive performance. Mode of action: Rivastigmine binds reversibly & selectively with acetylcholinesterase and inactivates it, thus inhibiting hydrolysis of acetylcholine.<br>

As a result the concentration of acetylcholine increases at cholinergic synapses in the brain at selectivity region.<br><br>
Ind: Mild to moderately severe dementia of the Alzheimer type.<br><br>

<strong>C/I:</strong> Known hypersensitivity to rivastigmine, other carbamate derivatives, or excipients of the formulation.
<br><br>

<strong>S/E:</strong> Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, dyspepsia, dizziness, headache.<br><br>
Precautions/warnings: Sick sinus syndrome, severe cardiac arrhythmias, gastroduodenal ulcerative conditions in predisposed patients, respiratory disease, urinary obstruction, seizure, pregnancy and lactation.<br><br>

Dosage: 1.5mg twice daily is the recommended starting dose. If well tolerated, it may be increased after a minimum of 2 weeks of treatment to 3mg twice daily, subsequently to 4.5mg twice daily, up to a maximum of 6mg twice daily. Adverse effects may respond to omitting one or more doses. If they persist, the daily dose should be reduced to the previous well tolerated dose.<br><br>

<strong>Drug inter:</strong> Cholinomimetic drugs, anticholinergic medications.<br><br>

Note: For further information please consult manufacturer's literature.  </p>
        </div><!-- collapsible -->
      	

        <div data-role="collapsible">
      	<h3>EXELON Cap. Novartis</h3> 
      	<p>Rivastigmine (as hydrogen tartrate) 
      	1.5mg, 3mg, 4.5mg & 6mg/capsule
      	1.5mg x 60's pack: 5670.00 MRP
      	3.0mg x 60's pack: 5670.00 MRP 4.5mg x 60's pack: 5670.00 MRP 6.0mg x 60's pack: 5670.00 MRP</p>
      	</div>

      	<div data-role="collapsible"> <!-- collapsible -->
      	    <h3>RIVAMER Cap. Sun Pharma</h3>
      	    <p>Rivastigmine (as hydrogen tartrate) 1.5mg/capsule
      	1.5mg x 30's pack: 300.00 MRP</p>   
      	</div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->



<!-- /................page............................ -->



<div data-role="page" id="Drugs used in Substance Dependence" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  Drugs used in <BR> Substance Dependence  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

      <div data-role="collapsible-set" data-theme="b">

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> NALTREXONE  </h3>
          <p>  NALTREXONE HCI: Tablet<br>
Naltrexone hydrochloride is an opioid antagonist and is effective in the treatment of opioid dependence and alcoholism. It is available as naltrexone hydrochloride USP 25mg & 50mg film-coated tablet.<br><br>

Mode of action: As an opioid antagonist, naltrexone blocks the effects of opioids by competitive binding (i.e analogous to competitive inhibition of enzymes) at opioid receptors. Naltrexone when co-administered with morphine on a regular basis, it blocks the physical dependence to morphine, heroin and other opioids. In subjects physically dependent on opioid, naltrexone precipitates withdrawal symptoms. Naltrexone markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids; 50mg of naltrexone will block the pharmacologic effects of 25mg of intravenously administered heroin for periods as long as 24 hours, doubling the dose of naltrexone provides blockade for 48 hours, and tripling the dose provides blockade for about 72 hours.
The mechanism of action of naltrexone in
alcoholism is not understood; however, naltrexone has been shown to reduce alcohol consumption in clinical studies.
Naltrexone produces some pupillary constriction, by an unknown mechanism.<br><br>

Ind: Naltrexone is indicated in the treatment of opioid dependence and alcoholism. It has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.<br><br>

<strong>C/I:</strong> Naltrexone is contraindicated in patients receiving opiold analgesics, patients currently dependent on opioids, patients in acute opioid withdrawal, any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids, any individual with a history of sensitivity to naltrexone or there is any cross-sensitivity with naloxone or the phenanthrene containing opioids, any individual with acute hepatitis or liver failure.<br><br>

S/E; Precautions & warnings: Please see manufacturer's literature.<br><br>

<strong>Dosage & admin:</strong> A patient is candidate for treatment with naltrexone if- i. the patient is willing to take a medicine, ii. the patient is opioid free for 7-10 days, iii. the patient dose not have severe or active liver or kidney problems, iv. the patient is not allergic to naltrexone and no other contraindications are present.
In opioid dependence, treatment should be initiated carefully with an initial dose of 25mg of naltrexone; if no withdrawal signs occur, the patient may be started with 50mg a day thereafter.
In alcoholism, a dose of 50mg once daily (up to 12 weeks) is recommended for most patients. If there is any question of occult opioid dependence, perform a naloxone challenge test and do not initiate naltrexone therapy until the naloxone challenge is negative.
Alternative dosing schedules: Once the patient has been started on naltrexone, 50mg every other day, or 150mg every third day. The degree of blockade produced by naltrexone may be reduced by these extended dosing intervals.<br><br>

<strong>Drug inter:</strong> Caution is advised if the concomitant administration of naltrexone and other drugs is required. The safety & efficacy of concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks. Lethargy and somnolence have been reported following doses of naltrexone and thioridazine. Patients taking naltrexone may not be benefited from opioid containing medications such as cough and cold preparations, antidiarrhoeal preparations and opioid analgesics.<br><br>

Note: For further information, please consult manufacturer's literature.  </p>
        </div><!-- collapsible -->
  
        
        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALTRAX Tab. Navana</h3>
            <p>Naltrexone hydrochloride USP 25mg & 50mg/tablet (f.c).
        25mg x 10's pack: 450.00 MRP 50mg x 10's pack: 850.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NODICT Tab. Sun Pharma</h3>
            <p>Naltrexone hydrochloride USP 50mg/tablet (f.c). 50mg x 10's pack: 630.00 MRP</p>   
        </div><!-- collapsible -->

      </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->


<div data-role="page" id="Antipsychotic Related Drugs" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> Antipsychotic Related Drugs   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

<ul data-role="listview" data-inset="true" data-theme="b">        
       
    <li><a href="#Atypical antipsychotic drugs">Atypical antipsychotic drugs</a></li> 
    <li><a href="#Antimanic drugs">Antimanic drugs</a></li> 
    <li><a href="#Antipsychotic drugs">Antipsychotic drugs</a></li> 
          
</ul>


  </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


</body> 
</html> 
